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 ABSTRACT 
Pancreatic cancer is a common cause of cancer death and is difficult to diagnose and treat. A 
prognostic index is a tool that can be used in clinical practice to predict survival. Thirty six 
prognostic factor studies were identified but the size and statistical methods were inappropriate. 
Valid statistical analyses are essential to make best use of data and optimise clinical application.  
Continuous variables are often simplified incorrectly by i) assuming linear relationships between 
predictors and log-hazard or ii) using dichotomisation. Non-linearity is addressed for the first time 
in this disease site using restricted cubic spline and fractional polynomial functions, ideal for 
smooth curved relationships. Multivariable models containing non-linear transformations gave a 
substantially better fit. Important effects of some covariates were unrecognised under simplistic 
assumptions. The fitted functions generated by the two methods were similar. A direct comparison 
of these strategies was based on a novel approach assessing the difference in the AIC values by 
calculating a sampling distribution in multiple bootstrap resamples. Model validation is also 
addressed for the first time in this disease and suggested minimal over-fitting with reproducible 
prognostic information when fitted to external data. 
This thesis provides the first validated prognostic tool in advanced pancreatic cancer developed 
using appropriate statistical methodology. Four risk-sets identified by the model could help 
clinicians target treatments to patients more appropriately and have an impact on future trial 
design and analysis. 
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CHAPTER 1: AIMS AND OBJECTIVES 
 
The overall aim of this research was to identify groups of patients with advanced pancreatic 
cancer with differing prognoses and to define the factors, at the time of diagnosis, which may 
predict the group to which a patient best belongs. In this way, treatments could then be targeted at 
specific groups who have the ability to cope with and possibly benefit from further toxic 
treatments. There is currently no prognostic tool in routine clinical use for prediction of survival 
from advanced pancreatic cancer. Such a tool would help clinicians identify subgroups of patients 
and help in their decision making regarding appropriate treatment strategies. Historically, 
randomised controlled trials have stratified patients at randomisation by disease stage but 
generally patients are not clinically separated into prognostic groups for consideration of treatment 
except surgically. 
 
Pancreatic cancer has an aggressive biological phenotype that appears to be largely resistant to 
therapy. As the effect of treatment is often minimal, large numbers of patients are needed to 
provide robust statistical evidence but sample sizes in pancreatic cancer trials tend to be small so 
a significant problem is how to compare treatments across trials due to case mix. Statistical 
models ideally need validating on external data to ensure portability to new datasets. 
 
This research investigates potential prognostic factors for survival in patients with advanced 
pancreatic cancer through the construction and validation of statistical models evaluating clinical, 
histological and laboratory factors whilst investigating the underlying assumptions, 
appropriateness and suitability of such models. Based on methodologically strong statistical 
modelling, an attempt to identify and classify patients into defined clinical prognostic subgroups of 
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differing risk was carried out to i) predict disease outcome ii) identify possible factors for 
stratification of patients in future prospective randomised trials and iii) improve the targeting of 
therapeutic modalities. Recommendations for the design and analysis of future randomised 
controlled trials have been made, specifically identification of possible important stratification 
factors and the appropriateness of different statistical modelling approaches including dealing with 
different data types. At the time of the conception of this research project in 2003, the National 
Institute for Clinical Excellence recommended gathering further evidence for the role of 
gemcitabine as a potential new therapy in pancreatic cancer patients (NICE, 2010). As such, it 
was timely that significant effort be placed on the design of future studies, including the 
stratification of patients prior to allocation of treatments based on identification of specific risk-sets. 
 
Prognostic modelling is based on multivariable analysis of time to event data and as such it is 
important to describe the statistical methods used to analyse time to event data as well as 
presenting clinical results. This thesis is organised into 10 chapters: Chapter 2 presents the 
clinical setting and background to pancreatic cancer, Chapter 3 introduces the standard statistical 
methods for analysis of time to event data, Chapters 4 and 5 provide an introduction to prognostic 
indices (Chapter 4) and the statistical methods for prognostic modelling (Chapter 5), Chapters 6 
and 7 discuss the underlying assumption of linearity between a predictor and outcome (Chapter 6) 
and presents a comparison of methods for dealing with non-linear relationships (Chapter 7), 
Chapter 8 presents further investigation of these methods in a much larger dataset of cardiac 
surgery patients, Chapter 9 provides an external validation of identified prognostic factors in 
pancreatic cancer and finally  Chapter 10 concludes with discussion, recommendations and 
direction of further research. 
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CHAPTER 2: CANCER OF THE PANCREAS 
 
 SUMMARY 
 The role of the pancreas is to make enzymes necessary to digest food and to produce 
insulin to enable the body to use glucose 
 Pancreatic cancer is the eighth most common cause of cancer death in the world, and 
fifth in the western world with poor long-term survival 
 Surgical resection is the only „curative‟ treatment performed in approximately 10%-15% 
patients 
 For the majority of patients with un-resectable tumours, standard treatment is the 
administration of gemcitabine chemotherapy 
 The aim of this research is to identify prognostic factors and prognostic subgroups of 
patients with advanced pancreatic cancer for appropriate targeting of therapies 
 Identification of important prognostic factors is desirable to enable accurate stratification 
of patients in randomised controlled trials 
 
2.1. Introduction 
The aim of this chapter is to provide a background to pancreatic cancer including world-wide 
incidence, survival and treatment. Known risk factors and treatments for pancreatic cancer are 
summarised and the example dataset is introduced. 
 
2.2. The Pancreas 
The pancreas is a solid gland which is 20 to 25cm in length, 4 to 6cm in width and 3 to 4cm in 
depth (Figure 2.1, provided by JP Neoptolemos). It is divided into 5 parts: the head, uncinate 
process, neck, body and tail and is attached in the back of the abdominal cavity behind the 
stomach. 
 
CHAPTER 2: CANCER OF THE PANCREAS 
5 
 
Figure 2.1: Location of the Pancreas 
 
 
The pancreas has two roles: i) to make enzymes necessary to digest food (carbohydrates, 
proteins and fats) in the intestines and ii) to produce insulin to enable the body to use glucose. 
Digestive enzymes and insulin are made by different parts of the pancreas. There are more than 
30 enzymes produced by groups of glands in the pancreas each responsible for breaking down 
different food types. The main enzymes are amylase (carbohydrate digestion), trypsin (digesting 
proteins) and lipase (digesting fat). Enzymes are collected in the main pancreatic duct and 
released into the duodenum where they are activated by duodenal juice. The pancreatic duct and 
the bile duct join together so pancreatic juice and bile can be emptied together since pancreatic 
enzymes and bile acid are both needed for fat digestion. Bile acid is produced by the liver and 
stored by the gall bladder and disperses fat before pancreatic enzymes break it down. If a 
pancreatic tumour blocks the main bile duct then bile acid is not released into duodenum but 
dispersed into blood system and out of the body through kidneys, which results in the eyes and 
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skin turning yellow due to a build up of bilirubin, known as obstructive jaundice. Tumours which 
block the pancreatic duct lead to poor digestion and weight loss. Insulin is a hormone to control 
the level of sugar in the blood by allowing glucose to pass into the body‟s cells. Glucose is 
required by all of the body‟s cells as a source of energy. Without insulin, glucose does not pass 
into the cells but remains in the blood causing diabetes mellitus. Insulin is made in cells mainly in 
the tail of the pancreas. Enzyme and insulin production are made by distinct populations of 
pancreatic cells.  
 
2.3. Cancer of the Pancreas 
Pancreatic cancer is one of the less common cancers ranking thirteenth in incidence worldwide, 
eleventh most common cancer in the UK (Cancer Research UK, 2010) with peak incidence being 
in the 65-75 age group (Parkin et al., 2005). Pancreatic cancer accounted for 232,306 cases and 
227,023 deaths in 2002 worldwide (Figure 2.2 (Parkin et al., 2005), adapted). In the UK there 
were 7,660 new cases in 2006 and 7,727 deaths in 2007 (Table 2.1 (Cancer Research UK, 2010), 
adapted). As such, pancreatic cancer is the eighth most common cause of cancer death in the 
world and fifth in the western world (Jemal et al., 2003;Parkin et al., 2005). Generally pancreatic 
cancer presents in older patients, only about 10% of patients present aged less than 50 years.  
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Figure 2.2: Worldwide Incidence and Mortality by Sex and Site, 2002 
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Table 2.1: Pancreatic Cancer Statistics – Key Facts 
Pancreatic Cancer UK Males Females Persons 
Number of new cases (UK 2006) 3731 3929 7660 
Rate per 100,000 population* 10.3 8.1 9.1 
Number of deaths (UK 2007) 3742 3985 7727 
Rate per 100,000 population* 10.0 7.9 8.9 
One-year survival rate (patients 
diagnosed 1998 to 2001, England) 
13% 13% NA 
Five-year survival rate (patients 
diagnosed 1998 to 2001, England) 
3% 2% NA 
* age-standardised to the European population; NA=not available 
 
Approximately 80% of patients present with a tumour located in the head of the pancreas. The 
most common type is the ductal adenocarcinoma arising from small ducts of the pancreas and 
accounting for 90% of all pancreatic cancers. The prognosis of pancreatic cancer patients is 
primarily based on resectability of a solitary tumour. Patients undergoing „curative resection‟ of a 
single primary tumour are associated with improved survival but curative resection is only possible 
in approximately 10 to 15% of patients (Alexakis et al., 2004;Sener et al., 1999). Significant 
improvements in surgical outcome have been obtained with increasing specialisation (Birkmeyer 
et al., 1999;Neoptolemos et al., 1997). Most failures following surgery are due to local recurrence 
or liver metastases which occur within one or two years. In over 85% of patients, pancreatic 
cancer is diagnosed at a stage of disease too advanced for curative surgery when the disease is 
largely resistant to conventional cancer treatments (chemotherapy, radiotherapy). 
 
Long-term survival remains poor with the reported overall 5-year survival rates of 0.4% to 4% 
(Bramhall et al., 1995;Carr et al., 1999;Jemal et al., 2003) and 5 to 25% for patients undergoing 
resection  (Beger, 1995;Bramhall et al., 1995;Carr et al., 1999;Neoptolemos et al., 2004;Stocken 
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et al., 2005;Yeo, 1998) with higher rates achieved in patients receiving treatment at specialised 
centres (Gordon et al., 1995;Sosa et al., 1998). For patients diagnosed in England and Wales, 
approximately 13% of patients survive longer than 12 months from diagnosis and only 2 to 3% 
survive longer than five years (Figure 2.3 (Cancer Research UK, 2010), adapted). Further benefits 
in survival are anticipated by identifying risk groups by which to target treatments. 
 
Figure 2.3: One- and five- year Relative Survival by Age and Sex, Patients Diagnosed with 
Pancreatic Cancer, England, 1998 to 2001, followed to the end of 2003 
 
 
 
2.4. Risk Factors 
Tobacco smoking is the single most defined risk factor and is said to account for up to one third of 
pancreatic cancers: smokers having double the risk compared to non-smokers (Doll et al., 
1994;Lin et al., 2002;Silverman et al., 1994) based on a dose-response relationship. Two benign 
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diseases: pancreatitis and diabetes, are associated with increased risk of pancreatic cancer. 
Patients with hereditary pancreatitis have a cumulative risk of pancreatic cancer at age 70 of 40% 
increasing to 75% with paternal inheritance (Howes et al., 2004;Lowenfels et al., 1997). Gene 
mutations have been identified which now allows screening of these families. Onset of type II 
diabetes has been associated with onset of pancreatic cancer and is present in over 50% of 
pancreatic cancer patients, the majority being diagnosed within two years (Everhart and Wright, 
1995;Huxley et al., 2005). The risk of developing pancreatic cancer in patients having diabetes for 
less than five years was doubled (odds ratio=2.1, CI=1.9 to 2.3) (Huxley et al., 2005). 
 
2.5. Surgical Treatment 
Surgical resection of a solitary tumour is the only „curative‟ treatment which can improve the 
outlook for patients (Wagner et al., 2004) but only 10% to 15% patients are eligible for the 
procedure due to advanced disease. The first successful resection was performed by German 
surgeon Kausch in 1909 as a two-stage operation. In 1942 Whipple perfected the procedure into a 
one-stage resection, similar to the operation performed today. The Kausch-Whipple resection is 
associated with post-operative weight loss. The modified pylorus-preserving Whipple resection 
preserves the stomach, pylorus and part of the duodenum and although less radical, is not 
associated with decreased survival (Bassi et al., 2005). Removal of a pancreatic cancer by 
resection is a major procedure with low surgical mortality, 2% if performed by experienced 
surgeon (Cameron et al., 1993) but with a high complication rate of 40% (Bassi et al., 2005).  
 
When resection is not possible, palliative surgery (biliary bypass) may relieve biliary or duodenal 
obstruction which can cause jaundice and pain. Older patients who may not be suitable, may have 
their jaundice relieved by inserting a tube (stent) through the tumour. If surgery is not performed 
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then symptoms of jaundice, pain, weight loss, pancreatic insufficiency, fatigue and depression 
need to be palliated medically. 
 
2.6. Chemotherapy and Radiotherapy Treatments 
Only two chemotherapy single agents have produced reproducible survival benefit: 5-fluouroracil 
(5-FU) and gemcitabine. These single agents have also been studied in combination with other 
drugs, notably folinic acid (FA) with 5-FU and platin based agents with gemcitabine. For those 
patients who undergo resection of their tumour, standard treatment in the UK is administration of 
adjuvant (postoperative) 5FU/FA chemotherapy, following the first large (n=289) randomised 
controlled trial (ESPAC-1) investigating the roles of both chemotherapy and radiotherapy 
treatments (Neoptolemos et al., 2004;Neoptolemos et al., 2001a;Stocken et al., 2005). Final 
analysis of the ESPAC-1 trial reported a 29% decreased risk of death with chemotherapy (hazard 
ratio=0.71, 95%CI: 0.55 to 0.92) (Neoptolemos et al., 2004), a benefit confirmed in a subsequent 
meta-analysis (hazard ratio=0.75, 95%CI: 0.64 to 0.90) (Stocken et al., 2005) and in analysis of 
composite data with the continuation ESPAC-3 trial (hazard ratio=0.70, 95%CI: 0.55 to 0.80) 
(Neoptolemos et al., 2009b). For the majority of patients with un-resectable tumours, standard 
treatment in the UK is the administration of gemcitabine (NICE, 2010), following a randomised 
controlled trial comparing gemcitabine and 5-FU (Burris et al., 1997). Clinical benefit response (a 
composite of measurements of pain, performance status and weight) was used as the primary 
measure of efficacy and the trial concluded gemcitabine to be more effective in alleviating disease 
related symptoms in a total of 126 patients.  
 
Recently two large, international, phase III trials compared gemcitabine (the standard treatment 
from the advanced setting) as an experimental treatment in the adjuvant setting; one compared 
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with a control arm (Oettle et al., 2007) and one compared against the standard 5FU/FA treatment 
(Neoptolemos et al., 2009a). A significant benefit for adjuvant chemotherapy compared with 
control was seen in 368 patients based on disease free survival (DFS) (Oettle et al., 2007). 
Median DFS for adjuvant gemcitabine was 13.4 (95%CI: 11.4 to 15.3) months compared with a 
median DFS of 6.9 (95%CI: 6.1 to 7.8) months for control, affirming the need for a trial comparing 
5FU/FA and gemcitabine. ESPAC-3 concluded that there was no significant survival difference 
between adjuvant gemcitabine and adjuvant 5FU/FA in 1088 patients (hazard ratio=0.94, 95%CI: 
0.81 to 1.08) but that the toxicity profile was more favourable for gemcitabine (Neoptolemos et al., 
2009a). This highlights how evidence for treatment in the advanced setting can pave the way for 
treatment to be investigated in the adjuvant setting and thus the need for all evidence to be robust 
and trustworthy. Similarly, a recent, large, Cancer Research UK trial (GEMCAP) including a meta-
analysis comparing standard gemcitabine treatment in the advanced setting with combination 
gemcitabine and capecitabine treatment has concluded an advantage for the combination 
treatment (meta-analysis hazard ratio=0.86, 95%CI: 0.75 to 0.98) (Cunningham et al., 2009) 
paving the way for the ongoing Cancer Research UK adjuvant trial (ESPAC-4) comparing the 
gemcitabine and capecitabine combination against gemcitabine alone.  
 
Use of adjuvant radiotherapy is not universal due to results of the first large (n=289) randomised 
controlled trial (ESPAC-1) showing a 28% increased risk of death in patients receiving adjuvant 
chemo-radiotherapy (hazard ratio=1.28, 95%CI: 0.99 to 1.66) (Neoptolemos et al., 2004). Initially 
defined in a ground-breaking study, the north American gastrointestinal study group (GITSG) 
reported a survival benefit for adjuvant chemo -radiotherapy in a study of 43 patients where 
median survival was 20 months in patients receiving chemo-radiotherapy compared with 11 
months without (Kalser and Ellenberg, 1985), hazard ratio not presented but estimated as 0.54 
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(95%CI: 0.27 to 1.05) (Stocken et al., 2005). Though the trial has been criticised for being small 
and with uncertainty surrounding the estimated treatment effect (wide confidence interval 
surrounding the estimated hazard ratio), it was regarded as sufficient evidence for the American 
National Cancer Institute (NCI) to recommend surgery plus chemo-radiotherapy as standard 
treatment in the United States. However the study required confirmation before being adopted as 
standard of care in Europe but the first large (n=289) randomised controlled trial has since shown 
no survival benefit for chemo-radiotherapy (Neoptolemos et al., 2004;Neoptolemos et al., 2001a). 
 
Neoadjuvant treatment is treatment given prior to any planned surgery to improve resectability of 
the primary tumour and minimising any remaining residual disease. Neoadjuvant treatment could 
be chemotherapy, radiotherapy or a combination but to date early phase studies (Palmer et al., 
2007) have not led to any large phase III trial. 
 
2.7. Example Dataset in Advanced Pancreatic Cancer 
This thesis is predominantly based on analysis of data from patients with advanced pancreatic 
cancer. Initially, statistical modelling was carried out on a dataset collated by British Biotech 
combining data from two international studies (Bramhall et al., 2002;Bramhall et al., 2001). 
External validation was carried out using an external dataset from the Cancer Research UK 
GEMCAP trial (Cunningham et al., 2009). However, during the research, an additional dataset of 
cardiac surgery patients became available (Pagano et al., 2009) and due to suitability further 
methodologically driven analyses were able to be carried out on these data. The initial dataset 
from 653 advanced pancreatic cancer patients collated by British Biotech is described below. 
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Two international phase III randomised controlled trials (BB128 (Bramhall et al., 2001) and BB193 
(Bramhall et al., 2002)) randomised 414 and 239 patients with advanced pancreatic cancer 
respectively: BB128 randomised patients between marimistat and gemcitabine; BB193 
randomised patients between marimistat with gemcitabine and gemcitabine alone. The studies 
had similar eligibility criteria: histologically or cytologically unresectable pancreatic cancer, within 8 
weeks of diagnosis or disease recurrence and Karnofsky performance status (KPS) of >50% 
(BB128) or >60% (BB193). Previous therapy for metastatic or locally advanced disease was an 
exclusion criteria. The primary outcome measure in both studies was survival time calculated from 
the date of randomisation to date of death from any cause. Randomisation was stratified by 
cancer stage (stage I/II, III or IV), KPS (50 to 70%, 80 to 100%), sex and study centre. On average 
patients in the two trials were randomised 20 and 15 days after diagnosis and started treatment 
the day following randomisation. The average age of patients was 63 years (range 29 to 89), 368 
(56%) were male, 439 (68%) had cancer stage IV disease, 436 (67%) presenting with metastases 
and 251 (39%) had lymph node involvement (Table 2.2). No significant survival benefit for 
marimastat over gemcitabine was seen in the BB128 trial (p=0.19) (Bramhall et al., 2001). 
Similarly no significant survival benefit was seen for combination gemcitabine and marimistat over 
gemcitabine alone in the BB193 trial (p=0.95) (Bramhall et al., 2002). 
CHAPTER 2: CANCER OF THE PANCREAS 
15 
 
Table 2.2: Patient Characteristics by Trial 
Variable BB128 
N=414 (63%) 
BB193 
N=239 (37%) 
TOTAL 
N=653 (100%) 
DEMOGRAPHICS 
* Age at entry 
(years) 
    Median 
Range 
63 
29 to 89 
62 
32 to 85 
63 
29 to 89 
Ethnic race White 
Black 
Oriental 
Other 
Missing 
364 (88%) 
27 (6%) 
7 (2%) 
15 (4%) 
1 
226 (95%) 
8 (3%) 
0 
5 (2%) 
0 
590 (90%) 
35 (6%) 
7 (1%) 
20 (3%) 
1 
Sex Male 
Female 
228 (55%) 
186 (45%) 
140 (59%) 
99 (41%) 
368 (56%) 
285 (44%) 
Treatment Gemcitabine 
Marimistat 
103 (25%) 
311 (75%) 
119 (50%) 
120 (50%) 
222 (34%) 
431 (66%) 
TUMOUR INFORMATION 
Cancer stage I 
II 
III 
IV 
Missing 
19 (4%) 
45 (11%) 
76 (19%) 
268 (66%) 
6 
13 (5%) 
27 (11%) 
28 (12%) 
171 (72%) 
0 
32 (5%) 
72 (11%) 
104 (16%) 
439 (68%) 
6 
Distant 
Metastases 
M0 
M1 
Missing 
129 (31%) 
265 (64%) 
20 (5%) 
65 (27%) 
171 (72%) 
3 (1%) 
194 (30%) 
436 (67%) 
23 (3%) 
Regional lymph 
nodes 
N0 
N1 
Missing 
153 (37%) 
164 (40%) 
97 (23%) 
90 (38%) 
87 (36%) 
62 (26%) 
243 (37%) 
251 (39%) 
159 (24%) 
Primary tumour T 
stage 
T0 
T1 
T2 
T3 
T4 
Missing 
5 (1%) 
114 (30%) 
90 (24%) 
167 (44%) 
6 (1%) 
32 
3 (1.5%) 
44 (20%) 
54 (25%) 
113 (53%) 
1 (0.5%) 
24 
8 (1.5%) 
158 (26%) 
144 (24%) 
280 (47%) 
7 (1.5%) 
56 
SERUM CHEMISTRY and HAEMATOLOGY 
Laboratory Variables 
* AST (SGOT) IU/L 
* TOTAL BILIRUBIN mol/L 
* ALK PHOSPHATASE IU/L 
* ALBUMIN g/L 
* LDH IU/L 
* BUN mmol/L 
* CA19/9 KU/l 
* HAEMOGLOBIN g/dL 
* WBC 109/L 
Median (Range), Missing 
24 (6 to 365), 17 
13.7 (3.4 to 277.0), 16 
136 (36 to 1660), 16 
38 (22 to 47), 17 
163 (77 to 1074), 21 
9.2 (2.9 to 34.3), 17 
686 (5 to 1,000,000), 17 
12.5 (5.5 to 16.1), 28 
7.6 (2.3 to 31.6), 28 
Median (Range), Missing 
26 (9 to 538), 12 
13.7 (3.0 to 135.1), 8 
157 (35 to 2064), 8 
38 (24 to 47), 8 
169 (29 to 1495), 11 
9.3 (4.3 to 27.9), 16 
800 (8 to 1,000,000), 30 
12.4 (8.3 to 19.1), 13 
8.3 (2.4 to 23.7), 13 
Median (Range), Missing 
25 (6 to 538), 29 
13.7 (3.0 to 277.0), 24 
140 (35 to 2064), 24 
38 (22 to 47), 25 
164 (29 to 1495), 32 
9.3 (2.9 to 34.3), 33 
710 (5 to 1,000,000), 47 
12.4 (5.5 to 19.1), 41 
7.9 (2.3 to 31.6), 41 
OUTCOME 
Event indicator Alive 
Dead 
22 (5%) 
392 (95%) 
19 (8%) 
220 (92%) 
41 (6%) 
612 (94%) 
* Follow-up of 
alive (months) 
Median 
Range 
20.1 
0.9 to 24.6 
19.4 
1.9 to 23.3 
20.7 
0.9 to 24.6 
* = continuous measurements 
CHAPTER 2: CANCER OF THE PANCREAS 
16 
 
2.8. Conclusion 
The British Biotech dataset provides a representative dataset of patients with advanced pancreatic 
cancer. The dataset combined two randomised controlled trials both based on similar eligibility 
criteria and both showing no differences in survival of the experimental treatment group. The 
dataset contains eighteen baseline clinical, histological, biochemical and demographic variables 
(including trial and treatment variables) considered appropriate for analysis, eight of which are 
categorical variables and 10 which are continuous measurements. It is a robust dataset containing 
a high event rate and long follow-up of alive patients. Appropriate statistical methods for the 
analysis of this kind of time to event data are described in the next chapter. 
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CHAPTER 3: SURVIVAL AND HAZARD FUNCTIONS 
 
 SUMMARY 
 Time to event data differs from continuous data due to censoring 
 Statistical analyses should utilise methods which account for censored data 
 Survival data can be summarised through estimates of the survivor function and the 
hazard function estimated from observed data 
 Kaplan-Meier estimates of survival account for death times and censored survival times 
and can be compared using the log-rank non-parametric test 
 The hazard ratio is the ratio of hazard rates and is used as a summary of the risk in one 
group of patients compared to another  
 Many survival analysis methods assume the hazard ratio is constant over time 
(proportional hazards) 
 
3.1. Introduction 
The aim of this chapter is to introduce the basic statistical methods used to analyse time to event 
(or survival) data. Typically patients are entered into a study over a period of time and followed 
post-treatment for assessment of the endpoint of interest, such as death, disease progression and 
so on. Time to event is usually defined as the time from entry into the study to time of the endpoint 
of interest. Not all patients in the study will experience the endpoint of interest and it is impractical 
and unethical to delay analysis until all patients have experienced this endpoint. Some patients 
may not have experienced the event since they i) have become „lost to follow-up‟ in the study 
through withdrawing from the study, ii) are deemed to be „cured‟ or iii) are entered later in 
recruitment phase with shorter but unbiased follow-up. Patients who are lost to follow-up or who 
do not experience the event of interest are (right) censored in the analysis and are treated 
differently than just patients with missing data. Censored patients are known to have „survived‟ 
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event-free for a certain length of time but the time of their event is unknown and is beyond the 
date they were last seen event free, known as the censor date (Figure 3.1 (Machin et al., 2006), 
adapted): 
 
Figure 3.1: Censored Survival Data 
 
 
 
 
 
 
 
 
 
Characteristically time to event data differs from continuous data due to this censoring. Censored 
survival times hold information about a patient‟s survival time up to the date of censor and should 
not be ignored just because the patient has not experienced the event of interest. Statistical 
analysis should utilise methods which account for censored data to avoid losing this important 
information and this makes analysis of time to event data more complex. Most methods assume 
the reason for censoring is non-informative, which assumes that censoring is not associated with 
outcome, else informative censoring is said to have occurred and standard statistical methods are 
invalidated. In this research, the reason for censoring is assumed to be non-informative. Of the 
653 patients randomised, 41 patients (6%) were alive with median follow-up 20.7 months (Table 
2.2). Minimum follow-up was 0.9 months and as such all patients had some follow-up (ranging to a 
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maximum of 24.6 months). Some drop-out in clinical trials is expected. A minimal number of 
advanced pancreatic cancer patients (5 patients(<1%)) were censored before 12-months of 
follow-up, a clinically relevant and reported time-point in advanced pancreatic cancer. Reasons for 
drop-out of the censored patients were not available. However, it is likely that drop-out is related to 
the fact that these are poorly patients, receiving toxic chemotherapy treatment with average age 
63 years, but not related to death and as such does not invalidate the assumption of non-
informative censoring. 
 
3.2. Survivor and Hazard Functions 
The distribution of survival data is generally described by two functions: the survivor function and 
the hazard function (Collett, 1994). The survivor function S(t) is the probability that a patient 
survives from the time or origin (entry to trial) to sometime beyond time t : 

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where T is a random variable associated with survival time with a probability density function f(t) 
and associated cumulative distribution function F(t), defined as the probability that survival time is 
less than some value t . 
The hazard function h(t) is approximately the probability of death between time t and t+δt , 
conditional on having survived up to time t : 
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where the probability that random variable T lies between time t and t+δt is conditional on T being 
>t.  h(t) then represents the instantaneous rate of death . 
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The survivor, hazard and probability density functions can be estimated from each other and as 
such the hazard function can be presented as a as a conditional failure rate and as a function of 
survival: 
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Survival data can be summarised through estimates of the survivor function and the hazard 
function and can be estimated from observed data using non-parametric methods if the form of f(t) 
is not specified, or else parametrically.  
 
3.3. Estimation of the Survivor Function  
The overall probability of survival to time t  (Machin et al., 2006) is: 
S(t) = p1 x p2 x p3 x … x pt  
where p1 is the probability of surviving at least to time 1, p2 is the conditional probability of 
surviving time 2 having survived time 1 and so on where time could be in days, months, years 
depending on the disease in question. For any time t: 
pt =  [number of patients followed for at least (t-1) and who survive time t] 
  [number of patients alive at the end of time (t-1)] 
Deaths occur at distinct times t1 < t2 < t3…tn where tn is the maximum death time observed. It then 
follows: 
pt =  (nt-dt)  or  pt = 1 - dt 
 nt nt 
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where nt denotes the number of patients alive at the start and at risk of death during short interval 
(t, t+1), dt denotes the number of deaths during the interval hence the number of patients surviving 
being nt-dt. As such the value of S(t) only changes when dt ≠ 0 so: 
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S(1), S(2), …., S(t) are known as the Kaplan-Meier estimates of survival, also known as the 
product-limit estimates (Kaplan and Meier, 1958). As shown, the Kaplan-Meier estimate of survival 
accounts not only for death times but also censored survival times utilising all information. A useful 
summary of survival data is a plot of the estimates of survival S(t) against t from which the median 
(where S(t)=0.5) and other percentiles of the distribution of survival times can be estimated. 
Survival curves are plotted as step functions since estimates of survival are assumed constant 
between death times. The number of patients remaining at risk should be indicated on the plot to 
provide information regarding the reliability of the survival estimates over time which are 
influenced by large proportions of censored patients. Confidence intervals for the survivor function 
may provide an indication of reliability of the survival estimates but are not a very efficient way of 
assessing the data being estimated at fixed time points. 95% confidence intervals can be 
calculated assuming a Normal distribution as S(t) + 1.96*se[S(t)]. The standard error (se) of the 
survivor function can be calculated using different methods (Collett, 1994;Machin et al., 2006). 
The LIFETEST procedure in  (SAS Institute Inc., 1999) calculates Kaplan-Meier estimates of 
survival with standard errors calculated using Greenwood's formula (Kalbfleisch and Prentice, 
1980) producing summary statistics and plots of survival estimates. 
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3.4. Comparison of Survivor Functions 
A test statistic measures the extent to which observed data depart from a null hypothesis, usually 
of no difference, across groups. The probability of obtaining data as extreme, or more extreme, 
when the null hypothesis is true provides the strength of evidence known as the p-value. A large 
p-value indicates it is likely to obtain the observed data if the null hypothesis, of no difference 
between groups, was true. A smaller p-value indicates increasing evidence against the null 
hypothesis to a point where the null hypothesis could be rejected. Although the p-value provides a 
measure of evidence to reject the null hypothesis, often the important information in prognostic 
factor studies is the estimation of prognostic ability of covariates including the actual direction of 
the estimated effect which can obtained from descriptive statistics (e.g. median survival estimates) 
and associated confidence intervals. 
 
The log-rank non-parametric test (also called the Mantel-Cox test) is the most widely used test to 
quantify the extent of any difference between groups of survival data containing censored 
observations. The advantage of this test is that it compares survival estimates across the duration 
of the curve not at a single particular time point, which can be misleading and inefficient. The log-
rank test statistic (Collett, 1994) is based on comparing expected number of deaths under the null 
hypothesis of no difference between groups with the observed number of deaths at each of the 
successive distinct death times t1 < t2 < t3…tn and is calculated as: 
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where g is the number of groups being compared. The log-rank test statistic is compared against 
percentage points of a chi-square distribution with g-1 degrees of freedom and determined to be 
significantly different or not at a particular significance (error) level, usually 5%. Other alternative 
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versions of the log-rank test are available when the number of events is small or the assumption 
of proportional hazards is violated (Machin et al., 2006). 
 
3.5. Estimation of the Survivor Function in Advanced Pancreatic Cancer 
A total of 653 patients with advanced pancreatic cancer were randomised. The majority of patients 
(612, 94%) had died by the time of analysis with a median follow-up time of 21 months for the 41 
patients still alive. The median survival estimate for the overall group was 4.7 months (95%CI: 4.2 
to 5.1) with 12-month survival estimate of 17.4% (95%CI: 14.5% to 20.3%). Median survival 
estimates were 4.2 (95%CI: 3.6 to 4.8) and 5.4 (95%CI: 4.8 to 6.0) for BB128 and BB193 
respectively with corresponding 17.0% (95%CI: 13.4% to 20.6%)and 17.9% (95%CI: 13.0% to 
22.8%)12-month survival estimates. Survival estimates did not differ significantly at the 5% level 
across the two trials (2LR=2.28, p=0.13, Figure 3.2):  
 
Figure 3.2: Survival Function by Trial 
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3.6. Estimation of the Hazard Function  
The risk of death at a particular time point t, or hazard rate h(t), can be estimated within specific 
small time intervals and is the risk of death within the interval given that a patient has survived to 
the start of that interval. It is estimated as a ratio of the number of deaths divided by the number at 
risk of death within the interval based on individual patient follow-up. There are various methods 
but the Kaplan-Meier method again defines time intervals based on actual death times at distinct 
times t1 < t2 < t3…tn where tn is the maximum death time observed. The Kaplan-Meier estimate of 
the hazard function (Collett, 1994) at time t is: 
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where dj is the number of deaths in the interval tj < t < tj+1, nj is the number of patients at risk at 
time tj and j is the width of the interval tj  < t  < tj+1  assuming the hazard function is constant 
between successive death times as with the Kaplan-Meier estimate of the survivor function. 
 
3.7. The Hazard Ratio 
At any time t the hazard ratio for two groups of patients is the ratio of the hazard rates at that time. 
The overall hazard rate over the whole follow-up period for a specific group of patients can be 
calculated using the observed and expected values calculated using the log-rank method. The 
hazard ratio (HR) is simply a ratio of the two hazard rates estimated as: 
BB
AA
EO
EO
HR   
where OA and OB are the observed numbers of deaths in groups A and B respectively and EA and 
EB are the expected numbers of deaths in groups A and B calculated using the log-rank method. A 
hazard ratio = 1 indicates equal hazard rates in the two groups. A hazard ratio < 1 indicates the 
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hazard of death is less for a patient in group A relative to a patient in group B. For the situation 
where there are only two groups, the log-rank test is testing the null hypothesis that the hazard 
ratio = 1.  95% confidence intervals for the hazard ratio cannot be calculated assuming a Normal 
distribution since possible values of the HR range from 0 to .  Log HR is approximately normally 
distributed which enables a 95% confidence interval to be based on: log HR + 1.96*se[log HR]. 
The standard error (se) of log HR can be calculated using: 
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A confidence interval spanning unity would indicate a non-significant or borderline significant 
difference in hazard rates between the two groups. As with the log-rank test, other alternative 
versions of the hazard ratio and confidence intervals are available when the number of events is 
small (Machin et al., 2006).  
 
Many survival analysis methods are based on the assumption of proportional hazards, that the 
hazard ratio is constant over time. The validity of this can be examined using a log cumulative 
hazard plot: a plot of log(-log[S(t)]) vs. log t where S(t) is the Kaplan-Meier estimate of the survivor 
function. With proportional hazards the curves for the groups should be approximately parallel. 
The PHREG procedure in SAS (SAS Institute Inc., 1999) calculates hazard ratios with 95% 
confidence intervals. The LIFETEST procedure in SAS plots log cumulative hazard curves. 
 
3.8. Estimation of the Hazard Function in Advanced Pancreatic Cancer 
Hazard rates were estimated for one-monthly time intervals to 18 months from trial entry and 
appeared similar for both trials and reasonably constant over time (Figure 3.3): 
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Figure 3.3: Monthly Hazard Rates by Trial 
 
 
 
 
 
 
 
 
 
 
 
The hazard ratio (HR) of the relative risk of death across the two studies was estimated HR=0.88 
for BB193 compared to BB128, indicating an overall 12% reduction in the risk of death in the 239 
patients in the BB193 trial compared to the 414 patients in the BB128 trial. The 95% confidence 
interval was (95%CI: 0.75 to 1.04) indicating that 95% of calculated intervals will contain the true 
HR, estimated in this sample to lie somewhere between a 25% reduction and a 4% increase in the 
risk of death for BB193 patients compared to BB128 patients. The confidence interval provides a 
range of values for the true HR estimated from the available data but with increasing uncertainty 
at the limits of the interval. The fact that the confidence interval spans unity also confirms the lack 
of any statistically significant difference between the two trials as previously reported by the log-
rank test statistic. 
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The assumption of proportional hazards was investigated using a log cumulative hazard plot and 
showed curves for the two trials to be approximately parallel (Figure 3.4): 
 
Figure 3.4: Log Cumulative Hazard Plot by Trial 
 
 
3.9. Conclusion 
Prognostic modelling, described in Chapter 4, is based on multivariable analysis of time to event 
data, described in Chapter 5, so it is important to describe the basic statistical methods used to 
analyse time to event data which are more complex due to censored data. The Kaplan-Meier 
estimates of survival for this dataset (12-month survival rate estimated as 17%) are similar to 
those reported in Chapter 1 (12-month survival rate for England and Wales reported as 13%). 
Alive patients have been followed for almost two years and the 2-year survival estimate (not 
plotted) is estimated as 3.6% (5-year rates reported as 0.4 to 4%, Chapter 1). As such, this 
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dataset provides data from a representative sample of patients with advanced pancreatic cancer, 
based on estimated survival distributions. The survival distributions do not appear to be 
significantly different across the two trials. The hazard ratio does not indicate a significantly 
different hazard rate for either trial. The hazard function appears constant over time and similar 
across the two trials. As such, there does not appear to be any significant factor why the trial data 
from the two studies may not be merged for investigating potential prognostic factors. Statistical 
methods should always account for the fact that patients come from two trials and also that 
patients have been randomised to different treatment groups, even if these effects appear non-
significant. The assumption of proportional hazards does not appear to be violated. Methods for 
assessing the prognostic ability of variables and developing prognostic indices are described in 
the next chapter. The statistical methods for identifying prognostic factors in the multivariable 
setting are described in Chapter 5. 
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CHAPTER 4: PROGNOSTIC INDICES 
 
 SUMMARY 
 Prognostic factor studies are intended to help clinicians in their decision making 
 A prognostic index is a clinical tool to predict the survival of patients after diagnosis 
 Evidence is also relevant for the appropriate design and analysis of cancer research 
 36 studies reported 34 possible prognostic factors for advanced pancreatic cancer, the 
majority questionable in terms of sample size and statistical methods  
 Published studies are often contradictory and as such few prognostic markers are in use 
 Prognostic studies should adopt a multivariable approach 
 Model validation is important to assess the extent of over-fitting and thus external validity 
and where possible should be conducted using an independent dataset 
 As such, model validation can be seen as a continuing process with the availability of new 
data 
 Internal model validation methods (the non-parametric bootstrap) allow assessment of the 
validity and stability of selected prognostic factors in the absence of independent data 
 Complete case analysis can result in biased or imprecise regression coefficients if 
missing data are not missing at random  
 Analysis of a complete dataset based on multiple imputation could be informative 
 
4.1. Introduction 
The aim of this chapter is to discuss the important methodological issues surrounding 
identification of prognostic factors and the development of a prognostic index including model 
validation techniques and dealing with missing data.  
 
The goal of prognosis is to predict the future. A prognostic index is a tool used by clinicians to 
predict the survival of patients after diagnosis. Prognosis may change over time but in terms of 
patient management is frozen at a specific time (often time of diagnosis) to enable treatment plans 
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to be put in place. Prognosis may be modified by therapy and assessment of possible prognostic 
factors is often the first step in determining a patient treatment plan. Comprehensive prognosis 
(Gospodarowicz et al., 2001) reflects the expected outcome of all potential competing risks not 
just those associated with the illness in question. Medical decision making is carried out on a daily 
basis based on comprehensive prognosis which is most relevant to the individual patient. 
Prognostic factor studies are intended to help clinicians in their decision making. Evidence of 
prognostic factors is also relevant for the appropriate design and analysis of evaluative research. 
Identification of important prognostic factors can contribute to the eligibility criteria and 
stratification of patients to ensure balance of these important factors across each treatment group 
in randomised controlled trials. The more the variability in outcome due to prognostic factors can 
be minimised, the more confident research can be of the true efficacy of a treatment. Similarly 
determination of prognostic factors can identify which subgroups of patients could be explored for 
their response to specific treatments and highlight poorer prognostic groups suitable for more 
experimental or palliative treatments. The purpose of prognostic factor studies was summarised in 
an evaluation of prognostic factors in breast cancer (Altman, 2001;Altman and Lyman, 1998) and 
include (Table 4.1): 
 
Table 4.1: Purpose of Prognostic Factor Studies 
 To guide clinical decision making, including treatment selection and patient counselling 
 To improve understanding of the disease process 
 To improve the design and analysis of clinical trials (for example, risk stratification) 
 To assist in comparing outcome between treatment groups in non-randomised studies 
allowing adjustment for case mix 
 To define risk groups based on prognosis 
 To predict disease outcome more accurately or parsimoniously 
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Prognostic factor studies tend to fall into two categories: exploratory or confirmatory 
(Gospodarowicz et al., 2001). Most are exploratory studies, usually with no pre-specified 
hypotheses involving multiple data-driven analyses of multiple factors, endpoints and subgroups, 
but reporting only those which show statistical significance. Poorly designed studies often yield the 
most dramatic but probably incorrect and misleading results yet may achieve a wide audience in 
inadvertently published in reputable journals. As such these exploratory studies tend to have 
misleading conclusions and are often inconsistent and contradictory, limiting their potential 
application and as a consequence few prognostic markers are in use. Confirmatory studies, to the 
contrary, are prospective studies with pre-defined hypotheses, endpoints and subgroups resulting 
in limited analyses. At least one confirmatory study should be carried out before a new prognostic 
factor or prognostic index is considered for use in clinical practice. Important characteristics of a 
confirmatory prognostic factor study (Simon and Altman, 1994) include (Table 4.2): 
 
Table 4.2: Characteristics of a Confirmatory Prognostic Factor Study 
 Treatment should be standardised or randomised and accounted for in the analysis 
 Hypotheses should be stated in advance, including specification of prognostic factors, 
coding of prognostic factors, endpoints and subsets of patients and treatments 
 Sample size and number of events should be sufficiently large that statistically reliable 
results are obtained. There should be at least 10 events per prognostic factor examined 
per subset analysed 
 Analyses should assess whether new factors add predictiveness after adjustment for or 
within subsets determined by known standard prognostic factors 
 Consideration should be given to the number of analyses conducted 
 Cut-off values for prognostic factors should be pre-specified or preferably avoided 
 
Both the American Joint Cancer Committee (AJCC) and International Union Against Cancer 
(UICC) encourage only statistically significant and independent prognostic factors be considered 
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for use in clinical practice based on multivariable analyses of large prospective datasets with 
sufficient evidence to detect small but clinically relevant differences in outcome. However, both 
acknowledge few studies exist resulting in their alternative approach grouping tumour, host and 
environment related factors (Section 4.6, Table 4.4). Sample size calculations for prognostic factor 
studies are not straightforward and often not carried out since the data are often retrospective or 
derived for another primary purpose, such as a clinical trial. Data from randomised controlled trials 
can be used to study prognosis but if the treatment under investigation is effective then a 
„treatment‟ variable should be included as a separate factor in the multivariable model (Machin et 
al., 2006;Moons et al., 2009;Simon and Altman, 1994). There are no straightforward methods for 
estimating sample size for multivariable prognostic studies. Power formulae in survival analysis 
are based on the relatively simple case of the comparison of randomised treatment groups using 
hypothesis testing. In prognostic studies it is an accurate estimate of the size of the effect of a set 
of covariates that is important. Possible prognostic covariates may be correlated with treatment so 
existing power formulae are not valid (Schmoor et al., 2000). Prognostic factors often display a 
larger effect than treatment effects suggesting prognostic factor studies could be smaller than 
randomised controlled trials. However adjustment for correlation again increases the sample size 
and a variance inflation factor has been developed for the situation of one correlated factor 
(Schmoor et al., 2000). In survival studies it is the number of events rather than the sample size 
that is important. The number of regression coefficients being estimated should be less than the 
number of events. Ideally, studies require at least several hundred outcome events (Moons et al., 
2009). As a guide, for each potential prognostic variable under consideration there should be at 
least 10 events to obtain reasonably stable estimates for each regression coefficient (Peduzzi et 
al., 1995). In the advanced pancreatic cancer dataset there are 612 events which should be 
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adequate for stable estimation of the prognostic ability of the eighteen possible independent 
factors under investigation. 
 
A pathway to obtaining high quality evidence regarding prognostic ability of a factor (Riley et al., 
2009) and guidelines for reporting tumour marker prognostic studies (McShane et al., 2005) were 
published in an attempt to encourage large, protocol-driven prospective studies with transparent 
and complete reporting. Thus enabling sensible judgement of the usefulness of the reported data 
and explaining why so few clinically useful markers emerge from hundreds of tumour marker 
reports in oncology. Poor study design and analysis and inadequate reporting of studies were 
identified as major barriers. 
 
4.2. Statistical Development of a Prognostic Index 
In oncology, baseline data collected from identified studies at the time of randomisation into a 
randomised controlled trial may be utilised to develop a prognostic model for survival. Clinicians 
implicitly use multiple factors to estimate an individual patient‟s prognosis. As such, prognostic 
studies should adopt a multivariable approach to the design and analysis (Moons et al., 2009). 
Multivariable regression methods are used for the simultaneous and flexible assessment of 
multiple baseline factors. Although individual variables may appear to be statistically significant 
prognostic factors, two or more factors may be aliased with one another and as such explain 
similar variability in the data. Multivariable regression methods aim to select those which appear to 
influence directly the outcome of interest and discard those which do not, over and above those 
already selected as important in the regression model. Multivariable regression methods can also 
take account and allow inclusion of already recognised prognostic factors. 
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Prognostic indices are derived from the final predicted regression model yielding a prognostic 
score for each patient. Prognostic scores can be grouped to form risk groups derived from the 
prognostic index based on cut-points of the index and survival curves can be calculated for each 
of these risk groups. Survival curves for these predicted risk groups could be biased (overfitting) 
since the same data are used for selecting the prognostic model as for estimating the effect of the 
model. Overfitting can occur in the development of prognostic models including large numbers of 
covariates when some of the structure of the data has been fitted to random noise in the data and 
is a measure of poor external validity. One method to assess of the extent of overfitting and 
achieve valid accurate estimates of prognostic value is to validate the model on an independent 
external set of data. However this is often not a possibility or may be inefficient if preserving an 
independent set requires withholding data from the model building process thus compromising 
estimation of the statistical functions. An alternative method is internal model validation based on 
statistical re-sampling techniques. 
 
4.3. The Nonparametric Bootstrap 
In the absence of an external dataset, internal model validation methods based on statistical re-
sampling simulation techniques allow assessment of the accuracy of statistical estimates and of 
the stability of a set of selected prognostic factors. The nonparametric bootstrap (Efron and 
Tibshirani, 1993) is a way of using the available data to simulate new datasets had the study been 
repeated multiple times with a different sample of patients. The new simulated datasets are the 
bootstrap samples created by sampling one patient at a time with replacement from the original 
dataset up to the same size of the original set of data. Using random selection with replacement 
means that an individual patient from the original data set can be included repeatedly within a 
bootstrap sample while others may not be included at all, called bootstrap replication. This 
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process is repeated usually until a maximum number (often 200) of simulated bootstrap samples 
have been created. Since the bootstrap samples are derived from the original data, the amount of 
variability in a particular parameter estimate across all bootstrap samples should then provide an 
unbiased estimate of the stability of that estimate from the analysis of original data. Bootstrapping 
can also be used to assess the stability of a selected set of variables (Altman and Anderson, 
1989).  
 
A bootstrap depends on the original sample of data being representative. If the sample is not 
representative, conclusions will be inappropriate hence it is important that a sample is a good 
representation of the population of patients under study. Bootstrap validation methods should be 
seen as a complimentary tool, not a replacement for external validation methods. Internal 
validation methods are used to assess overfitting when modelling the advanced pancreatic cancer 
data. An external validation set was expected to become available during the project and as such 
it was anticipated that the final model could also undergo external validation. As such, data-
splitting the original dataset was avoided thus maximising the available data to detect significant 
prognostic factors, using internal validation methods until the independent, external dataset 
became available.  
 
4.4. Missing Data and Imputation 
Incomplete prognostic data is common (Burton and Altman, 2004) but problematic. Statistical 
analytical methods, including maximum likelihood estimation, generally exclude patients with 
missing prognostic data. Analyses performed on a complete case basis with a subsequent 
reduction in available data for analysis, can impede construction of reliable models and can result 
in biased or under- or overestimation of regression coefficients and overestimation of variance if 
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missing data are not missing at random (MAR) affecting prognostic ability of the covariates 
(Burton and Altman, 2004). Missing completely at random (MCAR) data are data missing for 
reasons unrelated to outcome. Missing at random data are data missing for reasons related to 
other explanatory data but not outcome. Most statistical methods for dealing with missing data 
assume data are missing at random. Guidelines for reporting prognostic studies with missing 
covariate data (Burton and Altman, 2004) are based on assessment of the i) quantification of 
completeness of covariate data, ii) approaches for handling missing covariate data, 
recommending multiple imputation and iii) exploration of missing data, providing any known 
reasons.  Methods for handling missing data include multiple imputation methods.  
 
Imputing missing values and exploratory analysis of a complete imputed dataset could be 
informative compared with excluding subjects with incomplete data (Harrell, 2001) but 
computation needs to account for the imputation. Multiple imputation methods (Rubin, 
1987;Schafer, 1997) are based on random selection from the conditional distribution of the 
variable in question in light of other variables. Imputation is repeated m times where m>3 to 
account for variability related to the imputed values. Each m repeated imputation results in a 
complete dataset analysed using standard methods. Parameter estimates are averaged over the 
multiple imputations and variability across imputed datasets is a component when deriving 
estimates of the variance, thus including an estimate of uncertainty derived from the observed 
missingness and providing better estimates than a single imputation. Multiple imputation is viewed 
as the principal analysis by some (Harrell, 2001). 
 
In the advanced pancreatic cancer dataset, the majority of variables had <5% missing values 
(Table 2.2) and reasons for missing data were not available. Tumour stage, CA19-9 and WBC 
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were missing in less than 10% of patients. The missing biochemical data is likely to be linked to 
„centre‟. Missing tumour stage is directly related to cancer stage (99% complete data) and again is 
likely to be linked to „centre‟. Lymph node status was missing for 24% of patients. In this sample of 
metastatic pancreatic cancer patients, missing lymph node status is likely to represent a group of 
patients where status was not deemed applicable to assess and hence was considered in the 
analysis as classification variable using „negative‟ as a reference level and including „missing‟ as a 
classification level. As such, the assumption of MAR does not appear to be violated. Principal 
analysis was based on complete cases (85% with complete data on the factors of interest) but 
multiple imputation was explored to provide valid, inferential alternative results.  
 
4.5. Summary of Adopted Modelling Strategy 
A proposed strategy (Harrell et al., 1996) for maximising model accuracy and avoiding poorly fitted 
and over-fitted regression models in the development of multivariable prognostic models is 
summarised in Table 4.3.  
 
The strategy is adapted for the analysis of the advanced pancreatic cancer dataset. Specifically, 
data on 653 patients, a large dataset in this disease, were collected at the time of randomisation 
and quality assured by British Biotech to minimise data errors and missing data. It is a clinically 
reduced dataset, reduced to those variables which are clinically meaningful and available within 
an NHS outpatient clinic. The data are robust for statistical modelling with a 94% event (death) 
rate and an average follow-up of alive patients of almost two years. Patients with limited response 
data (lost to follow-up) are retained in the analysis but censored out at the date last seen alive. 
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Table 4.3: Summary of Modelling Strategy 
1. Assemble accurate data and as large a sample as possible with sufficient follow-up to 
capture events 
2. Formulate focused clinical hypotheses, expected relationships and possible interactions 
3. Discard observations with missing response data if missing at random 
4. Assess missing covariate data, exclude if small % patients otherwise impute missing data 
5. Data reduction techniques if number of covariates is large compared with outcome data 
6. Use entire sample in model development 
7. Check linearity assumption and make possible transformations 
8. Check additivity assumptions and investigate pre-specified clinically motivated plausable 
interaction terms 
9. Check for overly influential observations, may indicate over fitting, a need for rescaling or 
truncating highly skewed variables or highlight data errors 
10. Check distributional assumptions (stratification or time-dependent covariates if 
proportional hazards assumption is violated, distributional assumption of parametric 
models) 
11. Do limited backwards step-down variable selection – possible loss of information through 
stepwise techniques as do not address over fitting 
12. This is the „final‟ model 
13. Validate model for calibration and discrimination ability, preferably using bootstrapping. 
Steps 7 to 11 repeated approximately for each bootstrap sample. 
14. If using stepwise selection present a summary table of variability of important factors over 
bootstrap samples 
15. Estimate likely shrinkage of predictions from model, consider shrinking predictions 
accordingly. 
 
 
Multiple imputation was considered and presented as a supportive analysis to a complete case 
analysis, since the proportion of missing data is small. The assumption of „linearity‟ refers to the 
functional form of the relationship between each continuous covariate and log-hazard, which is 
assumed to be linear. This assumption is discussed further in Chapter 5 and was investigated for 
each of the ten continuous variables in the advanced pancreatic cancer dataset comparing and 
presenting different methods of transformation, including dichotomisation. This research was 
focused on the main effects of eighteen possible prognostic factors investigating appropriate 
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transformations for the correct modelling of these main effects. As such, interactions of identified 
main effects especially where main effects are more complex non-linear transformations, is part of 
planned further research. Approximately four times as many patients are required for sufficient 
evidence to detect interaction terms (Schmoor et al., 2000) and it is debatable if 612 events would 
be enough evidence. The proportional hazards assumption was investigated in Chapter 3 and was 
not considered to be substantially violated after accounting for unavoidable early deaths. Variable 
selection methods are discussed in Chapter 5, backward elimination being the adopted method for 
the analysis in the advanced pancreatic cancer dataset. Internal validation methods were used to 
avoid data-splitting the main dataset, maximising available data to detect significant prognostic 
factors until the independent, external dataset became available.  
 
4.6. Reported Prognostic Factors in Pancreatic Cancer 
Generally, ductal adenocarcinomas are separated from other pancreatic tumours, such as peri-
ampullary tumours, which have better prognoses. Prognosis for tumours of the head of pancreas 
has been favoured compared with tumours of the body or tail which are generally diagnosed at a 
later stage of disease due to lack of symptoms. A review by the International Union Against 
Cancer (UICC) (Roder and Ott, 2001) reported prognostic factors for pancreatic cancer as 
„essential‟, „additional‟, „new and promising‟ (Table 4.4). Essential prognostic factors are 
predominantly tumour related, TNM stage being the most important staging system based on size 
and location of the primary tumour: T1/T2 tumours are limited to the pancreas, T3 tumours invade 
local tissue (duodenum, bile duct, peripancreatic tissue) and T4 invade adjacent organs (stomach, 
spleen, colon, adjacent large vessels) (Roder and Ott, 2001). 
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Table 4.4: Prognostic Factors for Pancreatic Cancer 
Prognostic Factors Tumor Related Host Related Environment Related 
    
Essential TNM classification 
Lymph-node metastases 
Infiltration of peripancreatic 
tissue and organs 
Lymphatic vessel invasion 
Tumor size 
Curative resection (R0) 
 Possibility of resection 
High volume centers 
    
Additional Disseminated tumor cells in the 
bone marrow 
Disseminated tumor cells in the 
peritoneal cavity 
Performance 
status 
Adjuvant therapy 
    
New and promising DNA content 
Genetic instability 
Tumor suppressor genes p53, 
p16, DPC4, Bcl-2 
Protooncogenes: Ki-67 
Oncogenes 
K-ras 
Growth factors 
VEGF 
EGF/EGFR 
TGF-beta 
FDG-PET 
 Neoadjuvant concepts 
Antiangiogenesis 
Cytokine-secreting pancreatic 
adeno-carcinoma vaccine 
 
 
 
In resectable patients the most important prognostic factor may be involvement of the resection 
margins (Neoptolemos et al., 2001b). The first large randomised controlled trial (ESPAC-1) also 
reported grade of disease, lymph node status and tumour size as prognostic factors for survival 
following surgery (Neoptolemos et al., 2004).  
 
Due to the short survival of patients with advanced pancreatic cancer, it is possible there could be 
limited prognostic factors. A search of the WSci, EmBase and Ovid publication databases 
conducted in 2004 (Stocken et al., 2008) identified 36 published prognostic factor studies 
CHAPTER 4: PROGNOSTIC INDICES 
41 
 
(excluding posters and presentations) reporting a total of 34 possible prognostic factors for 
advanced pancreatic cancer patients (Table 4.5), grouped as surgical, clinical, laboratory or 
demographic: 
 
Table 4.5a: Published Prognostic Factor Studies 
Type (number) of 
studies 
Number of 
patients per 
study 
Prognostic Factors reported 
(frequency of reporting) 
Univariate (U) / 
Multivariable 
(MV) analysis 
      
Randomised 
Controlled Trial  
(n=4) 
207 to 322 Surgical: 
 
Clinical: 
 
Laboratory: 
Metastases 
Tumour location 
Performance status 
Treatment 
Alkaline phosphatase  
(3) 
(1) 
(3) 
(1) 
(1) 
 
4 MV 
      
Consecutive 
Series >500 
patients  
(n=3) 
782 to 2380 Surgical: 
 
 
Clinical: 
 
 
 
 
 
Laboratory: 
Demographic: 
Metastases 
Stage of disease 
Operation 
Performance status 
Diabetes 
Pain 
Appetite/weight 
Jaundice 
Treatment 
Albumin 
Age 
Specialist centre 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
 
2 MV 
1 U 
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Table 4.5b: Published Prognostic Factor Studies 
Type (number) of 
studies 
Number of 
patients per 
study 
Prognostic Factors reported 
(frequency of reporting) 
Univariate (U) / 
Multivariable 
(MV) analysis 
 
      
Consecutive 
Series 100 to 500 
patients  
(n=14) 
102 to 450 Surgical: 
 
 
 
 
 
 
 
Clinical: 
 
 
 
 
 
Laboratory: 
 
 
 
 
 
 
 
Demographic: 
Metastases 
Stage of disease 
Tumour location 
Operation 
Tumour size 
Duodenal invasion 
Peri dissemination 
Ascites 
Performance status 
Diabetes 
Pain  
Appetite/weight 
Symptom onset 
Treatment 
CA242 
CA19-9 
Leukocytes 
Gamma GT 
Albumin 
LDH 
CRP 
Iron 
Age 
(4) 
(2) 
(1) 
(2) 
(1) 
(1) 
(1) 
(1) 
(2) 
(1) 
(1) 
(3) 
(1) 
(2) 
(2) 
(2) 
(1) 
(1) 
(1) 
(1) 
(3) 
(1) 
(1) 
 
13 MV 
1 U 
      
Consecutive 
Series 
<100 patients  
(n=15) 
28 to 95 Surgical: 
 
 
 
 
 
 
Clinical: 
 
 
 
Laboratory: 
 
 
 
Metastases 
Stage of disease 
Grade of disease 
Nodal status 
Operation 
Tumour size 
Fibrosis 
Performance status 
Inflammation 
Appetite/weight 
Treatment 
CA19-9 
VEGF 
CEA 
Phase angle BIA 
SCA 
(1) 
(1) 
(1) 
(1) 
(1) 
(2) 
(1) 
(4) 
(1) 
(1) 
(1) 
(7) 
(1) 
(1) 
(1) 
(1) 
8 MV 
7 U 
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The majority of these studies were questionable in terms of sample size and statistical methods, 
most based on small retrospective studies sometimes with inadequate analyses leaving the 
significance of specific prognostic factors unclear. Some variables are related (e.g. small tumours 
are more likely to be lymph node negative) hence the need to assess the importance of each 
factor in light of all other variables using multivariable statistical analysis. Thirty-two studies 
(Bachmann et al., 2003;Cubiella et al., 1999;Engelken et al., 2003;Falconer et al., 1995;Friedman 
and Vandeneeden, 1993;Fujino et al., 2003;Halm et al., 2000;Ikeda et al., 2001;Ishii et al., 
1996;Karayiannakis et al., 2003;Kuhlmann et al., 2004;Lundin et al., 1995;Micke et al., 2003;Ni et 
al., 2005;Ohigashi et al., 2003;Paillaud et al., 2003;Ridwelski et al., 2001;Rothenberg et al., 
1996;Saad et al., 2002;Shibamoto et al., 1996;Stemmler et al., 2003;Storniolo et al., 1999;Talar-
Wojnarowska et al., 2003;Tas et al., 2001;Terwee et al., 2000;Trigui et al., 2000;Tsuruta et al., 
2001;Ueno et al., 2000;Watanabe et al., 2004;Yasue et al., 1994;Ziske et al., 2003;Gupta et al., 
2004)  were based on consecutive series of patients, often retrospective, often single-centre, of 
which 15 studies were based on fewer than 100 patients (Halm et al., 2000;Ikeda et al., 2001;Ishii 
et al., 1996;Karayiannakis et al., 2003;Micke et al., 2003;Ohigashi et al., 2003;Paillaud et al., 
2003;Rothenberg et al., 1996;Saad et al., 2002;Stemmler et al., 2003;Talar-Wojnarowska et al., 
2003;Tsuruta et al., 2001;Yasue et al., 1994;Ziske et al., 2003;Gupta et al., 2004). One study was 
a summary of five observational studies with varied inclusion criteria, inconsistent results and no 
prospective verification (Terwee et al., 2000). The largest series (2380 patients) identified factors 
based on univariate analyses and data containing a large proportion (57%) of censored patients 
(Storniolo et al., 1999). Four studies (Berlin et al., 2002;Ducreux et al., 2002;Johnson et al., 
2001;Maisey et al., 2002) were randomised controlled trials and reported five prognostic factors 
based on multivariable analyses: metastases, tumour site, performance status, alkaline 
phosphatase and treatment. 
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Six of the papers reported in the literature review (Table 4.6) claimed to have developed a 
prognostic index suitable for use in clinical practice when making therapeutic decisions and 
suitable for use when designing and analysing future clinical trials. The largest (Terwee et al., 
2000) was a study pooling 1020 patients with unresectable pancreatic cancer from five studies. 
The strength of the study is the large sample size but the authors admit there were 
inconsistencies in the results in the individual studies included with varied survival figures 
unexplained by the prognostic variables. These differences could be due to the exclusion of 
important risk factors since the study was limited to only three prognostic factors available across 
all five studies. Three of the remaining studies were retrospective and five were based 
consecutive series of patients, the largest including a total of 166 patients, the smallest including 
only 55 patients (47 deaths). None of these reported indices has been adopted into clinical 
practice in the UK and as such, there is currently no prognostic tool in routine use for prediction of 
survival in advanced pancreatic cancer by which clinicians could identify subgroups of patients 
who may or may not benefit from further treatment. 
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Table 4.6: Summary of Reported Prognostic Indices 
Study  Single/ 
Multicentre  
Patients 
(Deaths) 
Variables 
(Continuous)  
Analysis of Continuous 
Covariates 
Prognostic Factors 
Identified 
Validated Comments 
1  
(Terwee et 
al., 2000) 
Pooling of 5 
Multicentre 
studies 
1020 (?) 3 (1) for 5 studies 
6 (1 ) for 4 studies 
Non-linearity investigated Age 
Sex 
Metastases 
No Prospective 
Limited factors  
Included study and treatment 
2  
(Trigui et al., 
2000) 
25 centres 166 (?) 17 (5) Dichotomised Pain 
Ascites 
Weight loss 
Metastases 
No Prospective 
Excluded centre and Treatment 
3 
(Cubiella et 
al., 1999) 
Single 134 (134) 34 (18) Dichotomised at median Performance status 
Metastases 
No Retrospective 
Excluded treatment 
4 
(Ueno et al., 
2000) 
Single 103 (95) 20 (10) Dichotomised  CRP 
Performance status 
CA19-9 
No Retrospective 
Excluded treatment 
5  
(Ishii et al., 
1996) 
Single 65 (?) ? (?) Dichotomised  Performance status 
CEA 
Metastases 
No Retrospective 
Excluded treatment 
6  
(Ikeda et al., 
2001) 
Single 55 (47) 19 (8) Dichotomised  Performance status 
Lymph node swelling 
CA19-9 
No Prospective 
Excluded treatment 
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4.7. Clinical Trial Design 
The usual endpoint for efficacy of cancer treatments is all cause mortality and comparison of 
overall survival is often the primary outcome measure in randomised controlled trials in cancer. 
Other endpoints include progression free survival (time to progression or death whichever is first, 
also known as disease free survival), objective response rates, toxicity of experimental treatments 
and patient self-reported quality of life. Symptom assessment from the patient perspective (health 
related quality of life) is increasingly important in clinical trials where small survival differences in 
treatments are expected (Carter et al., 2009) and indeed clinical benefit response (a composite of 
measurements of pain, performance status and weight) was used as the primary measure of 
treatment efficacy in the licensing trial of gemcitabine in the advanced disease setting (Burris et 
al., 1997). 
 
To compare survival rates adequately across treatment groups and provide sufficient evidence of 
a survival difference requires large studies. Randomised controlled trials in pancreatic cancer 
usually require larger number of patients to enable detection of small expected treatment 
differences and as such may require multi-centre/ country participation. Random allocation of 
patients to treatment groups should be used to minimise selection bias and ensure patient and 
tumour characteristics are adequately balanced across the different treatment arms. Identification 
of important prognostic factors is desirable to enable accurate stratification of patients at the time 
of randomisation. Stratification factors are factors which are known to have a significant effect on 
outcome and as such should be balanced equally across treatment groups. Stratification factors 
used in pancreatic clinical trials in the adjuvant setting often include surgical centre and resection 
margin status (R0 patients are those with negative resection margins at surgery who have a better 
prognosis than patients with residual tumour left at surgery (R1) (Butturini et al., 
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2008;Neoptolemos et al., 2001b)). Stratification factors used in pancreatic clinical trials in the 
advanced disease setting include oncology centre, stage of disease (locally advanced patients are 
those with no distant metastases who have a better prognosis than patients with metastases) and 
performance status (patients with performance status 0 or 1 have better performance status 
associated with better prognosis than patients with performance status 2) (Cunningham et al., 
2009). 
 
4.8. Conclusions 
In summary, the advanced pancreatic cancer dataset contains 653 patients with 612 deaths and 
should enable stable estimation of the prognostic ability of the eighteen identified possible 
prognostic factors. Six previously reported prognostic indices included one large study of 1020 
patients but with only three common variables to investigate. The remaining five studies were 
based on <166 patients, four were single centre studies, three were retrospective. None of the six 
studies included any validation. A total of 36 prognostic factor studies were identified reporting a 
total of 34 prognostic factors and of these 11 were available for analysis in the advanced 
pancreatic cancer dataset. Of the 23 factors not collected, 15 had only been reported once. The 
most frequently occurring factors, not available in the advanced pancreatic dataset were 
performance status (reported in 10 studies) and appetite/ weight loss (reported in 5 studies). The 
functional form of the relationship between each continuous covariate and log-hazard was usually 
not investigated, usually being dichotomised. Non-linearity is addressed for the first time in this 
disease site and was investigated for each of the ten continuous variables in the advanced 
pancreatic cancer dataset. Model validation is addressed for the first time in this disease site; 
internal validation was carried out to assess the degree of overfitting, external validation was 
carried out based on an independent, external dataset. Multiple imputation methods were used as 
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a supportive analysis to the principal complete case analysis, to assess the impact of missing data 
which again had not been addressed previously in the literature. 
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 CHAPTER 5: STATISTICAL METHODS FOR PROGNOSTIC MODELLING 
 
 SUMMARY 
 A multivariable approach to analysis allows investigation of the relationship between 
survival and one or more possible factors 
 Non-parametric methods model the hazard function with no distributional assumptions 
 Akaike‟s Information Criteria is valid for comparing non-nested as well as nested models 
 Multivariable regression modelling can be used with categorical and continuous variables 
 Dichotomisation of continuous data is common but is inefficient and unnecessary 
 Continuous variables are often simplified by assuming a linear relationship between 
predictor and log-hazard which may not be appropriate 
 Assessment of model performance and validity is an integral aspect of model 
development 
 
5.1. Introduction 
The aim of this chapter is to describe the statistical methods for assessing treatment effects and 
identification of prognostic factors in the multivariable setting including constructing prognostic 
indices. Kaplan Meier and log-rank methods can be used in the analysis of a single possible 
prognostic factor but in reality many underlying factors may have an impact on length of survival 
and all factors need to be investigated and accounted for in the analysis. A multivariable modelling 
approach to the analysis of survival data allows investigation of the relationship between survival 
and one or more possible factors. A variety of statistical methods are available for multivariable 
modelling of survival data but generally most clinical studies, including randomised cancer clinical 
trials, use the proportional hazards regression model (Cox, 1972) to investigate possible 
prognostic factors and treatment effects. Cox proportional hazards regression and methods for 
assessing the underlying assumptions are discussed, specifically the assumption of proportional 
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hazards. The underlying linearity assumption for continuous covariates is introduced and 
discussed. Issues surrounding variable selection, comparison of different regression models and 
issues relating to missing covariate data are discussed. 
 
5.2. Cox Proportional Hazards Regression 
In parametric models there is some underlying assumption about the distribution of the hazard 
rate. For example, in a Weibull regression model the baseline hazard function is non-constant but 
rather increases or decreases monotonically over time, although does not change direction: 
1
0 )(
 tth  
where  is a scale parameter and  is a shape parameter, both >0, denoted W(, ). Weibull is 
often used when the survival distribution is assumed to be positively skewed i.e. with a heavy left 
tail, early events. Indeed when =1 then the hazard function is constant  and conforms back to 
the exponential distribution. Estimates of log  (intercept) and  (slope) can be taken from a log 
cumulative hazard plot where non-parallel lines indicate different shape parameter  across 
groups indicating non-proportionality. In pancreatic cancer clinical trials, especially those in the 
adjuvant setting where all patients undergo „curative‟ resection, patients may be more at risk of 
death post-surgery with diminishing risk as time increases. In this case the hazard rate may be 
dependent on follow-up time. The purpose of statistical modelling is to relate non-constant 
hazards to influential covariates. In contrast to the parametric models, non-parametric methods 
model the hazard function with no distributional assumption for survival times. Since parameters 
are estimated for each of the potential covariates, the Cox proportional hazards regression is 
described as a semi-parametric approach. 
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Cox proportional hazards regression models the hazard function directly and aims to detect the 
extent to which potential factors affect the form of the hazard function. The only assumption is that 
the hazards across groups are proportional to one another and thus the ratio of hazard functions 
does not vary with time. For two treatment groups the proportional hazards model (Collett, 1994) 
is: 
hA(t) = hB(t)  
where hA(t) and hB(t) are the hazards of death at time t for treatments A and B respectively and  
is a constant value of the ratio of the hazards (the hazard ratio) where  = hB(t) / hA(t).  An 
alternative more general expression is: 
)()( 0 theth
iX
i
      
where hi(t) is the hazard function for the ith of n patients, h0(t) is the baseline hazard function 
where all covariate values Xi equal zero and e
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where j=1 to p explanatory variables Xi and j are regression coefficients for expressing the 
relationship between the hazard of death and each covariate Xj. Then log  (the log hazard ratio) 
= X. For a vector of explanatory variables X the hazard ratio is interpreted as the hazard at time t 
for a patient relative to the hazard for a patient with all variable values of zero. The general 
proportional hazards model is then: 
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where 1X1i + 2X2i + ….. + pXpi =i  is known as the linear predictor of the model, also known as 
risk score or prognostic index. The proportional hazards model can also be regarded as the linear 
model for the logarithm of the hazard ratio. 
 
Inferences about the effects of the explanatory variables Xi on the log hazard ratio (estimating p 
coefficients) in the proportional hazards model can be made without making any assumptions 
regarding the form of the baseline hazard function h0(t) although estimates of the pcoefficients 
can be used to estimate h0(t) if needed. The unknown estimates of the p coefficients are 
computed using maximum likelihood estimation. The likelihood of the data is the joint probability of 
the observed data as a function of observed survival times and unknown  parameters. The 
estimates of  are values which are most likely given the observed data or maximum likelihood 
estimates which are values which maximise the likelihood function. For computation purposes, it is 
simpler to maximise the logarithm of the likelihood function using an iterative procedure such as 
the Newton-Raphson with Breslow‟s approximation for multiple tied events at a specific time. 
Computation of the standard errors for each  estimate (se[]) enable a 95% confidence interval 
confidence interval for  to also be estimated based on:  + 1.96*se[]. Since the distribution of 
the logarithm of the hazard ratio is more closely approximated with the normal distribution and  
log  = X  then a 95% confidence interval confidence interval for the true hazard ratio   can 
calculated by exponentiating the confidence interval calculated for 
 
If the confidence interval for does not include zero then this provides evidence that the value of 
 is non-zero. The null hypothesis, that p=0 in the presence of other terms in the model, can be 
tested using the Wald test which compares /se() against percentage points of a chi-square 
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distribution at a particular significance (error) level, often 5%. Generally individual estimates of p 
in are not completely independent of one another so testing separate hypotheses about  
parameters may not be interpretable. Alternative methods for comparing Cox proportional hazards 
models are based on the log-likelihood ratio statistic. 
 
5.3. Comparing Alternative Models  
How well a model fits to a specific set of survival data can be calculated using a statistic known as 
-2logL (-2*log-likelihood) which is a summary measure of the agreement between the model and 
the data. Since –2logL is dependent upon the number of observations in the data then its value is 
dataset specific and is increased with increased observations. As such it cannot be used to 
compare models across different datasets. Comparison of -2logL can be used to compare two 
nested proportional hazards models developed on the same set of data however formal testing is 
inadvisable since -2logL does not have a chi-squared distribution (Collett, 1994). Since only 
nested models should be compared using -2logL, Akaike‟s Information Criteria (AIC) (Akaike, 
1974) is valid for comparing non-nested as well as nested models by penalising the log-likelihood 
for model complexity by adding at least twice the number of parameters estimated: 
AIC=-2logL + k  
where  is a predetermined constant between 2 and 6 (determined according to  chosen 
significance level where q=2 or 3 approximates a 5% significance level) and k is the number of 
unknown  parameters in the model. Choosing a model based on the AIC is a successful strategy 
producing simplified models (Ambler et al., 2002).  
 
Smaller values of the AIC indicate a better model but it is unclear whether AIC statistics from non-
nested models can be compared with hypothesis testing. Akaike suggested (Akaike, 1974) that in 
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some circumstances testing could be used: “When there are different families approximating the 
true likelihood equally well the situation will at least locally be approximated by the different 
parameterizations of one and the same family. For these cases the significance of the difference 
of AIC‟s between two models will be evaluated by comparing it with the variability of a chi-square 
variable with the degree of freedom equal to the difference of the k‟s of the two models”. Using a 
fixed level of significance for the comparison of AIC is not appropriate i) in nested models with 
different k as it does not account for increased variability of estimates due to increased number of 
parameters and ii) in non-nested models with the same k. The AIC can be seen as a method of 
ranking models, where the model with the smallest AIC is ranked „best‟, the next smallest being 
„next best‟ and so on. In this way, a „best‟ model is declared but which may be more complex than 
and not as parsimonious as the „next best‟ model but with almost identical AIC statistics. 
Hypothesis tests are based on specific distributional assumptions. A way to avoid making 
distributional assumptions is to calculate AIC statistics and the difference in AIC‟s between the 
different models in multiple bootstrap resamples of the data. This provides a distribution for the 
differences in AIC between different models which requires no distributional assumptions and 
which can then be summarised appropriately. 
 
There are different variable selection techniques based on forward selection, backward elimination 
and stepwise selection procedures: forward selection begins with a null model and includes 
significant variables one at a time into the model, backward elimination begins with a full model of 
covariates and excludes non-significant variables one at a time, stepwise selection is based on 
forward or backwards selection but also considers all other variables for exclusion/ inclusion at 
each step, although previously deleted variables are normally permitted to re-enter the model only 
once. These procedures are often automated in statistical software packages but should be used 
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with caution since they may provide results which are dependent upon the selection technique 
used and may not account for any known hierarchy in the data. The „full‟ model including all 
variables can be difficult to interpret with large numbers of variables if many are not important. 
Forward and backward elimination selection methods are advantageous in selecting only 
variables with greater influence with high probability and eliminating variables with little influence 
resulting in a more general and useful model not substantially inferior to the „full‟ model (Sauerbrei 
et al., 2007). Selection procedures can be unstable in small datasets but instability can be 
addressed in an analysis of models from bootstrap replication as an internal validation in the 
absence of independent data for external validation. A recommended selection strategy is 
summarised (Table 5.1, (Collett, 1994),adapted): 
 
Table 5.1: Strategy for Model Selection 
1. Fit models that contain each variable one at a time. Compare with the null model to 
determine which variables on their own significantly reduce the value of -2logL. 
2. Important variables from Step 1 are fitted together. Variables which do not significantly 
increase -2logL when omitted are discarded. Once a variable has been dropped, the 
effect of omitting each of the remaining variables in turn should be examined 
3. Variables which were not important on their own are added one at a time and any that 
significantly reduce -2logL are retained in the model. 
4. A final check is made to ensure that no term in the model can be omitted without 
significantly increasing -2logL and that no term not included significantly reduces -2logL 
 
Forced inclusion refers to the inclusion of factors that were deemed important at the study design 
stage „forcing‟ into each model to account for the structure of the data forced through the study 
design. Possible candidate factors to consider would include stratification factors at randomisation 
including centre effect and in the case of prognostic modelling accounting for the underlying 
structure according the randomisation of treatment groups. It is recommended (Machin et al., 
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2006;Moons et al., 2009;Simon and Altman, 1994) that for randomly allocated treatments, 
treatment group should be forced into the model and the corresponding hazard ratio reported 
even if it turns out to be a non-significant variable, and equally so for variables used in any 
stratified randomisation procedure. Stratification factors at randomisation in the advanced 
pancreatic dataset were trial, cancer stage, and sex. 
 
5.4. Format of Variables 
Variables for consideration of inclusion in a multivariable model may be a mix of categorical 
(including binary) and continuous data. A strength of multivariable regression modelling is that it 
can be used with both categorical and continuous variables. It has been shown that the hazard 
ratio  = hB(t) / hA(t) for the binary case of two treatment groups and that  log  = X. For 
categorical variables with greater than two groups, individual categories are grouped into pairs as 
in the binary case known as dummy, indicator or „classification‟ variables. In the advanced 
pancreas data set, tumour stage is coded as either 0, 1, 2, 3, 4 for each patient. Providing there 
are sufficient observations in each individual category then classification variables could be 
created as (Table 5.2): 
 
Table 5.2: Possible Classification Variables for Tumour Stage 
 Class T1 Class T2 Class T3 Class T4 
Tumour stage 0 0 0 0 0 
Tumour stage 1 1 0 0 0 
Tumour stage 2 0 1 0 0 
Tumour stage 3 0 0 1 0 
Tumour stage 4 0 0 0 1 
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In this way, each classification variable reduces to a binary covariate and is modelled as 
previously described ensuring all the classification variables created from one specific categorical 
variable are included in the model simultaneously. Each categorical variable with k categories will 
have k-1 classification variables with estimation of k-1 corresponding parameter estimates.  
 
Continuous covariates are often categorised (frequently dichotomised) for clinical ease of 
interpretation. However this implies a step in hazard of exp() at a cut point which is may not be 
realistic, more likely is a smooth change in hazard. Dichotomisation of continuous data is common 
practice but is problematic and unnecessary. Since the variability in outcome within groups is 
ignored by categorisation then the variability between groups may be significantly underestimated 
since patients close to the cut point are analysed as being very different rather than being very 
similar, resulting in a serious reduction of statistical power to detect relationships between 
predictors and outcome, residual confounding and serious bias (Altman and Royston, 
2006;Royston et al., 2006a). The risk of bias occurs when the choice of cut point is data driven 
based on investigating multiple cut points but reporting only that which is most significant. The use 
of different cut points across multiple studies also hinders direct comparisons. Continuous 
variables are often simplified by assuming a linear relationship between predictor and log-hazard 
i.e. the log risk increases or decreases linearly as the value of the factor increases, which also 
may not be appropriate. Indeed the effects of important prognostic factors may go unrecognised 
due to these simplistic assumptions made in statistical modelling (Stocken et al., 2008). It is more 
preferable to retain the continuous nature of the variable whilst allowing some form of non-linearity 
accomplished by the application of a transformation to the independent variable (Box and Tidwell, 
1962). Misspecification of the functional form may lead to inappropriate conclusions but has not 
been previously investigated in pancreatic cancer studies. 
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The PHREG (experimental version TPHREG in SAS v9.1 now combined into PHREG in SAS 
v9.2) procedures in SAS (SAS Institute Inc., 1999) carry out Cox proportional hazards regression 
creating k-1 classification variables for categorical covariates with associated type-3 2 test based 
on k-1 degrees of freedom and also creating additional levels of a classification variables to 
account for missing data, if required. 
 
5.5. Model Performance 
After a model has been fitted to a set of observations, adequacy of that model can be investigated 
using residuals. Residuals are useful as they are calculated for each individual patient in the 
dataset and can be plotted to study for apparent patterns indicating lack of fit. Deviance residuals 
are residuals which should be symmetrically distributed about zero and as such can help identify 
outlying patients. An alternative approach is using Martingale residuals which can help assess 
functional form. Deviance residuals are Martingale residuals transformed to be more symmetric 
and can be output from the PHREG procedure in SAS (SAS Institute Inc., 1999) using the 
RESDEV statement. Prognostic risk groups can be derived from the individual patient prognostic 
scores and the survival distributions described for each of these risk groups. Internal model 
validation investigating the stability and external validity of a set of selected prognostic factors can 
be carried out by estimating the extent of model optimism (overfitting) in a model using statistical 
re-sampling simulation techniques. This can be carried out using the „validate‟ statement in the 
Design Library of the programming language R (The R Foundation for Statistical Computing, 
2008).  
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5.6. Statistical Development of a Prognostic Model in Advanced Pancreatic 
Cancer 
A strategy based on avoiding over-fitted regression models in the development (Harrell 1996, 
Collett) and reporting (McShane 2005) of multivariable prognostic models was followed. The first 
stage of data reduction in the advanced pancreatic cancer dataset was considering only factors 
that were clinically relevant and available within an NHS out-patient clinic. Eighteen baseline 
clinical, histological, biochemical and demographic variables (including trial and randomised 
treatment group) were considered appropriate for analysis as possible prognostic factors of 
survival (Table 2.2). The majority of variables had <5% missing values. Tumour stage, CA19-9 
and WBC were missing in less than 10% of patients and lymph node status was missing for 24% 
of patients. Metastases or lymph node status were considered in the analysis as classification 
variables using „negative‟ as a reference level. Tumour stage and cancer stage were considered 
as binary variables based on clinical confirmation and small numbers of patients within categories. 
Both variables were also investigated retaining the original ordered categories but this did not alter 
the results. The principal analysis was based on complete cases where patients had complete 
data on all of the prognostic factors of interest. Multiple imputation is considered in the following 
chapter following development of the final prognostic model. 
 
Initial analysis was based on standard methodology comparing Kaplan-Meier survival estimates 
using the log-rank test and estimating univariate hazard ratios for levels of each factor (Table 5.3, 
(Stocken et al., 2008), adapted):  
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Table 5.3: Univariate Log-Rank Analyses 
 Patient Death 12-
month 
Survival 
Median 
Survival 
(95% CI) 
2LR, p 
2W, p) 
HR (95% CI) 
Overall Survival 653 612 17% 4.7 (4.2 to 5.1) - - 
Trial                      BB128 
BB193 
414 
239 
392 
220 
17% 
18% 
4.2 (3.6 to 4.8) 
5.4 (4.8 to 6.0) 
2.28, p=0.13 1.0 
0.88 (0.75 to 1.04) 
DEMOGRAPHICS 
Age group        <=63 yrs 
>63 
343 
310 
320 
292 
21% 
13% 
5.1 (4.3 to 5.8) 
4.3 (3.5 to 4.9) 
4.42, p=0.036 
(7.55, p=0.006) 
1.0 
1.18 (1.01 to 1.39) 
Ethnic group         White 
Other 
590 
62 
554 
57 
18% 
12% 
4.6 (4.1 to 5.1) 
5.2 (3.5 to 6.0) 
0.20, p=0.65 1.0 
1.06 (0.80 to 1.41) 
Sex                      Female 
Male 
285 
368 
267 
345 
18% 
17% 
4.9 (4.2 to 5.8) 
4.5 (3.9 to 5.1) 
0.73, p=0.39 1.0 
1.07 (0.91 to 1.26) 
Treatment    Gemcitbine 
                   Marimistat 
222 
431 
204 
408 
18% 
17% 
5.5 (4.7 to 5.9) 
4.2 (3.5 to 4.9) 
2.79, p=0.095 1.0 
1.15 (0.98 to 1.36) 
TUMOUR INFORMATION  
Cancer             Early(I/II) 
Stage             Late (III/IV) 
104 
543 
92 
514 
26% 
16% 
6.8 (5.7 to 8.2) 
4.1 (3.5 to 4.7) 
14.72, p<0.001 1.0 
1.53 (1.26 to 1.86) 
Metastases                M0 
M1 
Missing 
194 
436 
23 
176 
414 
22 
30% 
12% 
17% 
6.8 (5.9 to 8.4) 
3.5 (3.2 to 4.0) 
5.5 (4.9 to 7.5) 
35.47, p<0.001 1.0 
1.69 (1.43 to 1.99) 
1.35 (0.88 to 2.09) 
Lymph nodes             N0 
N1 
Missing 
243 
251 
159 
226 
240 
146 
20% 
18% 
11% 
5.5 (4.8 to 6.0) 
4.5 (3.5 to 5.4) 
3.8 (3.2 to 4.9) 
6.73, p=0.035 1.0 
1.19 (1.00 to 1.43) 
1.29 (1.04 to 1.59) 
Tumour        Early(0/1/2) 
Stage               Late (3/4) 
Missing 
310 
287 
56 
291 
268 
53 
16% 
18% 
18% 
4.3 (3.7 to 4.9) 
4.9 (4.2 to 5.8) 
5.8 (3.5 to 7.9) 
1.63, p=0.44 1.0 
0.91 (0.77 to 1.08) 
0.87 (0.66 to 1.16) 
SERUM CHEMISTRY and HAEMATOLOGY 
AST              Normal 
Abnormal 
538 
86 
499 
84 
19% 
12% 
5.1 (4.6 to 5.7) 
2.8 (2.2 to 3.9) 
14.17, p<0.001 
(5.99, p=0.014) 
1.0 
1.55 (1.18 to 2.04) 
BILIRUBIN   Normal 
Abnormal 
464 
165 
429 
159 
20% 
11% 
5.1 (4.7 to 5.7) 
3.8 (3.3 to 4.4) 
9.32, p=0.002 
(6.27, p=0.012) 
1.0 
1.32 (1.09 to 1.61) 
ALK PHOS  Normal 
Abnormal 
442 
187 
411 
177 
20% 
13% 
5.5 (5.0 to 6.1) 
3.1 (2.6 to 3.5) 
20.20, p<0.001 
(56.05, p<0.001) 
1.0 
1.49 (1.23 to 1.81) 
ALBUMIN     Normal 
Abnormal 
583 
45 
544 
43 
19% 
7% 
5.1 (4.6 to 5.6) 
1.5 (1.0 to 2.7) 
31.37, p<0.001 
(74.34, p<0.001) 
1.0 
2.36 (1.49 to 3.72) 
LDH              Normal 
Abnormal 
543 
78 
505 
75 
20% 
5% 
5.2 (4.8 to 5.8) 
2.1 (1.5 to 2.8) 
37.05, p<0.001 
(36.16, p<0.001) 
1.0 
2.08 (1.50 to 2.88) 
BUN             Normal 
Abnormal 
407 
213 
382 
199 
20% 
13% 
5.1 (4.3 to 5.7) 
4.4 (3.5 to 5.1) 
3.43, p=0.064 
(5.28, p=0.022) 
1.0 
1.17 (0.98 to 1.40) 
CA19/9         Normal 
Abnormal 
98 
508 
86 
481 
28% 
16% 
6.3 (4.8 to 8.0) 
4.6 (4.0 to 5.1) 
7.74, p=0.005 
(4.84, p=0.028) 
1.0 
1.38 (1.12 to 1.70) 
Hb                Normal 
Abnormal 
79 
533 
77 
495 
8% 
20% 
3.7 (3.3 to 5.1) 
4.9 (4.4 to 5.6) 
6.88, p=0.009 
(10.64, p=0.001) 
1.0 
0.73 (0.55 to 0.95) 
WBC            Normal 
Abnormal 
483 
129 
446 
126 
21% 
8% 
5.5 (4.9 to 5.9) 
2.9 (2.4 to 4.0) 
34.36, p<0.001 
(46.52, p<0.001) 
1.0 
1.78 (1.40 to 2.26) 
LR=Log-Rank Statistic, W=Wald Chi-square Statistic under „linear‟ assumption, HR=Hazard Ratio for 
categories 
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Ten of the eighteen possible prognostic factors were collected as continuous measurements. 
Continuous data were initially investigated based on i) a step functional relationship with outcome 
using dichotomised covariates (normal/ abnormal based on central laboratory reference ranges) 
or ii) under the assumption of linearity with log-hazard. Step-functional relationships are affected 
by the cut-point used which can be pre-defined or data-driven. In these trial data, cut-points were 
pre-defined as normal/ abnormal (according to central laboratory reference ranges) as used in 
clinical practice, grouping abnormally low and abnormally high measurements together. 
 
Log-rank analyses indicated that potentially important factors were age, cancer stage (I/II vs. 
III/IV), metastases and laboratory measures AST, alkaline phosphatase, albumin, LDH, WBC, 
bilirubin, CA19-9 and haemoglobin. BUN and nodal status held borderline statistical significance 
at the 5% level. Trial, treatment (gemcitabine vs. marimistat), race (white vs. not-white), sex and 
tumour stage (T0,1,2 vs. T3,4) did not appear to be significantly related to survival.  
 
5.7. Assumption of Proportional Hazards 
For valid interpretation of the regression coefficients from a Cox proportional hazards model, the 
assumption of proportional hazards must hold. The proportional hazards assumption was 
investigated for each covariate using log cumulative hazard plot (Collett, 1994) which should give 
approximately parallel lines when proportional hazards are observed. The log cumulative hazard 
plot by trial (Figure 3.4) showed curves for the two trials to be approximately parallel. The same 
can be seen in the log cumulative hazard plot by treatment group (Figure 5.1): 
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Figure 5.1: Log Cumulative Hazard Plot by Treatment Group 
 
 
 
The shape of the log cumulative hazard curves are subject to greater measurement error in the 
early stages of follow-up and as such justifies the use of an appropriate test, rather than reviewing 
and interpreting plots. An appropriate test of proportionality is the inclusion and assessment of a 
time dependent covariate which is a method used to capture non-proportionality should it exist. A 
time dependent covariate is a variable X whose values change over time t. Since the values of X 
depend on t then the relative hazard with the baseline hazard is also dependent on time and the 
model no longer has proportional hazards. When proportional hazards are observed, the influence 
of a time dependent covariate X (X=factor*(ln(survival)-ln(mean survival))) should be minimal and 
non-significant in the proportional hazards model. The mean observed time in the 556 advanced 
pancreatic cancer patients with used in the complete case analysis was 6.8 months. Time 
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dependent covariates were calculated for factors of trial and treatment and were non-significant 
(p=0.24 and p=0.08 respectively). 
 
5.8. Cox Proportional Hazards Regression Models 
The hazard of death was assessed in the multivariable setting using Cox proportional hazards 
regression modelling based on the strategy presented in Table 5.1 (Collett, 1994). Variable 
reduction was based on a manual backward elimination method using a nominal significance level 
of 0.05 for elimination and including trial, sex, cancer stage (stratification factors at randomisation) 
and randomised treatment as „forced‟ variables in each model. A final check was made to ensure 
that no term in the model could be omitted and that none of the omitted terms could be included 
without significantly affecting the model. All variables omitted from the model based on backward 
elimination were considered and re-instated if they significantly improved the model. Continuous 
variables were investigated based on i) dichotomisation („categorical‟ model) or ii) under the 
assumption of linearity („linear‟ model) in this initial look at the data. 
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The final „categorical‟ model (Table 5.4, (Stocken et al., 2008), adapted) was based on 556 
patients (520 deaths) with complete data on the prognostic factors of interest and identified six 
highly significant prognostic factors: LDH, albumin, metastases, WBC, CA19-9 and bilirubin: 
 
Table 5.4: Dichotomising Continuous Variables 
FINAL ‘CATEGORICAL’ MODEL (n=556 patients, 520 deaths) 
AIC=5583.2 Variable 2 p-value HR (95% CI) 
Stratification factors TRIAL 7.0 0.008 0.77 (0.64 to 0.94) 
 *CANCER STAGE 0.9 0.36 1.16 (0.85 to 1.58) 
 SEX 1.8 0.18 0.89 (0.74 to 1.06) 
 TRT 3.4 0.065 1.19 (0.99 to 1.44) 
Independent factors ALBUMIN g/L 24.2 <0.001 2.30 (1.65 to 3.21) 
 LDH IU/L 25.1 <0.001 2.05 (1.55 to 2.72) 
 WBC 109/L 10.3 0.001 1.44 (1.15 to 1.79) 
 +METS 11.9 <0.001 1.54 (1.21 to 1.97) 
 BILIRUBIN mol/L 8.4 0.004 1.34 (1.10 to 1.64) 
 CA199 KU/l 9.4 0.002 1.48 (1.15 to 1.89) 
HR=hazard ratio 
* Stage (I/II vs. III/IV) 
+ Metastases (negative vs. positive): missing data included in analysis as a separate 
„classification‟ variable using lower level as the reference level 
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The final „linear‟ model, assuming a linear relationship between independent predictors and log-
hazard (Table 5.5, (Stocken et al., 2008), adapted) was based on 556 patients (520 deaths) with 
complete data on the prognostic factors of interest and identified five highly significant prognostic 
factors: albumin, alkaline phosphatase, LDH, WBC and metastases:  
 
Table 5.5: Assumption of Linearity of Continuous Variables 
(shaded areas highlight factors identified in the „Categorical‟ model) 
FINAL ‘LINEAR’ MODEL (n=556 patients, 520 deaths) 
AIC=5557.1 Variable 2 p-value HR (95% CI)^ 
Stratification factors TRIAL 8.1 0.005 0.76 (0.63 to 0.92) 
 *CANCER STAGE 0.008 0.93 1.01 (0.74 to 1.38) 
 SEX 3.8 0.051 0.84 (0.70 to 1.00) 
 TRT 3.2 0.073 1.19 (0.98 to 1.44) 
Independent factors ALBUMIN g/L 41.0 <0.001  0.72 (0.65 to 0.79) 
 LDH IU/L 13.3 <0.001  1.12 (1.05 to 1.19) 
 WBC 109/L 11.7 <0.001  1.24 (1.10 to 1.41) 
 +METS 10.5 0.001 1.50 (1.17 to 1.92) 
 ALKPHOS IU/L 21.1 <0.001  1.13 (1.07 to 1.19) 
HR=hazard ratio 
* Stage (I/II vs. III/IV) 
+ Metastases (negative vs. positive): missing data included in analysis as a separate 
„classification‟ variable using lower level as the reference level 
^ HR based on 5 unit increase in albumin g/L, WBC 109/L and 100 unit increase in LDH IU/L, 
alkaline phosphatase IU/L 
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Models were adjusted by stratification factors at randomisation (trial, sex, cancer stage) and 
randomised treatment group. „Metastases‟ was selected as a significant independent covariate in 
both the final „categorical‟ and „linear‟ models. The inclusion of „metastases‟ reduces the 
significant effect of „cancer stage‟ seen at univariate analysis (Table 5.3) since these two variables 
are highly correlated explaining similar variability in the data.  
 
The final selected „linear‟ model (Table 5.5) has a substantially lower AIC of 5557.1 compared with 
the final selected „categorical‟ model (Table 5.4) with an AIC of 5583.2.  As such, the „linear‟ 
model has a better fit even with one less prognostic factor based on five significant prognostic 
factors compared to six selected in the „categorical‟ model. Both models considered albumin, 
LDH, metastases and WBC to be highly significant (p<0.001) independent prognostic factors. The 
„linear‟ model considered alkaline phosphatase to also be important (p<0.001) but not in the 
categorical model, which considered CA19-9 (p=0.002) and bilirubin (p=0.004) to be important. 
 
5.9. Conclusions 
A multivariable approach, based on Cox proportional hazards modelling using backward 
elimination variable selection, was used to investigate multiple possible prognostic factors. These 
methods have the ability to include categorical (binary and classification variables) and continuous 
covariates. In previous published analyses of advanced pancreatic cancer data, continuous 
variables are usually dichotomised (categorised as normal/ abnormal based on central laboratory 
reference ranges) creating a step functional relationship with outcome. Continuous variables in the 
advanced pancreatic cancer dataset were dichotomised but since dichotomisation is unnecessary, 
they were also investigated under the assumption of linearity (a linear relationship with log-
hazard). The strength of evidence for factors selected as prognostic differs between the two 
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„categorical and „linear‟ models due to the underlying assumptions made regarding functional 
form. The final selected „linear‟ model had a substantially lower AIC and hence was a better fit to 
the data. However, the underlying assumption of linearity may not be correct but has not been 
investigated previously in advanced pancreatic cancer. The relationships of continuous variables 
and outcome should be investigated further since alternative formats may be more appropriate 
and thus efficient. Non-linearity can be addressed through transformation of the variable in 
question. One transformation method based on fractional polynomial transformations has been 
used to address non-linearity in other cancer datasets, such as breast and renal, but not in 
pancreas. Chapter 6 investigates non-linearity of the continuous variables in the advanced 
pancreatic cancer dataset and investigates the applicability of non-linear fractional polynomial 
transformations. Addressing any non-linearity should lead to more accurate and efficient 
prognostic models which can then be internally validated, model performance assessed and the  
impact of missing data investigated further.  
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CHAPTER 6: FRACTIONAL POLYNOMIAL FUNCTIONS 
 
 SUMMARY 
 Correct modelling of non-linearity can be critical to estimation of prognostic factors 
 Fractional polynomial regression models are particularly suitable for modelling smooth 
curved relationships between response and predictor  
 Second-degree fractional polynomial functions (FP2) have a maximum of one turning 
point and degrees >2 are rarely required 
 Fractional polynomial transformations can be implemented using SAS macros 
 Model performance for a model based on fractional polynomials is confirmed 
 
6.1. Introduction 
The proportional hazards model assumes a linear relationship between independent covariates 
and log-hazard. The linearity assumption implies that each unit increase in variable X results in 
the same increase in risk of event (e.g. death) but the risk may increase to a certain limit then 
plateau or even decrease hence violating the assumption of linearity. A more appropriate analysis 
should retain the continuous nature of the variable allowing for some form of non-linear 
relationship with the response variable. Polynomials have been used to correct for non-linearity 
but low order polynomials are often too limited and high order polynomials often do not fit well at 
extreme data points. It is important to account for non-linearity especially in the prognostic factor 
setting since it has been shown (Royston et al., 2006a) that a treatment effect can be 
underestimated unless a strongly prognostic non-linear covariate was modelled correctly using a 
suitable non-linear function, showing that correct modelling of non-linearity can be critical. 
Generally inclusion of an important mis-modelled non-linear covariate may cause unimportant 
variables correlated with it to enter the model spuriously (Royston and Sauerbrei, 2008). Also, 
important mis-modelled non-linear covariates may be excluded unless non-linearity is taken into 
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account (Stocken et al., 2008). Transformations such as log X, √X or 1/X have been used in an 
attempt to improve model fit. If log X is defined as X0 then these transformations can be seen to 
be different power functions Xp for different values of p. 
 
6.2. Fractional Polynomial Functions 
Fractional polynomial regression models provide a flexible parametric method for modelling 
curved relationships using few parameters and are particularly suitable for modelling smooth 
curved relationships between response and predictor (Royston and Altman, 1997). They were 
developed since smoothing splines were computationally intensive, do not provide predictive 
equations and do not extrapolate well (Royston and Altman, 1994). Fractional polynomials can be 
seen as an extension of Box and Tidwells‟ procedure for applying transformations in the ordinary 
least squares regression setting (Box and Tidwell, 1962). Fractional polynomials are an extended 
family of curves defining functions of the form 0+1Xp where p is taken from the set {-2, -1, -0.5, 
0, 0.5, 1, 2, 3} with non-integer and negative power terms as well a positive integer powers used 
in conventional polynomials, producing fractional polynomial models of degree 1 (FP1) with an 
additive predictor which is linear. A natural extension to the FP1 model is the FPm function where 
m is an integer >1 and are generalisations of quadratic functions. First-degree fractional 
polynomials (FP1) are simple transformations providing monotonic curves encompassing 
conventional polynomials defined as: 
φ*1(X;p) = 0+1Xp =0+ φ1(X;p) 
Second-degree fractional polynomial functions (FP2) have a maximum of one turning point. The 
definition of an FPm function with power terms p=(p1, p2) is: 
φ*2(X;p) = 0 + 1Xp1 + 2Xp2  =0  + Xp  = 0 + φ2(X;p) 
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With the set of p powers taken as {-2, -1, -0.5, 0, 0.5, 1, 2, 3} provides eight FP1 transformations, 
28 FP2 transformations with distinct powers (p1≠p2) and eight FP2 transformations with equal 
powers (p1=p2). The general definition of an FPm function is: 

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where X is a single covariate, m is a positive integer representing the degree of the fractional 
polynomial, pj is a vector of powers, j is a vector of coefficients and: 
if pj  pj-1 
if pj = pj-1  (Box-Tidwell transformation for repeated powers) 
where the expression Hj(X) can be substituted for jXji in the proportional hazards model 
(Equation 1, Chapter 5). The best powers p  are those associated with the highest likelihood, 
hence lowest deviance (-2log-likelihood), chosen from the small preselected set p=[-max(3,m), 
…., -2, -1, -0.5, 0, 0.5 , 1, 2, .., max(3,m)] where 0 represents the natural logarithmic 
transformation loge(X) and 1 represents no transformation (linear assumption). In health sciences, 
m<2 provide enough flexibility and m>2 are rarely required and are associated with increased 
instability (Royston and Altman, 1994;Royston and Sauerbrei, 2008). Degree m is selected on a 
priori grounds or increasing m until no further significant improvement in fit is achieved. Models 
are fitted using maximum likelihood with the „best‟ power vector being that with significantly lowest 
deviance (-2log-likelihood). The advantages of the fractional polynomial method are that 
implementation is simple and practical and that the resulting transformation may hold outside of 
the range of the observed data. There is a certain amount of inflexibility for manual model building 
in the multivariable setting, there are constraints in fitting a full model since variables may not be 
selected in the automated process. 
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Fractional polynomial transformations are implemented in SAS (SAS Institute Inc., 1999) using the 
%MFP8 macro (Meier-Hirmer et al., 2003) for each continuous covariate, based on a closed test 
function selection procedure (Ambler and Royston, 2001) to maintain approximately the type 1 
error rate. At the initial cycle all variables are sorted based on p-values of the full linear model. 
The best fitting fractional polynomial function is determined for the first covariate based on a 
difference in -2log-likelihood with one degree of freedom for each fractional polynomial term plus 
one for each power term. The functional form is retained and the process repeated for each 
covariate. Covariates with a larger p-value than the set alpha are excluded in this cycle but 
reinvestigated in the following cycle. The next cycle investigates each covariate in turn based on 
an initial functional format retained from the previous cycle. The macro terminates when the 
functional form does not change (convergence) based on differences in the -2log-likelihood, 
usually within 5 cycles. 
 
6.3. Modelling with Fractional Polynomials in Advanced Pancreatic Cancer 
The „best‟ functional form of each continuous covariate was assessed in the univariate setting 
based on comparison of the AIC. Smaller values of the AIC indicate a better model but the „best‟ 
model may be based on a complex transformation with almost identical AIC statistic to a less 
complex transformation. As such, the AIC had to be substantially lower to permit a complex 
transformation compared to a simple transformation. Substantial was indicated as a reduction in 
AIC of 4, based on an arbitrary decision rule taken from similar values as the chi-square 
distribution with 1 degree of freedom. If a simple log transformation reduced the AIC compared to 
the untransformed variable, then more complex fractional polynomial transformations were 
investigated. The use of log function as a screening tool for more complex functions may risk 
missing functions with a turning point but is a simple, appropriate, unbiased modelling strategy 
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adopted throughout. Second degree fractional polynomial transformations were investigated with 
a set of predefined powers {-2, -1, -0.5, 0, 0.5, 1, 2, 3} using a 5% level of significance. Each 
continuous covariate was then included in the multivariable analysis under either a linear, log or 
non-linear univariate fractional polynomial transformation. 
 
Univariate analysis of the 10 continuous variables identified that non-linear transformations were 
appropriate for three variables in their relationship with survival: bilirubin mol/L and LDH IU/L 
both as log transformations and CA19-9 KU/l as a second degree fractional polynomial 
transformation [CA19-90.5 + (CA19-90.5 x log(CA19-9))]. The seven remaining continuous 
covariates were analysed assuming a linear relationship with log-hazard (Table 6.1): 
 
Table 6.1: Univariate AIC statistics  
(shaded is selected transformation)  
Variable Linear Log FP 
Age 6870.4 6870.8 Na 
Albumin 6488.4 6493.7 Na 
AlkPhos 6526.0 6532.4 Na 
AST 6499.1 6498.5 Na 
Bilirubin 6563.4 6555.6 6554.5 
BUN 6462.9 6465.8 Na 
CA19-9 6288.6 6233.6 6223.8 
Haemoglobin 6347.0 6347.8 Na 
LDH 6441.5 6425.4 6425.4 
WBC 6318.5 6322.0 Na 
FP=Fractional Polynomial, na=not applicable since log transformation not substantial 
improvement over linear assumption 
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As before, all variables were considered in the multivariable setting in their most appropriate 
functional form using Cox proportional hazards regression based on a backward elimination 
selection method using a 5% significance level for exclusion of variables and including trial, sex, 
cancer stage (stratification factors at randomisation) and randomised treatment as „forced‟ 
variables in each model. A final check was made to ensure that no term in the model could be 
omitted and that none of the omitted terms could be included without significantly affecting the 
model. All variables omitted from the model based on backward elimination were considered and 
re-instated if they significantly improved the model. The final model based on transformed 
covariates („FP‟ model) was based on 556 patients (520 deaths) with complete data on the 
prognostic factors of interest and identified seven prognostic factors. Five factors were highly 
significant with p<0.001: albumin, CA19-9, WBC, alkaline phosphatase and LDH with AST and 
BUN being more borderline in the model (p=0.022 and 0.027) (Table 6.2): 
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Table 6.2: Model based on Fractional Polynomial Transformations 
(shaded highlight factors identified by both „categorical‟ and „linear‟ models) 
FINAL ‘FP’ MODEL (n=556 patients, 520 deaths) 
AIC=5510.7 Variable 2+ p-value HR (95% CI)^ 
Stratification factors TRIAL 14.5 <0.001 0.69 (0.57 to 0.83) 
 *CANCER STAGE 1.8 0.18 1.19 (0.92 to 1.53) 
 SEX 3.1 0.079 0.85 (0.71 to 1.02) 
 TRT 3.0 0.082 1.19 (0.98 to 1.43) 
Independent factors      Linear ALBUMIN g/L 42.3 <0.001  0.71 (0.64 to 0.79) 
1st degree FP Log(LDH)IU/L 14.5 <0.001 1.76 (1.31 to 2.34) 
Linear WBC 109/L 11.1 <0.001  1.25 (1.10 to 1.42) 
Linear ALKPHOS IU/L 14.2 <0.001  1.13 (1.06 to 1.20) 
Linear AST IU/L 5.3 0.022  0.91 (0.84 to 0.99) 
Linear BUN mmol/L 4.9 0.027  1.15 (1.02 to 1.30) 
2nd degree FP CA1990.5 KU/l 51.5 <0.001 NA 
2nd degree FP CA1990.5 KU/l x 
log(CA199)KU/l 
  NA 
HR=hazard ratio, FP= Fractional Polynomial, NA=not appropriate 
* Stage (I/II vs. III/IV), + Type-3 Wald 2 test 
^ HR based on 5 unit increase in albumin g/L, WBC 109/L, BUN mmol/L; 25 unit increase in AST 
IU/L and 100 unit increase in alkaline phosphatase IU/L 
 
 
Non-linear transformations were selected for LDH IU/L (log) and CA19-9 KU/l (second degree 
fractional polynomial).  
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The estimated function for LDH is shown graphically in Figure 6.1. The log function for LDH 
estimates increasing risk for increasing values of LDH: 
 
Figure 6.1: Estimated Functional Form for LDH IU/L  
(dots indicate actual data values) 
 
 
The estimated log hazard ratio function for CA19-9 is shown graphically in Figure 6.2. The second 
degree fractional polynomial function for CA19-9 estimates increasing risk up to an approximate 
CA19-9 value of 14,000 KU/l and then decreases with increasing CA19-9: 
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Figure 6.2a: Estimated Functional Form for CA19-9 KU/l 
(dots indicate actual data values) 
 
 
Figure 6.2b: Estimated Functional Form for CA19-9 KU/l 
(dots indicate actual data values <100,000 KU/l) 
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Three final models have been presented under three differing assumptions for dealing with 
modelling continuous covariates: dichotomisation („categorical‟ model, Table 5.4), assumption of 
linearity („linear‟ model, Table 5.5) and non-linear fractional polynomial transformation („FP‟ model, 
Table 6.2). The „FP‟ model has the lowest AIC of 5510.7, substantially lower compared with an 
AIC of 5583.2 for the „categorical‟ model and an AIC of 5557.1 for the „linear‟ model. The „FP‟ 
model selected seven important independent prognostic factors over and above the „forced‟ 
variables, the „categorical‟ model selected six and the „linear‟ model selected five.  
 
All three models considered albumin, LDH and WBC to be highly significant (p<0.001) 
independent prognostic factors. The strength of evidence as indicated by the Wald 2 statistic was 
similar for albumin in the „linear‟ and „FP‟ models but was underestimated by half in the 
„categorical‟ model. The Wald 2 statistic was similar for LDH in the „linear‟ and „FP‟ models but 
was overestimated by double in the „categorical‟ model. The strength of evidence was similar for 
WBC in all three models.  
 
The parameter estimate and overall significance of metastases were reduced in the „FP‟ model 
when continuous covariates were included in a more appropriate format. No non-linear 
transformation was required or applied to alkaline phosphatase IU/L which is why it was only 
selected as a highly significant and influential prognostic factor in both the „linear‟ and „FP‟ models. 
CA19-9 KU/l was also a highly significant and influential prognostic factor in both the „categorical‟ 
and „transformed‟ models. This variation is largely explained by the significant non-linear relation 
of CA19-9 to survival (Figure 6.2) and why it was considered important, albeit with massively 
reduced Wald 2 evidence, when dichotomised but not when assumed as linear. When 
considered as a transformed second degree fractional polynomial it‟s significance is much greater. 
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Bilirubin mol/L was only selected as a highly significant factor in the „categorical‟ model but was 
not included in either the „linear‟ or „transformed‟ models. AST IU/L and BUN mmol/L were only 
selected as borderline prognostic variables in the „transformed‟ model when other factors had 
been modelled appropriately. 
 
6.4. Model Performance 
The AIC statistic was smallest for the „FP‟ model (Table 6.2) and was substantially lower than 
either the „categorical‟ or „linear‟ models indicating a substantially better fit to the data. Deviance 
residuals for the „FP‟ model were plotted against the linear predictor and were randomly scattered 
and centred symmetrically around a residual value of zero ranging between -3.80 and 3.34 which 
suggests the data have not been mis-modelled (Figure 6.3): 
 
Figure 6.3: Deviance Residual Plot 
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At least four risk groups of patients with advanced pancreatic cancer are expected (personal 
communication Professor Bass Hassan, 2004): i) very ill patients with survival <2 months not 
usually ideal candidates for therapy due to rapid disease progression or late presentation of large 
bulk disease; ii) fit patients with loco regional disease, low bulk metastatic disease and a median 
life expectancy of approximately 9 months; iii) and iv) two groups of patients with „intermediate‟ 
prognosis between the two other clinical extremes, maybe patients with better prognosis but 
delayed clinical management. As such, patients were split into four equal sized groups based on 
quartiles of the distribution of linear predictor scores from the „FP‟ model. Linear predictor scores  
(LP) were calculated as: 
LP =i = 1X1i + 2X2i + ….. + pXpi  
LP = 0.37711*TRIAL + 0.17286*STAGEGP - 0.16115*SEX + 0.16934*TRTGP - 0.06802*ALB(g/L) + 
0.02383*CA199FP1(KU/l) - 0.00173*CA199FP2(KU/l) + 0.04409*WBC(109/L) + 
0.00119*ALKPHOS(IU/L) + 0.56220*LOGLDH(IU/L) - 0.00367*AST(IU/L) + 0.02772*BUN(mmol/L) 
with the following code: TRIAL (1=BB128, 2=BB193), STAGEGP (1=I/II, 2=III/IV), SEX (1=MALE, 
2=FEMALE), TRTGP (0=GEM, 1=GEMPLUS). Quartiles of the linear predictor scores (0.654140, 
1.036423, 1.596797) created the four groups. Kaplan-Meier survival estimates (Figure 6.4) show 
four distinct prognostic groups with descending median survival estimates of 8.5 (95%CI: 7.4 to 
10.1), 7.0 (95%CI: 5.8 to 8.4), 4.2 (95%CI: 3.5 to 5.0) and 2.0 (95%CI: 1.6 to 2.4) months and 
descending 12-month survival estimates of 30.5% (95%CI: 22.8% to 38.2%), 27.6% (95%CI: 
20.1% to 35.1%), 12.5% (95%CI: 6.9% to 18.1%) and 4.3% (95%CI: 0.9% to 7.7%): 
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Figure 6.4: Survival by Prognostic Group 
 
 
The hazard ratios for groups 2, 3 and 4 using prognostic group 1 as the baseline were: 
1.26 (95%CI: 0.98 to 1.61), 2.02 (95%CI: 1.58 to 2.60) and 4.57 (95%CI: 3.55 to 5.90) 
respectively demonstrating distinct risk with almost non-overlapping confidence intervals of 
increasing risk of death. 
 
A bootstrap re-sampling assessment of the extent of model optimism (over-fitting) in the final „FP‟ 
model was carried out based on 200 bootstrap re-samples using the „validate‟ statement in the 
Design Library of the programming language R (The R Foundation for Statistical Computing, 
2008). Bootstrap samples are created by sampling one patient at a time with replacement from the 
original dataset up to the same size of the original set of data, repeated until 200 simulated 
bootstrap samples have been created. Bootstrap samples provide an unbiased estimate of the 
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stability of the estimates from the analysis of original data. Somers Dxy rank correlation is the 
measure of association between predicted log hazard and observed survival time on which extent 
of optimism is assessed (Harrell, 2001). The apparent index Dxy is calculated as -0.3989 but a 
better estimate of how well the model will discriminate prognoses in the future is the index 
corrected Dxy calculated as -0.3787. The estimate of model optimism is -0.0203 and as such is 
small (less than 5%).  
 
The majority of variables had <5% missing values (Table 2.2). Tumour stage, CA19-9 and WBC 
were missing in less than 10% of patients and lymph node status was missing for 24% of patients. 
Metastases or lymph node status were considered in the analysis as classification variables using 
„negative‟ as a reference level and including „missing‟ as a classification level. Principal analysis 
was based on complete cases. Supportive analysis used multiple imputation to investigate the 
possible influence of variables with larger amounts of missing data and provided valid inferential 
alternative results. The MI procedure in SAS (SAS Institute Inc., 1999) was used to carry out 
multiple imputation based on five imputations using a Markov Chain Monte Carlo (MCMC) method 
(Schafer, 1997) that assumes multivariate normality to impute missing values. Each of the five 
complete data sets were analyzed using PHREG procedure in SAS (SAS Institute Inc., 1999) then 
the MIANALYZE procedure was used to generate valid statistical inferences about these 
parameters by combining results. Multiple imputation was a supportive analysis which allowed all 
653 patients to be included in the modelling process (Table 6.3): 
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Table 6.3: Supportive Analysis of Imputed Dataset 
(shaded highlight factors identified in all models) 
FULL ‘FP’ MODEL BASED ON IMPUTED DATA (n=653 patients, 612 deaths) 
 Variable t p-value 
Stratification factors TRIAL -4.1 <0.001 
 *CANCER STAGE -1.8 0.073 
 SEX -2.1 0.037 
 TRT 2.1 0.033 
Independent factors      Linear ALBUMIN g/L -5.2 <0.001 
1st degree FP Log(LDH)IU/L 3.0 0.004 
Linear WBC 109/L 3.9 <0.001 
Linear ALKPHOS IU/L 3.5 <0.001 
Linear AST IU/L -2.5 0.014 
Linear BUN mmol/L 2.1 0.034 
2nd degree FP CA1990.5 KU/l 6.1 <0.001 
2nd degree FP CA1990.5 KU/l x log(CA199)KU/l -5.6  
Binary METASTASES 3.2 0.001 
Binary RACE -0.4 0.72 
Binary *T STAGE 0.1 0.89 
Binary NODES 2.7 0.016 
Linear AGE 1.4 0.15 
Linear HAEMOGLOBIN g/dL -0.6 0.54 
1st degree FP Log(BILIRUBIN) mol/L 1.8 0.067 
HR=hazard ratio, FP= Fractional Polynomial 
* Stage (I/II vs. III/IV) 
 
 
The „full‟ model including all covariates and all 653 patients (612 deaths) confirmed all the 
variables included in the „FP‟ model but with increased significance for metastases (p=0.001) and 
the inclusion of nodal status (p=0.016) which had been excluded from all models prior to 
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imputation, suggesting a strong link to other variables already in the model requiring further 
investigation. 
 
6.5. Centre Effect 
A grouped frailty model (Therneau and Grambsch, 2000) is the term used to describe a survival 
model which incorporates a random effect (RE) element into hazard function to account for 
heterogeneity between patients. A random effect is a continuous variable that describes excess 
risk (frailty) for specific groups of patients. Those patients who are most „frail‟ are expected to 
have shorter survival time. Known and expected frailties are associated with hospital and surgeon. 
The aim of a frailty model is to account for any „centre effect‟ whilst adjusting for other prognostic 
factors. An important assumption is that frailty is independent of any censoring. The advanced 
pancreas clinical trials both stratified the randomisation procedure by centre and as such it seems 
sensible to investigate this further during the analysis. The frailty model is based on the 
proportional hazards model: 
)()( 0 theth
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where X and  correspond to the fixed effects in the model (covariates such as age and sex), ω is 
a vector containing the unknown random effects (frailties)  and  Z is an indicator of the „group‟ of 
dependent patients.  
 
Frailty models are not easy to implement in SAS Version 9.1 (SAS Institute Inc., 1999) for the Cox 
proportional hazards model (although may be easier in the updated SAS v9.2) and as such data 
were exported into the programming language R (The R Foundation for Statistical Computing, 
2008) where an approximate grouped frailty term is easier to include using a „frailty()‟ statement in 
the „Survival‟ Library based on a gamma distribution for the random effects. The frequent 
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assumption that frailty follows a gamma distribution is derived from the fact that the distribution for 
the frailty term must be positive since the hazard function cannot be negative. 
 
The advanced pancreas dataset included patients from 60 randomising hospitals. A random effect 
associated with centre was non-significant (Wald 2=2.66, p=0.103) when forced into the existing 
fractional polynomial model. 
 
6.6. Conclusions 
The analysis of continuous variables in the advanced pancreatic cancer dataset has shown that 
non-linear transformations were appropriate for some covariates, but had not been previously 
investigated in this disease setting. The analysis including transformed variables resulted in a 
model which was a substantially better fit and included significant prognostic factors which were 
excluded in models under the assumptions of either step-functional (excluded  alkaline 
phosphatase) or linear (excluded CA19-9) relationships. Through addressing the mis-modelling 
and non-linearity of continuous covariates, a more accurate prognostic model has been 
developed, displaying minimal overfitting. The model has the ability to be developed into a 
validated prognostic index based on robust statistical methodology, not previously presented in 
this disease site. Four distinct prognostic risk groups were identified based on information 
available in a routine NHS out-patient clinic. The transformation method used in the development 
of this model was based on fractional polynomial transformations but alternative transformation 
methods could also be used. Chapter 7 investigates an alternative more traditional method based 
on restricted cubic spline transformations and directly compares both transformation methods for 
the analysis of non-linear continuous variables in the advanced pancreatic cancer dataset. 
Chapter 8 continues the comparison of methods in an alternative disease with alternative survival 
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distribution based on a large dataset in cardiac surgery patients. Since an external dataset was 
anticipated, external validation of the prognostic model in advanced pancreatic cancer was 
possible and is the focus of Chapter 9.
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CHAPTER 7: COMPARISON OF NON-LINEAR FUNCTIONS 
 
 SUMMARY 
 Fractional polynomials is one approach for analysing non-linear covariates, an alternative 
is the restricted cubic spline approach 
 Restricted cubic splines are linear in estimated coefficients and restricted to be linear in 
the tails therefore allowing use of standard methods of inference 
 Restricted cubic spline transformations can be implemented using SAS macros 
 A bootstrap validation compares the model fit of the two polynomial based approaches 
 
7.1. Introduction 
The use of fractional polynomials is one of various approaches for analysing independent 
continuous covariates which do not comply with the assumption of linearity. An alternative and 
more conventional method is the restricted cubic spline approach which also utilises the full 
information when handling continuous variables with the aim of identifying important non-linear 
continuous prognostic factors. 
 
There is a certain amount of inflexibility for manual model building in the multivariable setting 
using the fractional polynomial macros and there are constraints in fitting a full model since 
continuous variables may not be selected in the automated process. As such, comparison with the 
more conventional restricted cubic spline method was considered. An advantage of the restricted 
cubic spline method is that no particular functional form needs to be specified. A drawback is the 
arbitrary choice of the number and position of knots of the cubic spline function which must be 
pre-specified but in most instances are not known. Extrapolation beyond the outer knots has also 
been found to be spurious (Harrell, 2001). The difference between two spline based procedures 
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and the fractional polynomial methods was investigated in longitudinal cohort studies in lung 
cancer (Govindarajulu et al., 2007). The area under three curves were compared (two spline 
based, one fractional polynomial) and concluded that the two spline based curves were more 
similar than either was to the fractional polynomial curve and that fractional polynomials were 
more global in nature in contrast to a more local fit of splines.  
 
In this chapter these two polynomial based strategies are compared directly for determining the 
functional form of the non-linear relationship between a continuous prognostic covariate and 
survival. A bootstrap validation was carried out which directly compared the models based on the 
difference in AIC statistics for the two polynomial based approaches within each bootstrap 
resample. 
 
7.2. Restricted Cubic Spline Functions 
The name „spline‟ came from a draftman‟s spline which is a flexible strip used to draw curves. 
Spline functions in statistics (Stone and Koo, 1985) are piecewise polynomials that are used for 
fitting curved relationships, that is polynomials connected across intervals of X and constrained to 
join at the interval endpoints or „knots‟. The simplest spline function is the linear spline function, 
that is the functions within each interval are linear and joined at the knot positions. The expression 
for a spline function S(X) of variable X (Harrell, 2001;Durrleman and Simon, 1989) is given as: 
n
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and can be substituted for jXji in the proportional hazards model (Equation 1, Chapter 5) where n 
is the degree of the spline function, k is the number of knots, t is the position of the knots 
(t1<t2<…<tk) or more practically: 
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S(X)=0 + 1X + 2(X-a) + 3(X-b) + 4(X-c) + ... 
where a, b and c are the position of the knots. As such, a spline function of variable X in a 
multivariable model will introduce k+n new variables and regression coefficients determined to 
optimise fit usually based on the log-likelihood function. The spline is not constrained to be 
continuous or „smooth‟ at the knots and as such does not fit highly curved functions well (Harrell, 
2001). Cubic polynomials have the ability to fit sharp curves and can be constrained to be smooth 
at knot positions a, b and c: 
S(X)=0 + 1X + 2X2 + 3X3 + 4(X-a)3 + 5(X-b)3 + 6(X-c)3 + ... 
requiring estimation of k+3 parameter estimates for each of k knots. Cubic splines have been 
found to behave poorly in the tails, before the first and after the last knot position (Stone and Koo, 
1985).  Restricted cubic splines are designed to control this unsatisfactory behaviour in the tails. 
Restricted cubic splines are linear in estimated coefficients and restricted to be linear in the tails 
therefore allowing use of standard methods of inference and computation requiring estimation of 
k-1 regression coefficients for each of k knots t1, ..., tk: 
S(X)=0 + 1X1 + 2X2 + 3X3 + ... + k-1Xk-1 
where: X1=X  
and for j=1, ..., k-2:  Xj+1 = (X-tj)3 – (X-tk-1)3(tk-tj) / (tk-tk-1) + (X-tk)3(tk-1-tj) / (tk-tk-1) 
The advantages of the restricted cubic spline method are that no particular functional form needs 
to be specified and the method produces smooth curves. Although the basis for restricted cubic 
splines allows for extrapolation beyond the outer knots, when these occur in the tails of the data, it 
has been found to be spurious (Harrell, 2001). A drawback is the arbitrary choice of the number 
and position of knots of the cubic spline function which must be pre-specified and that each k-1 
spline component spends an additional degree of freedom. Model fit has been shown to depend 
more on the number of knots rather than location (Stone, 1986) and 3 to 5 knots will usually 
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suffice (Durrleman and Simon, 1989;Heinzl et al., 1996;Hess, 1994) set at fixed percentiles of the 
observed data distribution to guard against influence of outliers on knot placement (Durrleman and 
Simon, 1989).  
 
Restricted cubic spline transformations were implemented using the %RCSPLINE macro (Harrell, 
1991) in SAS (SAS Institute Inc., 1999) to compute the k-1 components of the cubic spline 
function restricted to be linear before the first and after the last knots for each continuous 
covariate. Models with 3, 4 and 5 knots were compared based on knot positions identified by the 
SAS %DASPLINE macro (Harrell, 1991). The %RCSPLINE macro generates formulas to create 
classification variables that allow fitting of splines constrained to be linear in the tails and to be 
fitted in multivariable models. Knot positions identified by %DASPLINE are based on quanitiles 
according to the number of knots specified but forced to be real data points: 
    Knots       Quantiles 
        3       .05     .5      .95 
        4       .05     .35     .65     .95 
        5       .05     .275    .5      .725    .95 
        6       .05     .23     .41     .59     .77     .95 
        7       .025    .18333  .34166  .5      .65833  .81666  .975 
 
 
7.3. Univariate Comparison of Functions in Advanced Pancreatic Cancer 
Principal analyses of the advanced pancreatic cancer dataset was based on the assessment of 
the functional form of each continuous covariate in the univariate setting selecting a „best‟ fitting 
fractional polynomial and also a „best‟ fitting restricted cubic spline (with varying number and 
position of knots) based on comparison of AIC. Smaller values of the AIC indicate a better model 
but the „best‟ model may be based on a complex transformation with almost identical AIC statistic 
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to a less complex transformation. As such, the AIC had to be substantially lower to permit a 
complex transformation compared to a simple transformation. Substantial was indicated as a 
reduction in AIC of 4, based on an arbitrary decision rule taken from similar values as the chi-
square distribution with 1 degree of freedom. As before, the strategy was that if a simple log 
transformation reduced the AIC compared to the untransformed variable, then more complex non-
linear transformations were investigated further using restricted cubic splines (based on 3, 4 and 5 
knot models) and second degree fractional polynomials.   
 
Univariate analysis (Stocken et al., 2008) of the ten continuous variables identified that non-linear 
transformations were appropriate for three variables in their relationship with survival: bilirubin, 
LDH and CA19-9 (Table 7.1): 
 
Table 7.1: Univariate AIC statistics  
(shaded is selected transformation with lowest AIC) 
Variable Linear Log RCS-3 RCS-4 RCS-5 FP 
Age 6870.4 6870.8 na na na na 
Albumin 6488.4 6493.7 na na na na 
AlkPhos 6526.0 6532.4 na na na na 
AST 6499.1 6498.5 na na na na 
Bilirubin 6563.4 6555.6 6556.0 6557.9 6559.0 6554.5 
BUN 6462.9 6465.8 na na na na 
CA19-9 6288.6 6233.6 6235.8 * * 6223.8 
Haemoglobin 6347.0 6347.8 na na na na 
LDH 6441.5 6425.4 6430.1 6429.4 6431.1 6425.4 
WBC 6318.5 6322.0 na na na na 
RCS-k=Restricted Cubic Spline with k knots, FP=Fractional Polynomial 
na=not applicable since log transformation not substantial improvement over linear assumption 
* contains spline variables that are not included in the model, df=0 hence use 3-knot RCS 
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Restricted cubic spline transformations for bilirubin mol/L, LDH IU/L and CA19-9 KU/l were 
investigated based on 3, 4 and 5 knot models. For bilirubin and LDH, the AIC was not reduced by 
any spline polynomial and was not substantially reduced by the more complex fractional 
polynomial function (bilirubin^-0.5 and log(LDH) respectively) transformation compared to a simple 
log transformation. For CA19-9, the 5 knot restricted cubic spline transformation appeared to be 
better fit compared to the simple log transformation and better than the 3 or 4 knot spline models. 
However models with >3 knots introduced spline covariates that were not included in the model 
with degrees of freedom equal to 0 and as such the 3 knot model was used with knot positions at 
CA19-9 KU/l values of 10, 710 and 70,000. An alternative approach could be based on rescaling 
or truncating. The second degree fractional polynomial transformation identified for CA19-9 KU/l 
was [CA199^(0.5) + (CA199^(0.5)*log(CA199))] and had substantially reduced AIC compared to 
the log or spline transformations (Table 7.1).  The seven remaining continuous covariates were 
analysed assuming a linear relationship with log-hazard. 
 
The estimated risk over increasing values of CA19-9 KU/l was plotted for each transformation 
method to enable graphical comparison of the estimated functional format (Figure 7.1). The plots 
of the estimated functional form appear similar for CA19-9 but with a steeper elevated increasing 
hazard in lower values of CA19-9 less than 30,000 KU/l using the fractional polynomial function. 
The linear predictor was scaled so the log(HR) was zero at the midpoint of each continuous 
covariate to enable plots on the same axes, altering the fractional polynomial plot from that in 
Chapter 6 (Figure 6.2). 
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Figure 7.1a: Estimated Functional Form for CA19-9 KU/l: Restricted Cubic Spline Transformation 
(dots indicate actual data values) 
 
Figure 7.1b: Estimated Functional Form for CA19-9 KU/l: Fractional Polynomial Transformation 
(dots indicate actual data values) 
 
CHAPTER 7: COMPARISON OF NON-LINEAR FUNCTIONS 
93 
 
7.4. Multivariable Comparison of Functions in Advanced Pancreatic Cancer 
Each continuous covariate was included in the multivariable analysis under either a linear, log or 
non-linear univariate transformation based on the „best‟ fitting restricted cubic spline identified and 
the „best‟ fitting fractional polynomial identified. As before, all variables were then considered in 
the multivariable setting using Cox proportional hazards regression based on a backward 
elimination selection method using a 5% significance level for exclusion of variables and including 
trial, sex, cancer stage (stratification factors at randomisation) and randomised treatment as 
„forced‟ variables in each model. A final check was made to ensure that no term in the model 
could be omitted and that none of the omitted terms could be included without significantly 
affecting the model. All variables omitted from the model based on backward elimination were 
considered and re-instated if they significantly improved the model. Two final Cox proportional 
hazards regression models (Table 7.2) were developed based on i) restricted cubic spline and ii) 
fractional polynomial transformations, which could be directly compared based on AIC statistics: 
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Table 7.2: Cox Proportional Hazards Regression Models (n=556, deaths=520), shaded highlight factors identified by both models 
Restricted Cubic Spline Transformations 
AIC=5526.2 Transformation 
(knot position) 
log HR () se() 2W p-value HR (95% CI)^ 
Stratification factor TRIAL -0.35 0.099 12.7 <0.001 0.70 (0.58 to 0.85) 
Stratification factor * STAGE 0.21 0.13 2.6 0.11 1.23 (0.96 to 1.59) 
Stratification factor SEX -0.19 0.090 4.2 0.040 0.83 (0.70 to 0.99) 
Stratification factor TRT 0.18 0.098 3.5 0.063 1.20 (0.99 to 1.45) 
Continuous factor Linear ALB g/L -0.070 0.010 45.4 <0.001  0.70 (0.64 to 0.78) 
Continuous factor RCS3 # CA199 (10,710,70000)KU/l 0.000047 0.000007 43.3 <0.001 NA 
 CA1991 KU/l -0.0016 0.00025   NA 
Continuous factor Linear WBC 109/L 0.045 0.013 12.2 <0.001  1.26 (1.11 to 1.43) 
Continuous factor Linear ALKPHOS IU/L 0.00090 0.00028 10.5 0.0012  1.10 (1.04 to 1.16) 
Continuous factor Log Log(LDH)IU/L 0.39 0.14 8.4 0.0039 1.48 (1.14 to 1.93) 
Fractional Polynomial Transformations 
AIC=5510.7 Transformation log HR () se() 2W p-value HR (95% CI)^ 
Stratification factor TRIAL -0.38 0.099 14.5 <0.001 0.69 (0.57 to 0.83) 
Stratification factor * STAGE 0.17 0.13 1.8 0.18 1.19 (0.92 to 1.53) 
Stratification factor SEX -0.16 0.092 3.1 0.079 0.85 (0.71 to 1.02) 
Stratification factor TRT 0.17 0.097 3.0 0.082 1.19 (0.98 to 1.43) 
Continuous factor Linear ALB g/L -0.068 0.010 42.3 <0.001  0.71 (0.64 to 0.79) 
Continuous factor FP2 # CA199^(0.5)KU/l 0.024 0.0040 51.5 <0.001 NA 
 CA199^(0.5)*log(CA199)KU/l -0.0017 0.00031   NA 
Continuous factor Linear WBC 109/L 0.044 0.013 11.1 <0.001  1.25 (1.10 to 1.42) 
Continuous factor Linear ALKPHOS IU/L 0.0011 0.00032 14.2 <0.001  1.13 (1.06 to1.20) 
Continuous factor FP1 Log(LDH)IU/L 0.56 0.15 14.5 <0.001 1.76 (1.31 to 2.34) 
Continuous factor Linear AST IU/L -0.0037 0.0016 5.3 0.022  0.91 (0.84 to 0.99) 
Continuous factor Linear BUN mmol/L 0.028 0.013 4.9 0.027  1.15 (1.02 to 1.30) 
HR=Hazard Ratio, RCS3=3 knot Restricted Cubic Spline, FP1/2=1st or 2nd degree Fractional Polynomial, NA=not appropriate 
* Stage (I/II vs. III/IV); # CA199: RCS knots positioned at (10, 710, 70000), Type III Wald 2 test presented with 2 degrees of freedom 
^ HR based on 5 unit increase in albumin g/L, WBC 109/L, BUN mmol/L; 25 unit increase in AST IU/L and 100 unit increase in alkaline phosphatase IU/L 
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The sign of each corresponding variable in the models were identical and the significance of each 
variable similar except for LDH which was reduced in the restricted cubic spline model. Parameter 
estimates only differed substantially for the two transformed variables CA199 and LDH. The AIC 
was smallest for the model under the fractional polynomial transformation (5510.7 compared with 
5526.2). However the fractional polynomial model selected an additional two variables with 
borderline significance: AST (p=0.022) and BUN (p=0.027). The comparable AIC of the restricted 
cubic spline model including AST (p=0.050) and BUN (p=0.067) was 5522.7 showing the 
fractional polynomial model to remain a better fit to the data by a reduction of 12.0.  
 
7.5. Bootstrap Validation Comparing Non-Linear Functions 
Internal validation, to directly compare the fit of the restricted cubic spline and fractional 
polynomial strategies, was carried out by calculating the sampling distribution of the difference in 
the AIC statistics between the models in multiple bootstrap resamples of the data using an in-
house developed SAS program (Appendix) based on nonparametric bootstrap analyses (Efron 
and Tibshirani, 1993). The bootstrap analysis fitted the final models, one based on the restricted 
cubic spline transformations and one based on the fractional polynomial transformations, to a 
series of 1000 bootstrapped resamples taken from and with the same size as the original data. 
Smaller values of the AIC indicate a better model but it is unclear whether AIC statistics from non-
nested models will approximate the chi-square distribution for hypothesis testing. Using a fixed 
level of significance for the comparison of AIC is not appropriate in non-nested models with the 
same parameters. The difference in AIC statistics for the different models in multiple bootstrap 
resamples provides a distribution which can then be summarised appropriately with bootstrap 
percentile confidence intervals derived from the bootstrap distribution of the difference between 
the restricted cubic spline and fractional polynomial models.  
CHAPTER 7: COMPARISON OF NON-LINEAR FUNCTIONS 
96 
 
The %BOOT macro (Sarle, 2000) in SAS (SAS Institute Inc., 1999) is very computationally 
intensive carrying out non-parametric bootstrap analyses for simple random samples to produce 
inferences such as approximate standard errors, bias-corrected estimates and confidence 
intervals without knowing the type of distribution from which a sample has been taken assuming a 
normal sampling distribution. The %BOOT macro was used to calculate 1000 resamples of the 
original dataset using identical univariate transformations, if any, as in the original dataset. 
 
Modelling was carried out in 1000 bootstrap resamples forcing in trial, stage, sex, trt and CA19-9 
components (restricted cubic spline or fractional polynomial) and  considering all other variables 
for inclusion (including the borderline variables of AST and BUN) based on backward elimination 
variable selection method. Two models were created within each bootstrap sample, one based on 
restricted cubic spline transformations and one based on fractional polynomial transformations. 
The AIC for each model was output from the screen to a temporary SAS dataset and the 
difference (AIC[RCS]-AIC[FP]) between them calculated, a positive difference indicating a better 
fit by the fractional polynomial transformation model. This was repeated in each 1000 bootstrap 
resamples and the mean difference calculated with 95% confidence interval (Table 7.3). The AIC 
statistics had to be output from the screen rather than delivered to an output dataset within the 
modelling process, as the two AIC values differed. This was reported to SAS who replied “you 
have an excellent point” and confirmed they would investigate further and recommended 
outputting the AIC from screen using an „ods output‟ statement instead.  
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Table 7.3: Bootstrap Comparison of AIC based on 1000 Resamples 
 Bootstrap Mean AIC Bootstrap Percentile 
95% CI 
Restricted Cubic Spline 5498.1 5441.7 to 5667.1 
Fractional Polynomial 5487.1 5419.9 to 5648.5 
Difference (RCS-FP) 11.0 9.0 to 31.4 
 
The bootstrap mean AIC (Table 7.3) was smallest for the model containing fractional polynomial 
transformations and on average was a better fit than the model based on restricted cubic spline 
transformations by a bootstrap mean reduction of 11.0 (bootstrap percentile 95% CI: 9.0 to 31.4). 
 
7.6. Conclusions 
Fractional polynomial and restricted cubic spline functions are both polynomial functions 
particularly suitable for modelling smooth curved relationships between response and a predictor 
and both are easily implementable in SAS. Both models containing non-linear transformations in 
the advanced pancreatic cancer dataset gave a substantially better fit compared to the models 
which dichotomised or assumed linearity of continuous covariates. The fitted functions generated 
by restricted cubic splines and fractional polynomials were similar but the model AIC and 
bootstrap mean difference in AIC was smallest for the fractional polynomial model. The methods 
were generally different in the extremities, in the left-hand tails for CA19-9 (values less than 
30,000 KU/l), where there is often a paucity of data. Due to the availability of an extremely large 
dataset in a different disease site, the reproducibility of these results could be investigated in data 
with an alternative event rate and survival distribution to investigate the stability of the 
conclusions. Analyses of data from 42802 cardiac surgery patients are reported in Chapter 8. 
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CHAPTER 8: CARDIAC SURGERY EXAMPLE 
 
 SUMMARY 
 Prospective data were collected on 44902 patients undergoing cardiac surgery 
 5563 (12.4%) patients had died and median follow-up was 5.2 years 
 Further analyses possible due to the size of dataset with alternative event rate and 
survival distribution 
 Aim to investigate reproducibility of results seen when comparing non-linear methods in 
advanced pancreatic cancer dataset 
 In addition, a univariate unadjusted fractional polynomial transformation was recalculated 
within each of 200 bootstrap resamples and compared directly against a 5-knot restricted 
cubic spline 
 The influence of the size of the bootstrap samples was investigated 
 
8.1. Introduction 
Cardiovascular disease is the most common cause of premature death in the Western world and 
is closely related to socio-economic deprivation. Cardiac surgery includes a number of operations 
known to carry significant prognostic benefit. Prospective data were collected on 44902 patients 
undergoing cardiac surgery, followed for an median of 5.2 years, to assess whether social 
deprivation based on post-codes using the Carstairs score influences survival following surgery 
(Pagano et al., 2009). The event rate (5563 (12.4%) patients had died) and survival distribution 
(approximate 90% survival at 5-years) in this disease site is very different to advanced pancreatic 
cancer. 
 
The aim of the analysis was to investigate the reproducibility of the results and conclusions drawn 
from the comparison of non-linear methods in the advanced pancreatic cancer dataset, where the 
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fractional polynomial transformation gave a better fit compared to the restricted cubic spline 
transformation. Analysis was carried out based on 42802 patients (5486 deaths) with complete 
data on the prognostic factors of interest. Seven baseline clinical and demographic variables were 
considered potential prognostic factors of survival (randomising centre, smoking status, diabetes, 
surgical procedure, body mass index (BMI), Carstairs score (CS) and EuroScore (ES)), three 
collected as continuous measurements (BMI, CS and ES). Due to the extreme size of this cardiac 
surgery dataset, further comparison of the two polynomial based strategies was able to be carried 
out. Principal analysis investigated each continuous covariate in turn but allowing the univariate 
fractional polynomial transformation to be recalculated within each of 200 bootstrap resamples 
taken from the original dataset and compared against a 5-knot restricted cubic spline. Supportive 
analysis investigated the influence of sample size by decreasing the bootstrap resample sizes 
compared to the size of the original dataset. 
 
8.2. Univariate Comparison of Non-Linear Functions 
Analyses were based on an identical strategy adopted in the analysis of the advanced pancreatic 
cancer dataset. Principal analysis was based on the assessment of the functional form of each 
continuous covariate in the univariate setting selecting a „best‟ fitting fractional polynomial and 
also a „best‟ fitting restricted cubic spline (with varying number and position of knots) based on 
comparison of AIC. Smaller values of the AIC indicate a better model but the „best‟ model may be 
based on a complex transformation with almost identical AIC statistic to a less complex 
transformation. As such, the AIC had to be substantially lower to permit a complex transformation 
compared to a simple transformation. Substantial was indicated as a reduction in AIC of 4, based 
on an arbitrary decision rule taken from similar values as the chi-square distribution with 1 degree 
of freedom. As before, the strategy was that if a simple log transformation reduced the AIC 
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compared to the untransformed variable, then more complex non-linear transformations were 
investigated further using restricted cubic splines (based on 3, 4 and 5 knot models) and second 
degree fractional polynomials. 
 
Univariate analysis of the three continuous variables (BMI, CS and ES) identified that non-linear 
transformations were appropriate in their relationship with survival (Table 8.1). However, there is a 
historically accepted transformation for EuroScore which was analysed throughout under a log 
transformation. Restricted cubic spline transformations for BMI and CS were investigated based 
on 3, 4 and 5 knot models. 
 
Table 8.1: Univariate AIC Statistics  
(shaded is selected transformation) 
Variable Linear Log RCS-3 RCS-4 RCS-5 FP 
BMI 112643.0 112598.8 112497.3 112495.8 112497.8 112514.7 
Carstairs score 114547.7 114538.6 114533.9 114533.1 114535.0 114532.9 
*Euroscore 111920.9 111769.8 111720.7 111722.6 111723.7 111712.6 
RCS-k=Restricted Cubic Spline with k knots, FP=Fractional Polynomial 
* historical transformation is log 
 
 
AIC was not substantially reduced by restricted cubic spline transformations based on more than 3 
knots. Knot positions were set at BMI values of 20.999, 27.110 and 35.339 and at CS of -3.507, -
0.539 and 5.658. Second degree fractional polynomial transformations were identified for BMI as 
[BMI^0.5 + (BMI^0.5*log(BMI))] and CS as [(CS+5.2) + ((CS+5.2)^2)].  The fractional polynomial 
transformation had similar AIC to the restricted cubic spline for CS and was worse for BMI. 
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The estimated risk over increasing values of each continuous covariate were plotted for each 
transformation method to enable graphical comparison of the estimated functional format. The 
linear predictor was scaled so the log(HR) was zero at the midpoint of each continuous covariate 
to enable plots on the same axes. The plots of the estimated functional forms appear similar for 
BMI (Figure 8.1) with smoother transformation for peak values between 25 to 45 with fractional 
polynomial but with higher estimated risk in the tail for scores greater than 50 compared with the 
restricted cubic spline function, which was a substantially better fit at univariate analysis: 
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Figure 8.1a: Estimated Functional Form for BMI: Restricted Cubic Spline Transformation  
(dots indicate actual data values) 
 
 
Figure 8.1b: Estimated Functional Form for BMI: Fractional Polynomial Transformation  
(dots indicate actual data values) 
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Similarly, for Carstairs score, the plots of the estimated functional forms (Figure 8.2) appear 
similar but with lower estimated risk in the tail for scores greater than 10 compared with the 
restricted cubic spline function, both having a similar fit to the data at univariate analysis: 
 
Figure 8.2a: Estimated Functional Form for Carstairs Score: Restricted Cubic Spline  
(dots indicate actual data values) 
 
Figure 8.2b: Estimated Functional Form for Carstairs Score: Fractional Polynomial  
(dots indicate actual data values) 
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The methods are generally different in the extremities where there is often a paucity of data. In 
this example the difference between transformations occurred in the right hand tails for outlying 
BMI and Carstairs scores (greater than 50 and10 respectively). 
 
8.3. Multivariable Comparison of Non-Linear Functions 
As in the advanced pancreatic cancer dataset, all variables were then considered in the 
multivariable setting using Cox proportional hazards regression based on a backward elimination 
selection method using a 5% significance level for exclusion of variables and including centre 
(stratification factor at randomisation) as a „forced‟ variable in each model. A final check was made 
to ensure that no term in the model could be omitted and that none of the omitted terms could be 
included without significantly affecting the model. All variables omitted from the model based on 
backward elimination were considered and re-instated if they significantly improved the model. 
Two final Cox proportional hazards regression models (Table 8.2) were developed based on i) 
restricted cubic spline and ii) fractional polynomial transformations, which could be directly 
compared based on AIC statistics: 
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Table 8.2: Cox Proportional Hazards Regression Models (n=42802, deaths=5486) 
a) 
Restricted Cubic Spline Transformations 
AIC=109223.4 Transformation 
(knot positions) 
log HR () se() 2W p-value HR (95% CI) 
Stratification factor * CENTRE-1 
CENTRE-2 
CENTRE-3 
CENTRE-4 
CENTRE-5 
0 
-0.65 
0.20 
0.17 
0.23 
- 
0.047 
0.044 
0.044 
0.051 
527.4 <0.001 1.0 
0.52 (0.48 to 0.57) 
1.22 (1.12 to 1.33) 
1.19 (1.09 to 1.30) 
1.26 (1.14 to 1.39) 
Continuous factor  ^ log(ES) 1.25 0.029 1804.5 <0.001 3.49 (3.29 to 3.70) 
Continuous factor  RCS3 # BMI (21.0, 27.1, 35.3) 
BMI1 
-0.064 
0.069 
0.0066 
0.0088 
97.1 <0.001 NA 
NA 
Categorical factor ! SMOKING-0 
SMOKING-1 
SMOKING-2 
SMOKING-NK 
0 
0.22 
0.25 
0.83 
- 
0.034 
0.042 
0.45 
58.0 <0.001 1.0 
1.25 (1.17 to 1.34) 
1.28 (1.18 to 1.39) 
2.31 (0.96 to 5.56) 
Categorical factor DIABETES 0.26 0.036 53.2 <0.001 1.30 (1.21 to 1.39) 
Categorical factor $ CABG ONLY 
CABG+OTHER 
CABG+VALVE 
CABG+VALVE+OTHER 
OTHER 
VALVE ONLY 
VALVE+OTHER 
0 
-0.02 
0.23 
0.22 
0.014 
-0.038 
-0.027 
- 
0.095 
0.041 
0.16 
0.095 
0.039 
0.12 
43.8 <0.001 1.0 
0.98 (0.82 to 1.19) 
1.26 (1.17 to 1.37) 
1.25 (0.91 to 1.72) 
1.01 (0.84 to 1.22) 
0.96 (0.89 to 1.04) 
0.97 (0.77 to 1.23) 
Continuous factor  RCS3 # CS  (-3.5, -0.5, 5.7) 
CS1 
0.047 
-0.056 
0.014 
0.023 
16.7 <0.001 NA 
NA 
Continued... 
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b) 
Fractional Polynomial Transformations 
AIC=109223.2 Transformation log HR () se() 2W p-value HR (95% CI) 
Stratification factor * CENTRE-1 
CENTRE-2 
CENTRE-3 
CENTRE-4 
CENTRE-5 
0 
-0.65 
0.19 
0.17 
0.23 
- 
0.047 
0.044 
0.044 
0.050 
528.6 <0.001 1.0 
0.52 (0.48 to 0.57) 
1.22 (1.12 to 1.32) 
1.19 (1.09 to 1.30) 
1.26 (1.14 to 1.39) 
Continuous factor  ^ log(ES) 1.25 0.029 1806.4 <0.001 3.49 (3.29 to 3.70) 
Continuous factor  FP2 # BMI^0.5 
BMI^0.5*log(BMI) 
-8.31 
1.53 
1.078 
0.20 
100.0 <0.001 NA 
NA 
Categorical factor ! SMOKING-0 
SMOKING-1 
SMOKING-2 
SMOKING-NK 
0 
0.22 
0.25 
0.84 
- 
0.034 
0.042 
0.45 
56.9 <0.001 1.0 
1.25 (1.17 to 1.33) 
1.28 (1.18 to 1.39) 
2.32 (0.96 to 5.60) 
Categorical factor DIABETES 0.26 0.036 54.5 <0.001 1.30 (1.21 to 1.39) 
Categorical factor $ CABG ONLY 
CABG+OTHER 
CABG+VALVE 
CABG+VALVE+OTHER 
OTHER 
VALVE ONLY 
VALVE+OTHER 
0 
-0.18 
0.23 
0.22 
-0.017 
-0.038 
-0.024 
- 
0.095 
0.041 
0.16 
0.095 
0.038 
0.12 
44.1 <0.001 1.0 
0.98 (0.82 to 1.18) 
1.26 (1.17 to 1.37) 
1.25 (0.91 to 1.72) 
1.02 (0.84 to 1.23) 
0.96 (0.89 to 1.04) 
0.98 (0.77 to 1.24) 
Continuous factor  FP2 # CS+5.2 
(CS+5.2)^2 
0.062 
-0.0034 
0.017 
0.0012 
19.3 <0.001 NA 
NA 
HR=Hazard Ratio, RCS3=3 knot Restricted Cubic Spline, FP2=2nd degree Fractional Polynomial; NA=not appropriate; ^ Euroscore based on historical transformation 
* Centre: „classification‟ variable using „Centre-1‟ as the reference level, Type III test presented with 4 degrees of freedom 
! Smoking status: missing data included in analysis as a separate „classification‟ variable using „Non-smoker as the reference level, Type III Wald 2 test presented with 3 degrees of freedom 
$ Cardiac procedures: „classification‟ variable using „CABG Only‟ as the reference level, Type III Wald 2 test presented with 6 degrees of freedom;  
# Type III Wald 2 test presented with 2 degrees of freedom
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The models were identical in the variables selected as significantly prognostic. All variables were 
selected as highly significant in both models. The sign of each corresponding variable in the 
models were identical and the significance of each variable similar. Parameter estimates only 
differed significantly for the two transformed variables, BMI and CS. The AIC were almost identical 
for each model. 
 
8.4. Bootstrap Validation Comparing Non-Linear Functions 
Internal validation, to directly compare the fit of the restricted cubic spline and fractional 
polynomial strategies, was carried out by calculating the sampling distribution of the difference in 
the AIC statistics between the models in multiple bootstrap resamples. This was programmed in 
SAS (appendix) based on nonparametric bootstrap analyses, using an identical strategy as in the 
analysis of the advanced pancreatic cancer dataset. The bootstrap analysis fitted the final models, 
one based on the restricted cubic spline transformations and one based on the fractional 
polynomial transformations, to a series of 1000 bootstrapped resamples taken from and with the 
same size as the original data. Smaller values of the AIC indicate a better model but it is unclear 
whether AIC statistics from non-nested models will approximate the chi-square distribution. The 
difference in AIC statistics for the different models in multiple bootstrap resamples provides a 
distribution which can then be summarised appropriately with bootstrap percentile confidence 
intervals derived from the bootstrap distribution of the difference between the restricted cubic 
spline and fractional polynomial models. 
 
The %BOOT macro was used to calculate 1000 resamples of the original dataset using identical 
univariate transformations, if any, as in the original dataset. Modelling was carried out in 1000 
bootstrap resamples forcing in centre, BMI and CS components (restricted cubic spline or 
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fractional polynomial) and considering all other variables for inclusion based on a backward 
elimination variable selection method. Two models were created within each bootstrap resample, 
one based on restricted cubic spline transformations and one based on fractional polynomial 
transformations. Again, the AIC for each model was output from the screen to a temporary SAS 
dataset (rather than delivered to an output dataset due to different AIC values being output) and 
the difference (AIC[RCS]-AIC[FP]) between them calculated, a positive difference indicating a 
better fit by the fractional polynomial transformation model. This was repeated in each 1000 
bootstrap resamples and the mean difference calculated with 95% confidence interval (Table 8.3): 
 
Table 8.3: Bootstrap Analyses of final models based on 1000 Resamples 
 Bootstrap Mean AIC Bootstrap Percentile 
95% CI 
Restricted Cubic Spline 109273.2 106443.5 to 111903.8 
Fractional Polynomial 109273.1 106443.2 to 111903.6 
Difference (RCS-FP) 0.12 -8.7 to 9.2 
 
 
The bootstrap mean AIC (Table 8.3) were almost identical across the two models with a bootstrap 
mean reduction of 0.12 with the fractional polynomial transformation (bootstrap percentile 95% CI: 
-8.7 to 9.2) compared to the restricted cubic spline. 
 
The extreme sample size enabled further nonparametric bootstrap analyses to be carried out 
which enabled the univariate fractional polynomial transformation for each continuous covariate to 
be recalculated within each of 200 bootstrap resamples taken from the original dataset and 
comparing against a 5-knot restricted cubic spline. The %RCSPLINE and %MFP8 macros had to 
be adapted to enable them to run within the %BOOT macro in SAS. The macros automatically 
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delete temporary SAS datasets but had to be adapted to retain the temporary datasets to enable 
output of the -2log-likelihood from each model in each bootstrap resample. The %MFP8 macro 
calculates the -2log-likehood for each model from which the AIC can be calculated if the number 
of parameters in each model are known. The number of parameters for each continuous covariate 
can be output using the FFORM variable created by the %MFP8 macro. However, this is not 
updated by the number of other variables selected in a multivariable model. The full models could 
not be compared since the %MFP8 does not allow non-significant continuous covariates to be 
forced into the model. As such, an unadjusted univariate fractional polynomial transformation was 
calculated for each continuous covariate in each bootstrap resample and compared against a 5-
knot restricted cubic spline transformation. The -2log-likelihood was output from the screen to a 
temporary SAS dataset (rather than delivered to an output dataset due to different AIC values 
being output), the AIC was then calculated for each model and the difference (AIC[RCS]-AIC[FP]) 
between them calculated, a positive difference indicating a better fit by the fractional polynomial 
transformation model. This was repeated in each 1000 bootstrap resamples and the mean 
difference calculated together with the range of differences seen (Table 8.4). The %MFP8 macro 
is an automated procedure which provides a fractional polynomial transformation for variables 
only if they have a significant independent effect. As such, the „best‟ fitting fractional polynomial 
transformation may exclude the variable of interest and as such the proportion of samples where 
the variable of interest is excluded was also calculated. Also, the influence of the size of the 
bootstrap resamples was investigated by decreasing the bootstrap resample sizes from the size of 
the original dataset to 20000, 10000, 5000 and 1000 observations. 
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Table 8.4: Univariate Bootstrap Resampling with Varied Size Resamples 
200 Bootstrap Resamples comparing 5-knot RCS^ and FP functions 
Variable Bootstrap size Bootstrap Mean Difference in AIC * 
(Minimum to maximum) 
% excluded  
(FP only) # 
BMI 42802 -16.32 (-45.09 to 10.09) 0% 
 20 000 -5.44 (-24.14 to 11.83) 0% 
 10 000 -1.12 (-18.78 to 16.05) 0% 
 5000 0.32 (-16.64 to 16.19) 0% 
 1000 0.89 (-16.64 to 10.53) 46% 
CS 42802 -0.42 (-11.36 to 7.92) 0% 
 20 000 -0.01 (-12.52 to 7.96) 5% 
 10 000 0.31 (-8.60 to 7.01) 45% 
 5000 1.63 (-10.91 to 8.68) 72% 
 1000 3.80 (-7.73 to 12.20) 95% 
BMI=body mass index, CS=Carstairs score 
RCS=restricted cubic spline, FP=fractional polynomial 
^ 5 fixed knot positions based on original full data set 
* Difference based on AIC[RCS]-AIC[FP] within each bootstrap sample 
# automated FP macro excludes non-significant variables 
 
 
The univariate bootstrap mean AIC was lower for BMI with the restricted cubic spline function with 
a bootstrap mean reduction of -16.32 (the bootstrap mean difference ranging: -45.09 to 10.09), 
based on a sample size of 42802 as in the original dataset and as in Table 8.1. Similarly, the 
bootstrap mean AIC were almost identical for CS across the two functions (bootstrap mean 
reduction of 0.42, bootstrap mean difference ranging: -11.3 to 7.92), based on a sample size of 
42802 as in the original dataset and as seen in Table 8.1. 
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When investigating BMI in bootstrap resamples of reduced sizes, the size of the bootstrap mean 
difference seen in the full dataset was reduced in line with a reduction in samples size. In the 
smallest resample size of 1000, BMI was excluded in 46% of 200 fractional polynomial models yet 
still gave similar bootstrap mean AIC to the restricted cubic spline. BMI was not excluded in any of 
the fractional polynomial models when using a bootstrap resample size of 5000 or more. When 
investigating CS in bootstrap resamples of reduced sizes, the bootstrap mean difference was 
similar in sample sizes of 10,000 observations and above. With decreasing sample sizes of less 
than 10,000 observations, the bootstrap mean difference increases, being largest in the smallest 
resample size of 1000. CS was excluded from 95% of the models when using the smallest sample 
size of 1000 but was progressively selected being excluded in 72% of models of size 5000, 45% 
of models of size 10,000 and 5% of models of size 20,000. 
 
8.5. Conclusions 
The aim of the analysis was to investigate the reproducibility of the results and conclusions drawn 
from the comparison of non-linear methods in the advanced pancreatic cancer dataset, where the 
fractional polynomial transformation gave a better fit compared to the restricted cubic spline 
transformation. The main advantage of the cardiac surgery dataset is its extreme size, analysis 
being based on 42,802 patients. The cardiac surgery data has an alternative event and survival 
rate.  Direct comparison of the non-linear methods was based on the same model building 
strategy employed when investigating the advanced pancreas dataset. The results presented for 
the cardiac surgery dataset differ slightly from the published paper (Pagano 2009) where the 
analysis plan was based on a frailty model adjusting by other trial factors such as surgeon and 
using a default 5-knot spline for all continuous data other than EuroScore. In the analysis 
presented here, BMI and Carstairs score were transformed using 3-knot restricted cubic splines 
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and second degree fractional polynomial transformations. The fitted functions generated by 
splines and fractional polynomials were similar resulting in comparable models. The AIC were 
almost identical when comparing the final multivariable models. Similarly, there was almost no 
difference in the bootstrap mean difference when comparing AIC based on 1000 bootstrap 
resamples. Larger differences were seen between the two methods when resample sizes were 
reduced due to the reduction in available data to detect small effects and also to detect non-
linearity. When reducing the resample size of the bootstrap resample, consistency in the 
conclusions made from analysis of the full dataset were not seen until a resample size of 20,000 
for both BMI and Carstairs score, based on both the observed bootstrap mean difference and the 
inclusion/ exclusion of covariates by the fractional polynomial function. In analysis of the Carstairs 
score, the bootstrap mean difference in AIC is small despite a high proportion of exclusions by the 
fractional polynomial function showing this automated method to provide a simpler model with 
similar model fit. In summary, the fitted functions generated by splines and fractional polynomials 
were similar resulting in comparable models. The fractional polynomial transformation is derived 
through a fully automated procedure whereas separate procedures need to be carried out to 
determine the knots required  for the „best‟ fitting restricted cubic spline transformation. The 
fractional polynomial method is selected as the transformation of preference due to i) the simplicity 
of the fractional polynomial procedure, ii) the comparability of the results seen in the cardiac 
surgery dataset and iii) the better fit of the fractional polynomial model in the advanced pancreatic 
surgery dataset. External validation of a derived prognostic model is required to determine if is 
transportable and will accurately predict outcome in new patients. The focus of Chapter 9 is to 
externally validate the prognostic model, based on the fractional polynomial non-linear 
transformation method, derived for patients with advanced pancreatic cancer. 
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CHAPTER 9: EXTERNAL VALIDATION 
 
 SUMMARY 
 Internal validation methods are valuable in the absence of an external dataset  
 External validation is the most stringent validation process in a new group of patients 
 The prognostic model is fitted to an external dataset to assess predictive value 
 The prognostic model can be updated in light of new external data using an identical 
modelling strategy as that used in the development of the original model 
 Model performance of the updated model should be assessed 
 A prognostic index can be derived from the updated prognostic model  
 A statistically validated prognostic index for advanced pancreatic cancer was derived 
 Treatment effects within identified prognostic factors can be investigated 
 
9.1. Introduction 
There are two main validation methods, internal and external validation. Internal validation 
methods, described and presented earlier (Chapter 4), are very valuable methods in the absence 
of an external dataset but are of less value than validation on a completely independent dataset. 
An external dataset in advanced pancreatic cancer was expected to become available during the 
project and as such it was anticipated that the final derived prognostic model could undergo 
external validation. As such, data-splitting the original dataset was avoided thus maximising the 
available data in order to detect significant prognostic factors and using internal validation 
methods until the independent, external dataset became available.  
 
External validation is the most stringent validation process and assessment of accuracy of a 
prognostic model (Harrell, 2001) based on evaluating the model in a new group of patients, 
despite being subject to differences in geographical location of patients and calendar differences. 
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It provides an important opportunity to review, strengthen and update a prognostic model with new 
data (Royston and Sauerbrei, 2004). The primary role of model validation is to ascertain if a 
derived prognostic model has external validity, that is that the model may be transportable and will 
accurately predict outcome in other patients not used in the model building process, and thus by 
inference in future patients. There are three major causes of failure of a model to validate: i) 
overfitting/ model optimism, ii) changes in the measurement of variables and iii) major changes in 
the inclusion criteria of patients (Harrell, 2001). 
 
The aim of this chapter is to describe and present an external validation of the prognostic model 
derived in advanced pancreatic cancer. A validated prognostic index of clinical and laboratory 
criteria in advanced pancreatic cancer will enable stratification of patients into risk-sets to enable 
different treatment approaches to be targeted to different subgroups of patients. Routine 
availability and use of a validated prognostic index could ensure patients receive the most 
appropriate and targeted treatment modalities.  
 
9.2. External Validation Dataset in Advanced Pancreatic Cancer 
An improved, statistically validated prognostic index for advanced pancreatic cancer was 
calculated based on independent, external data from 533 patients recruited in a prospective 
randomised controlled trial in advanced pancreatic cancer (Cunningham et al., 2009). The trial 
was designed to determine if there was any survival advantage in patients receiving gemcitabine 
in combination with capecitabine compared to current standard treatment of gemcitabine alone. 
The primary outcome measure was overall survival. Combination treatment was associated with a 
non-significant improvement in survival (Hazard Ratio=0.86; 95% confidence interval: 0.72 to 
1.02; p=0.08) compared to gemcitabine alone, consistent across prognostic subgroups of cancer 
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stage and performance status (stratification factors at randomisation). The trial showed nominally 
significantly improved objective response rates (19.1% vs. 12.4%; p=0.034) and progression free 
survival (Hazard Ratio=0.78; 95% confidence interval: 0.66 to 0.93; p=0.004) in favour of 
combination treatment (pre-specified secondary outcome measures).  
 
In an external validation, datasets should be investigated (Machin et al., 2006) for differences in 
terms of: 
1. Patient eligibility and disease characteristics  
2. Differences in data items and measurements including endpoints and follow-up 
3. Possible bias through missing data 
4. Size of treatment effects and timing of treatment from diagnosis. 
Both the development and validation datasets had similar patient eligibility criteria: histologically or 
cytologically unresectable pancreatic cancer, within 8 weeks of diagnosis or disease recurrence 
and adequate performance status. Previous therapy for metastatic or locally advanced disease 
was an exclusion criteria. Randomisation of patients in the validation dataset was stratified by 
cancer stage (locally advanced (stage III/IVA) or metastatic (stage IVB)) and performance status 
(0,1 vs. 2). The primary outcome measure in all trials was survival time calculated from the date of 
randomisation to date of death from any cause. 
 
Sample size of the validation set should provide sufficient evidence to detect prognostic factors of 
specific magnitude. The number of observed events for validation of a model (Ovalidation) with k 
regression coefficients has been suggested as: 10 x kvalidation < Ovalidation < 20 x kvalidation (Machin et 
al., 2006). A total of 529 patients in the validation dataset had died and as such indicates sufficient 
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evidence to investigate the 12 regression coefficients identified in the developed prognostic model 
(Table 6.2). 
 
A total of 1186 patients were available for analysis across the two datasets  (Table 9.1). Factors 
were generally balanced across the two datasets with the average age being 62 years (range 26 
to 89), 681 (57%) male, 799 (67%) presenting with metastases and 450 (38%) with known lymph 
node involvement. All patients in the validation dataset had cancer stage III or IV compared to 
84% in the development dataset. Similarly 67% of patients in the validation dataset had tumour 
stage III or IV compared with 44% in the development dataset. Five common biochemical 
variables were collected across both studies: bilirubin, alkaline phosphatase, albumin, LDH and 
CA19-9. 
 
Overall, the majority of patients (1141, 96%) had died by the time of analysis with a median follow-
up time of 19.9 months (Range: 0.9 to 44.0) for the 45 patients still alive. The median survival 
estimate for the group is 5.6 months (95%CI: 5.3 to 5.9) with 12-month survival estimate of 20.0% 
(95%CI: 17.7% to 22.3%). 
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Table 9.1: Common Variables across Datasets 
Variable Development 
N=653 (55%) 
Validation  
N=533 (45%) 
TOTAL  
N=1186 (100%) 
DEMOGRAPHICS 
* Age at 
entry (yrs) 
    Median 
Range 
63 
29 to 89 
62 
26 to 83 
62 
26 to 89 
Ethnic race White 
Other 
Missing 
590 (90%) 
62 (10%) 
1 
510 (97%) 
17 (3%) 
6 
1100 (93%) 
79 (7%) 
7 
Sex Male 
Female 
368 (56%) 
285 (44%) 
313 (59%) 
220 (41%) 
681 (57%) 
505 (43%) 
Treatment Gem alone 
Gem+ 
222 (34%) 
431 (66%) 
266 (50%) 
267 (50%) 
488 (41%) 
698 (59%) 
TUMOUR INFORMATION 
Cancer stage I 
II 
III 
IV 
Missing 
32 (5%) 
72 (11%) 
104 (16%) 
439 (68%) 
6 
0 
0 
156 (29%) 
377 (71%) 
0 
32 (3%) 
72 (6%) 
260 (22%) 
816 (69%) 
6 
Distant 
Metastases 
M0 
M1 
Missing 
194 (30%) 
436 (67%) 
23 (3%) 
155 (29%) 
363 (68%) 
15 (3%) 
349 (30%) 
799 (67%) 
38 (3%) 
Regional 
lymph nodes 
N0 
N1 
Missing 
243 (37%) 
251 (39%) 
159 (24%) 
167 (31%) 
199 (38%) 
167 (31%) 
410 (35%) 
450 (38%) 
326 (27%) 
Primary 
tumour T 
stage 
T0 
T1 
T2 
T3 
T4 
Missing 
8 (1%) 
158 (24%) 
144 (22%) 
280 (43%) 
7 (1%) 
56 (9%) 
0 
13 (2%) 
71 (14%) 
91 (17%) 
266 (50%) 
93 (17%) 
8 (1%) 
170 (14%) 
215 (18%) 
371 (31%) 
273 (23%) 
149 (13%) 
SERUM CHEMISTRY and HAEMATOLOGY 
Laboratory Variables 
* AST (SGOT) IU/L 
* BILIRUBIN mol/L 
* ALK PHOSPHATASE IU/L 
* ALBUMIN g/L 
* LDH IU/L 
* BUN mmol/L 
* CA19-9 KU/l 
* HAEMOGLOBIN g/dL 
* WBC 109/L 
Median (Range), Missing 
25 (6 to 538), 29 
13.7 (3 to 277), 24 
140 (35 to 2064), 24 
38 (22 to 47), 25 
164 (29 to 1495), 32 
9.3 (2.9 to 34.3), 33 
710 (5 to 1,000,000), 47 
12.4 (5.5 to 19.1), 41 
7.9 (2.3 to 31.6), 41 
Median (Range), Missing 
NA 
11 (2 to 35), 3 
173 (39 to 2188), 4 
38 (18 to 52), 3 
331 (21 to 1616), 66 
NA 
820.5 (0.6 to 14,000,000), 15 
NA 
NA 
Median (Range), Missing 
- 
12 (2 to 277), 27 
153 (35 to 2188), 28 
38 (18 to 52), 28 
211 (21 to 1616), 98 
- 
745.9 (0.6 to 14,000,000), 62 
- 
- 
OUTCOME 
Event 
indicator 
Alive 
Dead 
41 (6%) 
612 (94%) 
4 (1%) 
529 (99%) 
45 (4%) 
1141 (96%) 
* Follow-up 
alive (mo) 
Median 
Range 
20.7 
0.9 to 24.6 
30.2 
8.6 to 44.0 
19.9 
0.9 to 44.0 
NA=not available, * = continuous measurements 
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Median survival was estimated as 4.7 months (95%CI: 4.2 to 5.1) with 12-month survival estimate 
of 17.4% (95%CI: 14.5% to 20.3%) in the development dataset compared with a median survival 
of 6.8 months (95%CI: 6.1 to 7.4) and 12-month survival estimate of 23.2% (95%CI: 19.6% to 
26.8%) in the validation dataset (Figure 9.1): 
 
Figure 9.1: Survival by Dataset 
 
BB=British Biotech Development dataset; GC=GEMCAP Validation dataset 
 
9.3. Model Fit and Discrimination 
The fit of the developed prognostic model (Table 6.2), is investigated by forcing the regression 
coefficients from the derived prognostic model onto the validation dataset and assessing its 
predictive value by comparison of predicted and observed survival estimates and residuals. 
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Prognostic separation is the term used to explain statistical discrimination between prognostic 
scores when categorising patients into different prognostic risk-sets. Discrimination between 
subgroups of patients is based on the comparison of predicted and observed survival. Predicted 
prognostic information can be quantified in the original dataset used for model building using 
Predicted Separation (PSEP) methods (Altman and Royston, 2000) and it‟s equivalent calculated 
in the validation dataset termed Observed Separation (OSEP). PSEP is an index of separation of 
predicted prognostic information defined as:  
PSEP = pworst – pbest   
where pworst = predicted probability of dying for a patient in the group with the worst prognosis and 
pbest =  predicted probability of dying for a patient in the group with the best prognosis. Close 
agreement of PSEP and OSEP values would indicate usefulness of the prognostic model. The 
PSEP method has been shown to have some drawbacks as a validation tool (Royston and 
Sauerbrei, 2004;Royston et al., 2004) namely that the separation of a model may be quantified by 
the amount of variability in the linear predictor scores. An improved measure related to PSEP, is 
the D statistic which was suggested as an alternative measure of the discrimination and 
prognostic ability of a survival model. The generality of a prognostic model across k datasets can 
be evaluated by internal-external cross-validation on D by omitting each study in turn, estimating 
model parameters using remaining studies and evaluating D in the omitted study. This procedure 
has limited use when k=2 and as such discrimination of the prognostic model in advanced 
pancreas cancer is based on the PSEP method. 
 
The proportional hazards written on the log-hazard scale is: 
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Linear predictor scores (LP) from the derived prognostic model (Table 6.2), including fractional 
polynomial transformations for non-linear covariates, were calculated as: 
LP=i = 1X1i + 2X2i + ….. + pXpi  
LP = -0.37711*TRIAL + 0.17286*STAGEGP - 0.16115*SEX + 0.16934*TRTGP + 
0.02383*CA199FP1(KU/l) - 0.00173*CA199FP2(KU/l) - 0.06802*ALB(g/L) - 0.00367*AST(IU/L) + 
0.00119*ALKPHOS(IU/L) + 0.02772*BUN(mmol/L) + 0.04409*WBC(109/L) + 0.56220*LOGLDH(IU/L) 
with the following code: TRIAL (1=BB128, 2=BB193), STAGEGP (1=I/II, 2=III/IV), SEX (1=MALE, 
2=FEMALE), TRTGP (0=GEM, 1=GEMPLUS). 
 
One of the three major causes of failure of a model to validate was „changes in the measurement 
of variables‟. The validation dataset did not include measurements for WBC, AST and BUN. Also 
the validation dataset is not influenced by the TRIAL variable. One option is to remove these 
variables from the derived prognostic model and re-estimate the regression coefficients for the 
remaining variables, available across both datasets. However, it is preferable to keep the 
regression coefficients adjusted by all known factors as estimated in the original prognostic model 
but remove the factors which are not available in the validation dataset. This is equivalent to 
assuming that omitted variables take the value zero which will directly affect the linear predictor 
score but will not bias groupings into risk sets which is based on available and validated factors. In 
this way the size of the effect of each identified prognostic factor as estimated in the original 
prognostic model is validated directly for variables available across both datasets.  
 
As such, individual scores were calculated for patients in the validation dataset according to linear 
predictor above but removing terms for WBC, AST, BUN and TRIAL:  
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LP = 0.17286*STAGEGP - 0.16115*SEX + 0.16934*TRTGP + 0.02383*CA199FP1(KU/l) - 
0.00173*CA199FP2(KU/l) - 0.06802*ALB(g/L) + 0.00119*ALKPHOS(IU/L) + 0.56220*LOGLDH(IU/L) 
with the following code: STAGEGP (1=I/II, 2=III/IV), SEX (1=MALE, 2=FEMALE), TRTGP 
(0=GEM, 1=GEMPLUS).  
 
Model fit was assessed comparing differences in the direction of the parameter estimates and 
comparing observed and predicted survival estimates using PSEP and OSEP statistics. Patients 
were split into four groups based on the quartiles of the distribution of linear predictor scores used 
in the original model development (0.654140, 1.036423, 1.596797). A total of 455 of the 533 
patients had complete data for the identified factors. Only 17 patients were allocated to prognostic 
group 1, 67 patients to group 2, 157 patients to group 3 and the remaining 214 patients to 
prognostic group 4. Kaplan-Meier survival estimates (Figure 9.2) show the four prognostic groups 
with descending median survival estimates of 12.0 (95%CI: 9.0 to 17.2), 8.8 (95%CI: 7.5 to 10.9), 
8.9 (95%CI: 7.1 to 10.3) and 4.4 (95%CI: 3.9 to 5.7) months and descending 12-month survival 
estimates of 47.1% (95%CI: 23.4% to 70.8%), 32.8% (95%CI: 21.5% to 44.1%), 31.0% (95%CI: 
23.7% to 38.3%) and 15.4% (95%CI: 10.6% to 20.2%): 
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Figure 9.2: Survival by Prognostic Group 
 
The plot indicates some similarity in prognostic groups 2 and 3 from 9-months survival and 
beyond. Prognostic groups 2 and 3 have a similar survival distribution to prognostic group 1 in the 
development dataset (median survival estimate 8.5 (95%CI: 7.4 to 10.1) months, 12-month 
survival estimate 30.5% (95%CI: 22.8% to 38.2%)) re-iterating the better survival seen in patients 
in the validation dataset. The hazard ratios for groups 2, 3 and 4 using prognostic group 1 as the 
baseline were: 1.09 (95%CI: 0.64 to 1.86), 1.23 (95%CI: 0.75 to 2.04) and 2.07 (95%CI: 1.26 to 
3.39) respectively. 
 
PSEP was calculated in the development dataset based on 12-month survival rates of the four 
prognostic groups (Figure 6.4) as pbest = 1-0.305=0.695, pworst = 1-0.043=0.957 and thus PSEP = 
0.262. OSEP was calculated in the validation dataset based on 12-month survival rates of the four 
prognostic groups (Figure 9.2) as pbest = 1-0.471=0.529, pworst = 1-0.154=0.846 and thus OSEP = 
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0.317. The observed separation is increased by an absolute difference of 5.5% and this is typical 
of some extent of overfitting in the original analysis. Since PSEP and OSEP were similar then the 
conclusion is that the prognostic information appears reproducible. 
 
9.4. Updating the Prognostic Model 
Once the prognostic model has been evaluated on an independent dataset, it may be updated in 
light of the new dataset. Updating the prognostic model was carried out by pooling the data from 
both datasets. Since some prognostic factors have already been identified from the original 
dataset then it is does not seem sensible to re-start the model building process, rather fit these 
identified factors to the pooled date to re-estimate the regression coefficients (Machin et al., 
2006). To account for any significant survival differences between the datasets and treatment, 
then additional terms for DATASET and TREATMENT were included to obtain adjusted estimates 
of the regression coefficients. Final models were developed and compared based on 1036 
patients (993 deaths) with complete data on the prognostic factors of interest. The same modelling 
strategy used to develop the original prognostic model was used based on common variables 
across the two datasets (Table 9.1). 
 
Univariate analysis of the six continuous variables identified that non-linear transformations were 
appropriate for three variables in their relationship with survival based on comparison of AIC: 
bilirubin mol and alkaline phosphatase IU/L both as log transformations and CA19-9 KU/l as a 
second degree fractional polynomial transformation [CA19-9 -0.5 + log(CA19-9)], updated from that 
in the original prognostic model. The three remaining continuous covariates were analysed 
assuming a linear relationship with log-hazard. Cancer stage was included in the development 
dataset as a binary variable coded on a clinical basis as „I/II‟ vs. „III/IV‟. In the validation dataset 
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only stage III and IV patients were recruited and it did not seem sensible to combine these. 
Investigation of the AIC of models containing only cancer stage showed a better model with 
reduced AIC when using four individual levels of stage (AIC2levels=13948.2, AIC4levels=13910.1). As 
such, cancer stage was considered as an ordered categorical variable with four levels and 
incorporated into the multivariable model using classification variables. 
 
As in the development of the original prognostic model, multivariable modelling was carried out 
using Cox proportional hazards regression modelling with variable reduction based on a manual 
backward elimination method using a nominal significance level of =0.05. Primarily models 
included prognostic variables already identified and common to both datasets (Cancer Stage, Sex, 
CA19-9, Albumin, Alkaline Phosphatase, LDH) using updated functional formats as specified. 
Validation group and treatment were also included in each model. Six additional variables 
common across both datasets were considered using classification variables for tumour stage, 
metastases and nodes (missing included as a classification level in both metastases and nodes). 
The updated multivariable model containing prognostic factors identified previously, but with 
updated regression coefficients: 
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Table 9.2: Updated Prognostic Model 
 Variable log HR () se() 2W# p-value HR (95% CI)^ 
Stratification factor DATASET -0.49 0.078 39.8 <0.001 0.61 (0.53 to 0.71) 
Stratification factor TRT 0.054 0.066 0.67 0.41 1.06 (0.93 to 1.20) 
Classification variable * STAGE-2 
STAGE-3 
STAGE-4 
-0.34 
-0.077 
0.23 
0.24 
0.22 
0.21 
25.8 <0.001 0.71 (0.44 to 1.15) 
0.93 (0.61 to 1.41) 
1.26 (0.84 to 1.88) 
Binary variable SEX -0.16 0.065 6.2 0.013 0.85 (0.75 to 0.97) 
Continuous factor Linear ALB g/L -0.058 0.0072 66.6 <0.001  0.75 (0.70 to 0.80) 
Continuous factor FP2 # CA199^(-0.5)KU/l 0.77 0.37 48.0 <0.001 NA 
 log(CA199)KU/l 0.11 0.018   NA 
Continuous factor FP1 Log(ALKPHOS)IU/L 0.16 0.049 10.7 0.0010 1.17 (1.07 to 1.29) 
Continuous factor Linear LDH IU/L 0.00040 0.00021 3.8 0.053  1.04 (1.00 to 1.09) 
HR=Hazard Ratio, FP1/2=1st or 2nd degree Fractional Polynomial, NA=not appropriate 
* Stage: four level classification variable using level I as the reference level 
# Type III Wald 2 test 
^ HR based on 5 unit increase in albumin g/L and 100 unit increase in LDH IU/L 
 
 
 
The updated prognostic model, considering all common variables across the pooled datasets, 
selected identical factors as in the original model, except for those factors not collected in the 
validation dataset. No other variables common to both datasets were selected as additional 
prognostic variables. Differences between the two models included the format of the variables 
specifically; stage of disease which was expanded from a binary to a four-level ordinal variable, 
alkaline phosphatase IU/L modelled under a log transformation (Figure 9.3) as opposed to being 
linear previously, CA19-9 KU/l modelled with an alternative fractional polynomial transformation 
(Figure 9.4) and LDH IU/L modelled under the assumption of linearity, dropping the log 
transformation imposed previously: 
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Figure 9.3: Estimated Functional Form for Alkaline Phosphatase IU/L 
(dots indicate actual values) 
 
 
Figure 9.4: Estimated Functional Form for CA19-9 KU/l 
(dots indicate actual values) 
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This updated model provides updated estimates of the regression coefficients of identified factors 
re-estimated in the pooled data and adjusted by dataset and treatment. Parameter estimates for 
those variables under an alternative format differed. Those variables not reformatted (SEX, 
TREATMENT, ALBUMIN) showed similar parameter estimates with smaller standard errors, as 
expected due to the increased number of events, although interpretation of the TREATMENT 
variable should be avoided due to varying treatments across the datasets and trials, its main 
purpose being to adjust other parameter estimates. 
 
9.5. Model Performance 
Deviance residuals for this updated model were plotted against the linear predictor and were 
randomly scattered and centred symmetrically around a residual value of zero ranging between -
4.28 and 3.32 which suggests the data have not been mis-modelled (Figure 9.5): 
 
Figure 9.5: Deviance Residual Plot 
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As previously, patients were split into four equal sized groups based on quartiles of the distribution 
of linear predictor scores from the updated prognostic model. Linear predictor scores (LP) were 
calculated as: 
LP = -0.49006*DATASET + 0.05398*TRTGP - 0.33869*STAGE2 - 0.07656*STAGE3 + 
0.22828*STAGE4 - 0.16126*SEX + 0.76745*CA199FP1(KU/l) + 0.10686*CA199FP2(KU/l) - 
0.05836*ALB(g/L) + 0.15941*LOGALKPHOS(IU/L) + 0.0004020*LDH(IU/L) 
substituting 1 for the classification variable for  STAGE component as appropriate, else 0, and 
using the following code: DATASET (1=BB, 2=GC), TRTGP (0=GEM, 1=GEM+), SEX (1=MALE, 
2=FEMALE).  
 
Quartiles of the linear predictor scores were (-1.68213386, -1.32708021, -0.93425151) which 
created the four groups. Kaplan-Meier survival estimates (Figure 9.6) show four distinct prognostic 
groups with updated, descending median survival estimates, with non-overlapping confidence 
internals, of 9.7 (95%CI: 8.8 to 10.9), 7.2 (95%CI: 6.1 to 8.2), 5.1 (95%CI: 4.2 to 5.9) and 2.4 
(95%CI: 2.1 to 2.8) months and updated, descending 12-month survival estimates of 36.7% 
(95%CI: 30.8% to 42.6%), 28.0% (95%CI: 22.5% to 33.4%), 16.3% (95%CI: 11.8% to 20.8%)and 
3.9% (95%CI: 1.5% to 6.3%): 
 
CHAPTER 9: EXTERNAL VALIDATION 
129 
 
Figure 9.6: Survival by Prognostic Group 
 
The updated hazard ratios for groups 2, 3 and 4 using prognostic group 1 as the baseline 
were: 1.26 (95%CI: 1.06 to 1.51), 1.79 (95%CI: 1.50 to 2.14) and 4.39 (95%CI: 3.65 to 
5.27) respectively showing non-overlapping and tighter intervals in this updated model.  
 
9.6. Defining the Prognostic Index 
Since a prognostic index is to be used on future patients when treatment option remains to be 
decided and could be different to that in the model, then the DATASET and TREATMENT terms 
were removed from the updated prognostic model. This is equivalent to assuming that omitted 
variables take the value zero which will directly affect the linear predictor score but will not bias 
groupings into risk sets which is based on available and validated factors. Regression coefficients 
for remaining covariates were retained providing a new and updated prognostic index (PI) for use 
in prospective patients based on only those patient characteristics known at the time of diagnosis 
(Table 9.3): 
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Table 9.3: Prognostic Index 
 
PI = -0.33869*STAGE2 - 0.07656*STAGE3 + 0.22828*STAGE4 - 0.16126*SEX +    
0.76745*CA199FP1(KU/l) + 0.10686*CA199FP2(KU/l) - 0.05836*ALB(g/L) + 
0.15941*LOGALKPHOS(IU/L) + 0.0004020*LDH(IU/L) 
 
 
substituting 1 for the classification variable for  STAGE component as appropriate, else 0, and 
using the following code: SEX (1=MALE, 2=FEMALE)  
and classifying patients into prognostic risk sets with the associated estimates of survival and 
hazard ratios (Table 9.4): 
 
Table 9.4: Survival Estimates and Estimated Risk of Death for Prognostic Groups 
Risk Score Prognostic 
Group 
Estimate of 
Median Survival  
(95% CI) 
Estimate of 12-month 
Survival  (95% CI) 
HR (95% CI) 
Score < -0.995 1 9.5 (8.2 to 10.4) 36.0% (30.1% to 41.9%) 1.00 
-0.995 < Score < -0.661 2 7.1 (6.3 to 8.0) 26.4% (21.0% to 31.8%) 1.36 (1.13 to 1.62) 
-0.661 < Score < -0.293 3 4.9 (4.1 to 5.8) 16.3% (11.8% to 20.8%) 1.81 (1.51 to 2.17) 
Score > -0.293 4 2.7 (2.4 to 3.3) 6.2% (3.3% to 9.1%) 3.29 (2.74 to 3.95) 
 
 
Two of the three major causes of failure of a model to validate (Harrell, 2001) have been 
addressed whilst deriving this prognostic index: i) the estimate of overfitting in model development 
was minimal (<1%) with minimal prognostic separation (5.5%) when validated and ii) the validation 
dataset was based on a similar patient population with similar inclusion criteria. The third cause of 
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failure was due to changes in the measurement of variables since the validation dataset did not 
record data for three variables (WBC, AST and BUN) selected for inclusion in the original model 
(Table 6.2). WBC was considered highly significant in the original model whereas the influence of 
AST and BUN were more borderline. These variables will require further evaluation of their 
prognostic importance. In response to the suggested post-validation queries (Altman and Royston, 
2000):  
1. Are the same variables still important? Yes, but 3 were not evaluable at validation. 
2. Is the functional form of the prognostic model correct? Yes, similar but updated. 
3. Are the estimated regression coefficients compatible? Yes, where formats remain.  
4. How well does the model fit the new data? Minimal overfitting identified. 
5. Is the ordering of the prognostic groups preserved? Yes, and more distinct. 
6. Are the event rates between the prognostic groups significantly different? No. 
 
The updated, validated prognostic index in advanced pancreatic cancer is based on clinically 
relevant information routinely available at the time of diagnosis: cancer stage, sex, albumin, CA19-
9, alkaline phosphatase and LDH. The index identified four distinct and clinically relevant risk-
groups of patients which will enable routine stratification of patients and allow appropriate 
treatments to be targeted to groups of patients. It is intended that this prognostic calculator will be 
available to clinicians through the world wide web, attached to pancreas cancer specific web-sites.  
 
9.7. Additional Information Collected In the Validation Dataset 
The validation dataset trial collected additional factors to development dataset (diabetes, 
pancreatitis, tumour grade and site, ALT and creatinine), the most important being performance 
status. WHO performance status has been shown elsewhere to be an important prognostic factor 
CHAPTER 9: EXTERNAL VALIDATION 
132 
 
(Chapter 4). It was selected as a stratification factor at randomisation and was identified as a 
potentially important prognostic factor based on univariate analysis (Figure 9.7): 
 
Figure 9.7: Survival by Performance Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional exploratory analysis of the validation dataset was carried out independent of the 
development dataset but based on an identical modelling strategy. A Cox proportional hazards 
regression model was developed using 388 patients (384 deaths) with complete data on the 
clinical factors of interest and included stage of disease (p=0.0035) and performance status 
(p<0.001), stratification factors at randomisation, as well as randomised treatment group. The 
model identified five additional prognostic factors: albumin, CA19-9, size of primary tumour (all 
p<0.001), alkaline phosphatase (p=0.014) and LDH (p=0.034). Non-linear transformations were 
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appropriate for albumin g/L, CA19-9 KU/l, size of primary tumour and alkaline phosphatase IU/L 
indicating strong non-linear effects on log-hazard. A model including all 533 patients (529 deaths) 
based on multiple imputation methods to control for missing covariate data, selected grade of 
disease as an additional prognostic variable (p=0.034) which had been excluded from all models 
prior to imputation suggesting a link to other variables. A Cox model, excluding consideration of 
LDH and size of primary tumour due to missing data associated with these variables based on an 
498 patients (494 deaths), included presence of a stent (p=0.0086) again suggesting a link to 
other variables, notably size of primary tumour. Clinical guidance has indicated concern over the 
accuracy of the measurement of the primary tumour size in patients with advanced disease with 
possibly multiple metastases, as such the clinical significance of size of primary tumour is limited. 
Clinical guidance has also highlighted presence of a stent to be directly related to other laboratory 
data, specifically bilirubin, alkaline phosphatase and AST for measuring jaundice in patients.  
 
As such, the independent prognostic influence of primary tumour size and presence of a stent do 
not require further investigation. However, the independent prognostic influence of performance 
status and grade of disease and the relationships of these with other prognostic variables should 
be explored in further studies, highlighting the importance of collecting this data in future to allow 
the prognostic index to be updated with new relevant information when it becomes available. 
 
9.8. Treatment Effects across Prognostic Subgroups 
Interpretation of the treatment variable in the updated prognostic model was avoided due to the 
varying treatments across the datasets, its main purpose being to adjust other parameter 
estimates. Treatment effect across prognostic groups were investigated graphically, without 
significance testing, in the validation dataset using Forest plots (Early Breast Cancer Trialists' 
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Collaborative Group., 1990) to assess consistency of the hazard ratio of the treatment effect 
across categorical prognostic covariates. The treatment effect was consistent across prognostic 
subgroups of cancer stage and performance status (stratification factors at randomisation) 
(Cunningham et al., 2009) (Figure 9.8, adapted): 
 
Figure 9.8: Treatment Effect within Prognostic Subgroups 
 
 
 
 
 
 
 
 
 
 
 
 
Subpopulation treatment effect pattern plots (STEPP) (Bonetti and Gelber, 2000) were used to 
assess graphically treatment-covariate interactions across identified continuous prognostic 
covariates. Plots were based on creating approximately 20 subgroups of 50 consecutive patients 
with increasing values of CA19-9 KU/l, with 30 overlapping patients between subgroups. The 
hazard ratio of the treatment effect was scattered around the value of one (no difference in 
treatments) with no apparent trends for increasing values of CA19-9 KU/l (Figure 9.9), albumin g/L 
Events/Patients GEMCAP events Hazard Ratio & CI Reduction
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   = 0.2; p=.65  Interaction between 2 groups 2
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(100.0% ) ( 98.8% )
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(Figure 9.10), and alkaline phosphatase IU/L (Figure 9.11) and with confidence intervals spanning 
unity: 
Figure 9.9a: STEPP plot of Hazard Ratio of Treatment Effect for increasing CA19-9 to 10,000 KU/l 
 
Figure 9.9b: STEPP plot of Hazard Ratio of Treatment Effect for increasing CA19-9 to 1,000 KU/l 
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Figure 9.10: STEPP plot of Hazard Ratio of Treatment Effect for increasing Albumin g/L 
 
Figure 9.11: STEPP plot of Hazard Ratio of Treatment Effect for increasing Alkaline Phosphatase IU/L 
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9.9. Conclusions 
None of the previously published prognostic factors studies in advanced pancreatic cancer had 
been validated. The prognostic model developed in Chapter 6 has now been internally and 
externally validated. External validation is the most stringent form of validation and allows a 
prognostic model to be reviewed and updated with new data. The model was externally validated 
using new data from 455 advanced pancreatic cancer patients. Prognostic separation techniques 
showed the prognostic information in the original prognostic model to be reproducible in new 
patients. The advantage of external validation is that the prognostic model can be updated based 
on the new data. An updated model revealed that no other variables common in both datasets 
were selected for inclusion in the model. The functional format and regression coefficients were 
updated based on the pooled data producing more accurate estimates. Four distinct clinically 
relevant prognostic risk groups were identified with updated, non-overlapping and tighter 
confidence intervals for the survival and hazard ratio estimates. A validated prognostic index was 
derived from the updated prognostic model based on only clinically relevant information routinely 
available at the time of diagnosis. This prognostic index is the first to be based on robust and 
appropriate statistical methodology and is the first to have been statistically validated. The 
validation process has also identified possible prognostic factors which require further 
investigation and validation and as such should are recommended as required data collection in 
future studies. 
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CHAPTER 10: DISCUSSION AND RECOMMENDATIONS 
 
10.1. Summary 
This thesis provides the first definitive, validated, prognostic tool developed using a large 
international representative sample of patients with advanced ductal adenocarcinoma of the 
pancreas based on appropriate and robust statistical methodology and intended to be accessible 
to clinicians through convenient media, including the world-wide-web. This research has enabled 
recommendations for the design and analysis of future randomised controlled trials, specifically 
identification of possible important stratification factors and the appropriateness of different 
statistical modelling approaches including dealing with different data types. Cancer Research UK 
supported the development of this prognostic tool through a Population and Behavioural Sciences 
project grant (reference: C19491/A6150, Lead investigator: DD Stocken).  
 
10.2. Clinical Relevance of Research 
The clinical focus of this research is pancreatic cancer which is an important disease to research 
as it is a common cause of cancer death and is difficult to diagnose and treat. Prognosis is 
important to help clinicians in their decision making when identifying patients who may be suitable 
for further treatment and are also relevant for the appropriate design and analysis of future clinical 
trials. 
 
Pancreatic cancer is the eighth most common cause of cancer death in the world and fifth in the 
western world (Jemal et al., 2003;Parkin et al., 2005). It is particularly difficult to treat because of 
its remote location, late presentation and resistance to conventional chemotherapy. Prognosis is 
primarily based on resectability with improved survival for the 10 to 15% of patients suitable for 
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„curative resection‟. As such, long-term survival remains poor with a reported 5-year survival of 
<5% (Bramhall et al., 1995;Carr et al., 1999;Jemal et al., 2003) increasing to 25% in resected 
patients (Bramhall et al., 1995;Carr et al., 1999;Neoptolemos et al., 2009b;Stocken et al., 
2005;Yeo, 1998). Survival benefits are anticipated by identifying risk groups of patients in whom 
treatment strategies can be targeted. The overall aim of this research was to identify the factors at 
the time of diagnosis which predict the risk group to which a patient best belongs, based on robust 
and appropriate analyses.  There is currently no prognostic tool in routine use for prediction of 
survival from advanced pancreatic cancer. Such a tool would help clinicians identify subgroups of 
patients and help in their decision making regarding appropriate treatment strategies. 
 
Randomised controlled trials researching treatments for pancreatic cancer have been limited by 
the aggressive nature of this disease with it‟s resistance to therapy and it‟s associated short 
survival. To provide sufficient evidence to confirm a small expected survival advantage with 
treatment requires large studies with random allocation of patients to treatment groups to minimise 
bias. Sample sizes in pancreas cancer trials have tended to be small and as such raises the 
problem of comparing across studies due to differences in the samples of patients. Generally 
patients are not clinically separated into prognostic groups for consideration of treatment except 
surgically (Wagner et al., 2004). Cancer Research UK funded the first large (n=289 patients) 
randomised controlled trial of adjuvant treatment in patients undergoing curative resection 
(Neoptolemos et al., 2004). This trial had a direct impact on patient care changing the standard of 
care from surgery alone to surgery plus chemotherapy and has led the way for further follow-on 
adjuvant studies (Neoptolemos et al., 2009a). Gemcitabine became the standard of care for 
patients with non-resectable (advanced) disease based on a smaller study (n=126 patients) using 
clinical benefit response (a composite measure of pain, performance status and weight) as the 
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primary outcome (Burris et al., 1997) but with the recommendation (NICE, 2010) to gather further 
evidence for the role of gemcitabine. A recently reported large Cancer Research UK randomised 
controlled trial (n=533 patients) in the advanced disease setting concluded a benefit for 
combination gemcitabine plus capecitabine compared against gemcitabine alone (Cunningham et 
al., 2009). Historically, randomised controlled trials have stratified by country and resection margin 
status (adjuvant trials) and centre, stage of disease and performance status (advanced trials). 
Identification of important prognostic factors will not only enable identification of risk groups for the 
appropriate targeting of treatments, but also enable accurate stratification of patients into future 
clinical trials.  
 
A review of prognostic factors conducted in 2004 (Stocken et al., 2008) identified 36 prognostic 
factor studies reporting a total of 34 possible prognostic factors for advanced pancreatic cancer 
patients including demographic, clinical (including performance status, weight loss, treatment), 
surgical (including palliative procedures, site and stage of disease) and laboratory (including 
CA19-9, LDH, alkaline phosphatase and albumin). The majority of studies were questionable in 
terms of sample size and statistical methods and investigated different possible factors in differing 
formats across studies. Six previously reported prognostic indices included one large study of 
1020 patients but with only three common variables to investigate. The remaining five studies 
were based on <166 patients, four were single centre studies, three were retrospective, all 
excluded consideration of centre effect and treatment effect and dichotomised continuous 
covariates when constructing the prognostic index. Statistical models derived on independent 
datasets ideally need validating on external data to ensure external validity and generalisability 
across new datasets. None of the six studies included any validation. There is currently no 
statistically robust, validated prognostic tool in routine clinical use which could help clinicians 
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predict survival and target treatments to advanced pancreatic cancer patients more appropriately 
and have an impact on future trial design and analysis. 
 
10.3. Methodology and Findings 
This research was based on robust data from three large, phase III randomised controlled trials 
representative of patients with advanced pancreatic cancer with a high event rate (96%), long 
follow-up (average 20 months) and an overall one-year survival rate of 17% (Bramhall et al., 
2002;Bramhall et al., 2001;Cunningham et al., 2009) similar to the 13% one-year survival rate 
reported for England and Wales (Cancer Research UK, 2010). Two datasets were combined for 
model building (n=653) and one was used as an external validation dataset (n=533). The high 
number of events enabled stable estimation of the prognostic ability of eighteen possible clinical, 
histological, biochemical and demographic prognostic factors. 
 
Valid statistical analyses are essential to make best use of data and optimise clinical application. 
Cox proportional hazards regression model (Cox, 1972) investigates the relationship between 
survival and one or more possible factors detecting the extent to which potential factors affect the 
hazard function. A multivariable approach, based on Cox proportional hazards modelling using 
backward elimination variable selection, was used to investigate multiple possible prognostic 
factors with the ability to include categorical and continuous covariates. Continuous variables are 
often simplified by assuming a linear relationship between predictor and log-hazard i.e. the log risk 
increases or decreases linearly as the value of the factor increases, which may not be appropriate 
and could be misleading. Dichotomisation of continuous data is common but problematic. Since 
the variability in outcome within groups is ignored by categorisation then the variability between 
groups may be significantly underestimated as patients close to the cut point are analysed as 
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being very different rather than being very similar, resulting in a serious reduction of statistical 
power to detect relationships between predictors and outcome, residual confounding and serious 
bias (Altman and Royston, 2006;Royston et al., 2006a). It is important to account for non-linear 
relationships with outcome in the prognostic factor setting since it has been shown that a 
treatment effect can be underestimated unless a strongly prognostic non-linear covariate was 
modelled correctly using a suitable non-linear function (Royston et al., 2006a). The functional 
forms of the relationships between continuous covariates and log-hazard were not reported in 
previous studies in advanced pancreas cancer and were usually dichotomised.  Non-linear 
relationships were addressed for the first time in this disease site and were investigated for each 
of the ten continuous variables in the advanced pancreatic cancer dataset used for model 
building. 
 
Fractional polynomial (Royston and Altman, 1994) and restricted cubic spline (Stone and Koo, 
1985) functions are both polynomial functions particularly suitable for modelling smooth curved 
relationships between response and a predictor. Fractional polynomial functions are an extended 
family of curves defining functions with non-integer and negative power terms, first-degree 
transformations providing monotonic curves and second-degree transformations having a 
maximum of one turning point. Restricted cubic spline functions are piecewise polynomial 
functions constrained to join and be smooth at the endpoints of each interval (knot position) and 
restricted to be linear in the tails (before first and after last knots). Both restricted cubic splines and 
fractional polynomial transformations for non-linear continuous covariates are easy to implement 
within standard generalised modelling methods providing the number of knots in restricted cubic 
splines is small, else parameter estimation must be penalised to stabilise functions. There are 
convenient fractional polynomial (Meier-Hirmer et al., 2003) and restricted cubic spline macros 
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(Harrell, 1991) available in SAS (SAS Institute Inc., 1999) and R (The R Foundation for Statistical 
Computing, 2008). Regression using fractional polynomials have shown that important additional 
prognostic information could be extracted where less sophisticated approaches miss (Sauerbrei et 
al., 1999;Royston et al., 2006b). Spline functions with multiple knot positions in smaller samples 
using many degrees of freedom can generate uninterpretable „wiggles‟ and instability and can 
become interpretable (Sauerbrei et al., 2007). One study comparing fractional polynomial and 4-
knot restricted cubic spline models (Hollander and Schumacher, 2006) concluded that the 
fractional polynomial was the preferred approach in achieving a simple model and secondly, if a 
variable was linear in its relationship with log-hazard, the fractional polynomial method identified 
as linear more often. The fractional polynomial macro has the advantage that it can 
simultaneously select appropriate transformations within the multivariable model building process. 
No spline-based procedure for simultaneously selecting variables and functional forms has found 
wide acceptance (Sauerbrei et al., 2007). Fractional polynomials also have the added potential 
ability to be able to extrapolate beyond the limits of the data and the ability to fit functions with 
longitudinal and time dependent non-linear covariates (Lambert et al., 2005;Lehr and Schemper, 
2007) unlike spline transformations.  
 
The analysis of continuous variables in the advanced pancreatic cancer dataset has shown that 
non-linear transformations were appropriate for some covariates. Models containing non-linear 
transformations in the advanced pancreatic cancer dataset gave a substantially better fit 
compared to the models which dichotomised or assumed linearity of continuous covariates and 
included significant prognostic factors which were excluded in models under the assumptions of 
either step-functional (excluded alkaline phosphatase IU/L) or linear (excluded CA19-9 KU/l) 
relationships. The fractional polynomial and restricted cubic spline models confirmed previously 
CHAPTER 10: DISCUSSION AND RECOMMENDATIONS 
144 
 
reported prognostic factors: albumin, CA19-9, alkaline phosphatase and LDH. Both models also 
identified WBC as a prognostic factor which had not been previously reported at that time, but has 
been reported subsequently (Siddiqui et al., 2007). The fractional polynomial model also identified 
two additional possible prognostic factors with borderline significance, not previously reported: 
AST and BUN but these were not selected as prognostic in the restricted cubic spline model, 
requiring confirmation in further studies.  Most importantly, the effect of CA19-9 was not apparent 
in the model under the log-linear assumption, the effect of alkaline phosphatase was not apparent 
in the model which dichotomised variables indicating how the significant effect of these variables 
may go unrecognised due to simplistic assumptions made in statistical modelling.  
 
The fitted functions generated by splines and fractional polynomials were similar, resulting in 
comparable models but the AIC was smallest for the fractional polynomial model indicating a 
better fit to the data. Different models are directly compared using Akaike‟s Information Criteria 
(Akaike, 1974). Smaller values of the AIC indicate a better model but it is unclear whether AIC 
statistics from non-nested models will approximate the chi-square distribution. The AIC can be 
seen as a method of ranking models and as such the method forces a „best‟ model which may be 
more complex and not as parsimonious as the „next best‟ model but with almost identical AIC 
statistics. To avoid this, comparison of the restricted cubic spline and fractional polynomial 
strategies was carried out by calculating the sampling distribution of the difference in the AIC 
statistics between the models in multiple bootstrap resamples of the data. This was executed 
using an in-house developed SAS program. The distribution could then be summarised 
appropriately avoiding the need for distributional assumptions. The AIC statistics had to be output 
from the screen rather than the preferred option of delivering to an output dataset, as 
recommended by SAS (SAS Institute Inc., 1999), after reporting that the AIC values delivered to 
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screen and the output dataset differed, interestingly. The bootstrap mean AIC was smallest for the 
model containing fractional polynomial transformations and on average was a better fit than the 
model based on restricted cubic spline transformations by a bootstrap mean reduction of 11.0 
(bootstrap percentile 95% CI: 9.0 to 31.4) in 1000 bootstrap resamples. The methods were 
generally different in the extremities where there is often a paucity of data and it could be argued 
that the restriction imposed in the tails in restricted cubic splines leads to greater stability. One 
possible solution could be to use the mid 90% of the range of „noisy‟ continuous data with outlying 
extremes.  
 
None of the six reported prognostic indices investigated centre effect. A grouped frailty model is a 
survival model which incorporates a random effect (RE) element into hazard function to account 
for heterogeneity between patients. An investigation of any centre effect within in this dataset 
using frailty modelling revealed no evidence of systematic differences in outcome across centres 
possibly due to the overall poor prognosis of patients with this disease and absence of effective 
treatments. Multiple imputation methods (Rubin, 1987) were used as a supportive analysis to the 
principal complete case analysis, to assess the impact of missing data which was minimal in the 
advanced pancreatic cancer dataset but again had not been addressed previously in the literature. 
 
Model validation was addressed for the first time in this disease site and is the assessment of the 
accuracy of statistical estimates and of the stability of a set of prognostic factors. Internal 
validation was carried out to assess the degree of model optimism (over-fitting) which is a 
measure of poor external validity leading to inflated estimates of model fit and is a potentially 
important source of bias in prognostic models. Internal validation methods based on statistical 
resampling simulation techniques (Efron and Tibshirani, 1993) suggested minimal optimism and 
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since the degree of overfitting estimated for the model is minimal, rescaling the model estimates 
appears neither helpful nor necessary. External validation is the most stringent form of validation 
and allows a prognostic model to be reviewed and updated with new data. The regression 
coefficients from the derived prognostic model were fitted to external data from 455 advanced 
pancreatic cancer patients and the predictive value of the model assessed by comparison of 
predicted and observed survival estimates. Prognostic separation techniques (Altman and 
Royston, 2000) showed the prognostic information in the original prognostic model to be 
reproducible in new patients. The advantage of external validation is that the prognostic model 
can be updated based on the new data. An updated model revealed no other variables common in 
both datasets, were selected for inclusion in the model. The functional format and regression 
coefficients were updated based on the pooled data producing more accurate estimates. Four 
distinct clinically relevant prognostic risk groups were identified with non-overlapping and tighter 
confidence intervals for the survival and hazard ratio estimates. This is the first prognostic model 
developed in advanced pancreatic cancer to have undergone both internal and external validation. 
 
Prognostic indices are derived from the validated regression model and prognostic scores 
grouped to form risk sets. A statistically validated prognostic index was derived from the updated 
prognostic model based on only clinically relevant information routinely available at the time of 
diagnosis. Four distinct clinically relevant risk-sets of patients were identified which could help 
clinicians to target treatments to prognostic groups of patients more appropriately. This prognostic 
index is the first to be based on robust and appropriate statistical methodology and is the first to 
have been statistically validated. The prognostic index should have the ability to aid decision 
making by identifying patients with better prognosis, possibly for inclusion in clinical trials of more 
toxic therapies, or identifying those with worse prognosis, possibly more suitable for more 
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palliative treatments off-study, especially since a greater number of palliative and toxic 
combinations of treatments are becoming available and being trialled in this disease. The 
validation process has also identified possible prognostic factors which require further 
investigation and validation and as such should are recommended as required data collection in 
future studies. It is intended that a prognostic calculator of the final validated index will be 
available through a pancreatic/ trials unit specific web-pages, based on an access front end for 
ease of use, being directly available to the clinical community and with the ability to be updated 
with future data from randomised controlled trials. 
 
10.4. Derived Prognostic Model 
Linear Predictor = -0.37711*TRIAL + 0.17286*STAGEGP - 0.16115*SEX + 0.16934*TRTGP + 
0.02383*CA199FP1(KU/l) - 0.00173*CA199FP2(KU/l) - 0.06802*ALB(g/L) - 0.00367*AST(IU/L) + 
0.00119*ALKPHOS(IU/L) + 0.02772*BUN(mmol/L) + 0.04409*WBC(109/L) + 0.56220*LOGLDH(IU/L) 
substituting the following code: TRIAL (1=BB128, 2=BB193), STAGEGP (1=I/II, 2=III/IV), SEX 
(1=MALE, 2=FEMALE), TRTGP (0=GEM, 1=GEMPLUS). 
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10.5. Validated Prognostic Index 
Prognostic Index = -0.33869*STAGE2 - 0.07656*STAGE3 + 0.22828*STAGE4 - 0.16126*SEX +    
0.76745*CA199FP1(KU/l) + 0.10686*CA199FP2(KU/l) - 0.05836*ALB(g/L) + 
0.15941*LOGALKPHOS(IU/L) + 0.0004020*LDH(IU/L) 
 
substituting 1 for the classification variable for  STAGE component as appropriate, else 0, and 
using the following code: SEX (1=MALE, 2=FEMALE) and classifying patients into prognostic risk 
sets with the associated estimates of survival and hazard ratios (Table 10.1): 
 
Table 10.1: Survival Estimates and Estimated Risk of Death for Prognostic Groups 
Risk Score Prognostic 
Group 
Estimate of 
Median Survival  
(95% CI) 
Estimate of 12-month 
Survival  (95% CI) 
HR (95% CI) 
Score < -0.995 1 9.5 (8.2 to 10.4) 36.0% (30.1% to 41.9%) 1.00 
-0.995 < Score < -0.661 2 7.1 (6.3 to 8.0) 26.4% (21.0% to 31.8%) 1.36 (1.13 to 1.62) 
-0.661 < Score < -0.293 3 4.9 (4.1 to 5.8) 16.3% (11.8% to 20.8%) 1.81 (1.51 to 2.17) 
Score > -0.293 4 2.7 (2.4 to 3.3) 6.2% (3.3% to 9.1%) 3.29 (2.74 to 3.95) 
 
 
10.6. Generalisability 
It may be argued that prognostic models derived using randomised controlled trial data are 
restricted to the patient population governed by the strict eligibility criteria of the trial and as such 
may lack generalisability (Moons et al., 2009). Within pancreatic cancer trials, the eligibility criteria 
are usually mindful of the need to recruit on a national or international basis and are generally not 
overly restrictive. However, all patients do have to be fit enough to undergo any of the trial 
treatments and this does introduce the possibility of there being an additional worse prognostic 
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group of patients that are too ill to undergo any further treatment, hence excluded from clinical 
trials and not available for inclusion in the prognostic modelling. Data from randomised controlled 
trials are usually the largest datasets available in this disease and as such provide the most 
available evidence by which to investigate potentials prognostic factors. 
 
Since trials of pancreatic cancer are being conducted by academia and pharmaceutical 
companies on an international level then it would seem sensible to derive a common outcomes 
dataset for this disease to ensure all trials subscribe to collection of a minimally important dataset 
with specific agreed outcome measurements. This could be addressed through the MRC Hubs for 
Trials Methodology Research (http://www.mrc.ac.uk/Newspublications/News/MRC005063) which 
are already investigating this in different disease sites and will ensure that potentially important 
information is routinely collected across all research projects undertaken within specific disease 
areas. 
 
10.7. Application in Cardiac Surgery 
The aim of the analysis was to investigate the reproducibility of the results and conclusions drawn 
from the comparison of non-linear methods in the advanced pancreatic cancer dataset, where the 
fractional polynomial transformation gave a better fit compared to the restricted cubic spline 
transformation. Data from 42802 patients with cardiovascular disease (Pagano et al., 2009) were 
analysed as an additional example to investigate the stability of the conclusions in an alternative 
dataset with alternative event rate and survival distribution. Non-linear transformations were 
identified for all three continuous factors: historical log transformation for EuroScore and either 3 
knot restricted cubic spline or second degree fractional polynomial transformations for both BMI 
and Carstiars Score.  
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The fractional polynomial and restricted cubic spline models were similar in that they selected 
identical variables for inclusion with high significance, similar magnitude and almost identical AIC 
values. Comparison of the restricted cubic spline and fractional polynomial strategies was carried 
out by calculating the sampling distribution of the difference in the AIC statistics between the 
models in multiple bootstrap resamples of the data. This was executed using an in-house 
developed SAS program. The distribution could then be summarised appropriately avoiding the 
need for distributional assumptions. The bootstrap mean AIC were also similar across the 
fractional polynomial and restricted cubic spline models with a bootstrap mean reduction with the 
fractional polynomial transformation of 0.12 (bootstrap percentile 95% CI: -8.7 to 9.2) in 1000 
bootstrap resamples.  
 
One of the main advantages of this additional dataset is the large sample size allowing further 
bootstrap analyses to be carried out which enabled an unadjusted univariate fractional polynomial 
transformation for each continuous covariate to be recalculated within each of 200 bootstrap 
resamples taken from the original dataset and comparing against a 5-knot restricted cubic spline 
using in-house developed SAS program. The %RCSPLINE and %MFP8 macros also had to be 
adapted to enable them to run within the %BOOT macro in SAS since they automatically delete 
temporary SAS datasets which were required to enable output of the -2log-likelihood, hence 
further calculation of the AIC, from each model in each bootstrap resample. The comparison of 
models was interesting since a final selected fractional polynomial model may be selected as the 
null model (i.e. no prognostic significance under any transformation including the linear model) 
and as such it was important to address the number of times each bootstrap sample compared a 
null model against the 5-knot restricted cubic spline. The large size of this additional dataset 
allowed this process to be repeated reducing the bootstrap resample sizes from that of the size of 
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the original dataset. When reducing the bootstrap size, consistency with conclusions made from 
analysis of the full dataset were not seen until a sample size of 20,000 resamples based on both 
the observed bootstrap mean difference and the inclusion/ exclusion of covariates by the fractional 
polynomial function. The fitted functions generated by restricted cubic splines and fractional 
polynomials were similar with similar model fit but larger differences were seen when the resample 
sizes were reduced in favour of the fractional polynomial functions albeit a reduction in available 
evidence to detect non-linearity. 
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10.8. Recommendations 
 Stage of disease, sex, CA19-9, Albumin, Alkaline Phosphatase and LDH have been 
identified as statistically validated prognostic factors 
 WBC, AST and BUN were prognostic in the development dataset but require external 
validation 
 Performance status and grade of disease were prognostic in the validation dataset but 
require external validation 
 All of these data should be routinely collected in future studies, minimising missing data, so 
the prognostic index can be continually updated and validated 
 Multivariable analysis should be standard, automated selection procedures used with care 
 Analyses should include dataset(s), stratification factor(s) and treatment group(s) as „forced‟ 
covariates to adjust parameter estimation of effect size of possible prognostic factors 
 Functional form should always be assessed specifically the underlying assumption of 
linearity between continuous covariates and log-hazard 
 Dichotomisation is not a solution for non-linearity, rather non-linear transformations should 
be considered 
 Fractional polynomial transformations are an alternative approach to restricted cubic spline 
transformations for multivariable model building of continuous covariates with non-linear 
relationships with log-hazard 
 Frailty models should be considered to investigate clustering in response, specifically due 
to centre or country effect and particularly where the number of events per cluster is small 
 Internal validation should be carried out, estimates adjusted for overfitting if necessary 
 Predicted separation methods to quantify prognostic ability of the model should be reported 
 The prognostic index should be based on characteristics known at the time of diagnosis, 
excluding dataset and treatment group, but retaining parameter estimates adjusted by 
these factors 
 The prognostic index can be used to classify patients into one of four distinct clinically 
relevant risk groups 
 Estimates of predicted survival and hazard ratios are available for  each prognostic group 
 A prognostic calculator could be made available on a pancreatic/ trials specific web page 
 The prognostic index could aid patient management and treatment decision making 
 Stratification for randomisation of patients in future trials could be based on the most 
significant of the validated prognostic factors specifically, Stage of disease, CA19-9 and 
Albumin 
 Stratification could be based on categorising laboratory variables according to their normal 
laboratory range but retaining the continuous nature of each covariate at analysis 
 Stratification factors could be updated based on other identified factors, once validated 
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10.9. Further Research 
 Investigate the inclusion of interactions of non-linear continuous covariates in the 
prognostic model and consider the amount of evidence available to be able to detect (the 
need for ~four times as many patients to detect an interaction) 
 Investigate the functional form of longitudinal non-linear continuous covariates, such as 
CA19-9 measurements during the treatment phase 
 Investigate the prognostic value of quality of life, longitudinal data usually collected 3-
monthly from the date of randomisation in prospective randomised controlled trials 
 Further investigate „centre‟ effect and more specifically ‟country‟ effect in the international 
trials of adjuvant treatment for resected pancreatic cancer considering  interactions with 
prognostic factors 
 Apply the adopted strategy for the development of prognostic models in the adjuvant 
setting with full statistical validation in an international group of patients undergoing 
„curative‟ surgery 
 Investigate alternative parametric models which assume specific distributions for the data 
but if appropriate can result in a more efficient estimation procedure yielding more precise 
parameter estimates, smaller standard errors, more clinically meaningful results and more 
accurate prediction of survival 
 
 
CHAPTER 10: DISCUSSION AND RECOMMENDATIONS 
154 
 
10.10. Final Conclusions 
This thesis has further advanced the knowledge of prognostic factors in pancreatic cancer and 
has developed a validated prognostic index intended for use by clinicians to help in treatment 
decision-making and inform clinical trial design. This thesis has applied advanced statistical 
techniques in the development and validation of the prognostic index, has evaluated empirically 
the application of different polynomial based methods for addressing non-linearity in continuous 
data and further endorses the use of these methods. This research has provided 
recommendations for statistical analysis of pancreatic cancer datasets, recommendations for 
clinical use of the prognostic index and future clinical trial design and recommendations for further 
research in this area. 
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APPENDIX 
 
/*******************************************/ 
/**** PROGNOSTIC FACTORS IN ADV PANC CA ****/ 
/****  FP VS RCS BOOTSTRAP RESAMPLING   ****/ 
/*******************************************/ 
 
LIBNAME BB 'H:\Debs\pfadvpancca'; 
%INCLUDE 'H:\Debs\pfadvpancca\FORMAT.SAS'; 
 
proc format; 
  value trialfmt 1='BB128' 2='BB193'; 
  value racefmt 1='WHITE' 2='BLACK' 3='ORIENTAL' 4='OTHER'; 
  value sexfmt 1='MALE' 2='FEMALE'; 
  value deadfmt 0='ALIVE' 1='DEAD'; 
  value STATFMT 0='NEG' 1='POS' 2='MISS'; 
  VALUE TRTFMT 0='GEM+PLACEBO' 328='GEM+MARIM' 901='GEM' 1328='MARIM10'  
1329='MARIM25' 1337='MARIM5' ;  
  VALUE TRT2FMT 0='GEM' 1='MARIM'; 
  VALUE AGEFMT 1='<=63' 2='>63'; 
  VALUE NORMFMT 0='NORMAL' 1='ABNORMAL'; 
  VALUE STAGEFMT 1='I/II' 2='III/IV'; 
RUN; 
 
/**** SETUP COMPLETE CASE FP AND RCS DATA 
/**** n=556 complete case, 520 events 
/**** univariate transformations 
 
/* %INCLUDE 'H:\Debs\phd\RCS macro\rcspline.sas'; 
RUN; 
 
DATA BB.CC; 
  SET BB.BBMERGE; 
  LOGBILI=LOG(BILI); 
  LOGLDH=LOG(LDH); 
  CA199FP1=CA199**0.5; 
  CA199FP2=CA199**0.5*LOG(CA199); 
  %RCSPLINE(CA199, 10, 710, 70000); 
  IF STAGEGP NE . AND ALB NE . AND CA199 NE . AND LDH NE . AND WBC NE . AND ALKPHOS NE . 
  AND AST NE . AND BUN NE . ; 
RUN; 
*/ 
 
/**** BOOTSTRAP ANALYSIS: COMPARE FP vs. RCS using AIC */ 
 
FILENAME JACKBOOT 'H:\Debs\phd\jackboot.sas'; 
%INCLUDE JACKBOOT; 
 
%MACRO ANALYZE (DATA=, OUT= ); 
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/* FP MODEL USING AUTOMATED BACKWARD SELECTION */ 
 
ods output FitStatistics=AICFP; 
PROC TPHREG DATA=&data; 
  CLASS M (MISSING REF='0') N (MISSING REF='0'); 
  MODEL SURVDOE*DEAD(0)= TRIAL STAGEGP SEX TRTGP CA199FP1 CA199FP2  
      M N ALB AGE AST ALKPHOS BUN HAEM WBC LOGBILI LOGLDH 
     / SELECTION=BACKWARD INCLUDE=6 RL; 
run; 
 
DATA FP;   
  SET AICFP; 
  where criterion='AIC     '; 
  AICFP=WithCovariates; 
  keep criterion AICFP; 
RUN; 
 
DATA FP2; 
  SET FP;  BY criterion; 
  IF LAST.criterion; 
RUN; 
 
 
/* RCS MODEL USING AUTOMATED BACKWARD SELECTION */ 
 
ods output FitStatistics=AICRCS; 
PROC TPHREG DATA=&data; 
  CLASS M (MISSING REF='0') N (MISSING REF='0'); 
  MODEL SURVDOE*DEAD(0)= TRIAL STAGEGP SEX TRTGP CA199 CA1991  
     M N ALB AGE AST ALKPHOS BUN HAEM WBC LOGBILI LOGLDH 
     / SELECTION=BACKWARD INCLUDE=6 RL; 
run; 
 
DATA RCS;   
  SET AICRCS; 
  where criterion='AIC     '; 
  AICRCS=WithCovariates; 
  keep criterion AICRCS; 
RUN; 
 
DATA RCS2; 
  SET RCS;  BY criterion; 
  IF LAST.criterion; 
RUN; 
 
 
/* MERGE RESULTS */ 
 
DATA AIC; 
  SET FP2;  
  SET RCS2; 
  AICDIFF=AICRCS-AICFP; 
RUN; 
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/* SUMMARY STATISTICS ACROSS SAMPLES */ 
/* IF AICDIFF= + then AICFP<AICRCS indicating FP is better fit */ 
 
DATA &OUT; 
  SET AIC; 
  RUN; 
%MEND; 
 
title1 'BB: BOOTSTRAP ANALYSIS COMPARING AIC DIFFERENCE IN FP VS RCS MODELS'; 
title2 '1,000 bootstrap samples'; 
%BOOT(DATA=BB.CC, ALPHA=.05, SAMPLES=1000, RANDOM=123); 
run; 
quit; 
run; 
 
 
/************ END ************/ 
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/********************************************/ 
/****  PROGNOSTIC FACTORS IN HEART DATA  ****/ 
/**** BOOTSTRAP COMPARISON OF FP AND RCS ****/ 
/********************************************/ 
 
/**** RERUN with: BOOTSTRAP SIZE=1000, 5000, 10 000, 20 000, SAMPLES=200 */ 
 
LIBNAME NF 'H:\Debs\phd\HEART'; 
RUN; 
 
PROC FORMAT; 
  VALUE op  1 = "CABG Only"  2 = "Valve(s) Only"  3 = "CABG+Valve(s)" 
  4 = "CABG+Other" 5 = "Valve(s)+Other" 6 = "CABG+Valve(s)+Other" 
  7 = "Other" ; 
RUN; 
 
%INCLUDE 'H:\Debs\phd\RCS macro\rcspline.sas'; 
RUN; 
 
%INCLUDE 'H:\Debs\phd\FP macro\boxtid.sas'; 
%INCLUDE 'H:\Debs\phd\FP macro\brename.sas'; 
%INCLUDE 'H:\Debs\phd\FP macro\datasave.sas'; 
%INCLUDE 'H:\Debs\phd\FP macro\exinc.sas'; 
%INCLUDE 'H:\Debs\phd\FP macro\exlabb.sas'; 
%INCLUDE 'H:\Debs\phd\FP macro\fpmodels.sas'; 
%INCLUDE 'H:\Debs\phd\FP macro\funcfm.sas'; 
%INCLUDE 'H:\Debs\phd\FP macro\labs.sas'; 
%INCLUDE 'H:\Debs\phd\FP macro\MFP8.SAS'; 
%INCLUDE 'H:\Debs\phd\FP macro\xtop.sas'; 
%INCLUDE 'H:\Debs\phd\FP macro\xvars.sas'; 
RUN; 
 
FILENAME JACKBOOT 'H:\Debs\phd\jackboot.sas'; 
%INCLUDE JACKBOOT; 
RUN; 
 
/* CREATE COMPLETE CASE DATASET FOR ANALYSIS AND COMPARISON OF MODELS 
/* COMPARING 5-KNOT RCS BE MODEL WITH MV FP MODEL: SET UP 5K TRANS */ 
 
/* 
DATA NF.BOOT2; 
  SET NF.HEART2; 
  IF FU_DAYS NE . AND BMI NE . AND SMOKING2 NE .; 
  %RCSPLINE(BMI, 20.998698976, 24.84, 27.11, 29.714285714, 35.338593031); 
  %RCSPLINE(CS, -3.5072, -2.0447, -0.539, 1.9408, 5.6578); 
  %RCSPLINE(ES, 1, 3, 5, 7, 11); 
RUN; 
PROC CONTENTS DATA=NF.BOOT2; 
run; 
*/ 
 
/****  BOOTSTRAP ANALYSIS ****/ 
 
%MACRO ANALYZE (DATA=, OUT= ); 
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/* FP MODEL USING AUTOMATED MPF8 MACRO */ 
  
DATA NF.TEMPNF; 
SET &data; 
RUN; 
 
%mfp8 (DSNAME= NF.TEMPNF, 
 YNAME=FU_DAYS, 
 XNAME=BMI , 
    MODEL=S, 
    PW=-2 -1 -0.5 0 0.5 1 2 3, 
    M=2, 
    CENSVAR=DEATH_AT_FU, 
    CENSVAL=0,  
    TIES=BRESLOW, 
 ALPHA=0.05, 
 MSELECT=RA2, 
 MACPATH=H:\Debs\phd\FP macro, 
 DSOUT=FPOUT, 
 SHOWRES=r /* n */ 
 ); 
RUN; 
 
DATA NFFP; 
  SET FPOUT1;  
  OUT=1; 
RUN; 
 
/* FFORM: -1="Omitted", 0="Linear", 1="First Degree", 2="Second Degree", 3="Third Degree" */ 
 
PROC SORT DATA=NFFP; BY OUT; 
DATA NFFP2; 
  SET NFFP;  BY OUT; 
  IF LAST.OUT; 
  DEVFP=DEVIANCE; 
  IF FFORM=-1 THEN Q=0; 
  IF FFORM IN (0 1) THEN Q=1; 
  IF FFORM=2 THEN Q=2; 
  IF FFORM=3 THEN Q=3; 
  AICFP=DEVIANCE+(2*Q);  
  KEEP DEVFP AICFP ; 
RUN; 
 
 
/* RCS MODEL USING TPHREG */ 
 
ods output FitStatistics=NFRCS; 
PROC TPHREG DATA= &data; /*no summary;*/ 
 MODEL FU_DAYS*DEATH_AT_FU(0) = BMI BMI1 BMI2 BMI3 / RL;   
RUN; 
 
DATA NFRCS2;   
  SET NFRCS; 
  where criterion='-2 LOG L'; 
  DEVRCS=WithCovariates; 
  AICRCS=DEVRCS+(2*4);  /* BETA ESTIMATE FOR RCS(5) */ 
  keep criterion DEVRCS AICRCS; 
RUN; 
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DATA NFRCS3; 
  SET NFRCS2;  BY criterion; 
  IF LAST.criterion; 
RUN; 
 
 
/* MERGE RESULTS */ 
 
DATA DEV; 
  SET NFFP2;  
  SET NFRCS3; 
  DEVDIFF=DEVRCS-DEVFP; 
  AICDIFF=AICRCS-AICFP; 
RUN; 
 
 
/* COMPARISON OF AIC WITHIN BOOTSTRAP RESAMPLES: IF DEVDIFF= + then FP is better fit */ 
 
DATA &OUT; 
  SET DEV; 
  RUN; 
%MEND; 
 
title1 'NF HEART DATA: BOOTSTRAP ANALYSIS COMPARING AIC IN FP VS RCS MODELS'; 
title2 '200 bootstrap samples, SAMPLE SIZE =20,000'; 
%BOOT(DATA=NF.BOOT2, ALPHA=.05, SAMPLES=200, SIZE=20000, RANDOM=2001);  
run; 
quit; 
run; 
 
 
/******************** END ********************/ 
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